

EXHIBIT 3

to

**PAUL D. BRACHMAN DECLARATION
IN SUPPORT OF INTUITIVE'S MOTION FOR
LIMITED SUPPLEMENTAL DISCOVERY**

ATTACHMENT 49

HIGHLY CONFIDENTIAL – ATTORNEYS’ EYES ONLY

UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF CALIFORNIA

SURGICAL INSTRUMENT SERVICE
COMPANY, INC.,

Plaintiff / Counterclaim Defendant,

v.

INTUITIVE SURGICAL, INC.,

Defendant / Counterclaim Plaintiff.

Case No.: 3:21-cv-03496-VC

Second Rebuttal Expert Report of Richard F. Bero, CPA, CVA
March 1, 2023

HIGHLY CONFIDENTIAL – ATTORNEYS’ EYES ONLY

TABLE OF CONTENTS

I.	Introduction.....	1
A.	Assignment	1
B.	Basis for my second rebuttal report	1
C.	Expert experience and compensation.....	2
D.	Basic damages assumptions.....	3
II.	The Smith Rebuttal Report	3
III.	The Bero Report’s inclusion of damages associated with the X/Xi EndoWrist instruments is assumed, and appears reasonable based on the evidence in the case	4
IV.	The Bero Report properly analyzed the “but-for” market	5
A.	The Smith Rebuttal Report speculates Intuitive would hypothetically increase da Vinci Surgical System pricing and lower EndoWrist instrument pricing.	5
B.	The Smith Rebuttal Report’s hypothetical Intuitive pricing approach is not consistent with Intuitive’s contemplated actions	6
C.	The Smith Rebuttal Report’s hypothetical Intuitive pricing approach fails to account for Intuitive’s identified secondary market benefits.....	6
V.	The Bero Report conservatively considered SIS costs associated with not owning “intellectual property”	7
A.	Incorporating SIS’s costs based on Rebotix’s expected selling prices to SIS results in higher lost profits as shown on Second Rebuttal Schedule 1.0.....	11
VI.	The Bero Report properly considered SIS’s relationships with Rebotix (and Restore) ...	12
A.	The Smith Rebuttal Report speculates on what Rebotix or Restore “could” or “may” have done.	12
B.	The Smith Rebuttal Report fails to account for SIS’s vendor/customer relationships.	13
C.	Rebotix’s goal was a long-term relationship with SIS due to its national customer accounts	14
VII.	The Bero Report’s market penetration rate is reasonable and appropriate	14

HIGHLY CONFIDENTIAL – ATTORNEYS’ EYES ONLY

A.	The Smith Rebuttal Report seems to (misleadingly) suggest the Bero Report’s penetration rates (i.e., 2% to 12%) are reliant on three purported “benchmarks”	14
B.	The Bero Report’s 2% to 12% penetration rates appear reasonable relative to Intuitive’s August 2019 estimated 41% to 50% penetration rate	15
C.	The Bero Report’s 2% to 12% penetration rates appear reasonable relative to Stryker’s 8.5% to 9% expected penetration rates	16
D.	The Bero Report’s 2% to 12% penetration rates appear reasonable relative to Deutsche Bank’s 4% to 6% penetration rates	17
E.	The Smith Rebuttal Report’s reference to Vizient, if anything, highlights the Bero Report’s conservative penetration rates	17
F.	The Bero Report’s 60% expiration rate is reasonable	18
G.	The Bero Report’s conversion rates of 15% in Year 1, 50% in Year 2, and 70% in Year 3 appear reasonable.....	20
H.	The Bero Reports assumption FDA approval was not needed appears reasonable.	21
I.	The Bero Report’s collection rate of 70% is reasonable.....	21
VIII.	The Bero Report’s Disgorgement Damages pertaining to SIS’s claims under the Lanham Act are appropriate.....	23
A.	The Smith Rebuttal Report apparently is unaware of the Lanham Act allegations in the Complaint	24
IX.	The Smith Rebuttal Report makes unsupported deductions in its Lanham Act analyses. 25	
A.	The Smith Rebuttal Report primarily reduces disgorgement damages by eliminating X/Xi EndoWrist sales	26
X.	Conclusion	26

HIGHLY CONFIDENTIAL – ATTORNEYS’ EYES ONLY

I. Introduction**A. Assignment**

I previously submitted an expert report dated December 2, 2022 (the “Bero Report”) and a rebuttal expert report dated January 18, 2023 (the “Bero Rebuttal Report”) in this matter.¹ In the Bero Report, I provided expert opinions on damages on behalf of Surgical Instrument Service Company, Inc. (“SIS”) in *Surgical Instrument Service Company, Inc. v. Intuitive Surgical, Inc.*, Case No. 3:21-cv-03496-VC.² As described in the Bero Report, I understand SIS has accused Intuitive Surgical, Inc. (“Intuitive” or the “Defendant”) of the following five counts: (1) Tying; (2) Exclusive Dealing; (3) Monopolization; (4) Attempted Monopolization; and (5) Unfair Trade Practices – Violation of Lanham Act.³ I referred to these counts, collectively, as the “Alleged Wrongdoings.”

In the Bero Rebuttal Report, I addressed Intuitive’s claimed damages for its five counterclaims as contained in the Expert Report of Loren K. Smith, PH.D., dated December 2, 2022 (the “Smith Report”).⁴

On January 18, 2023, Loren K. Smith, PH.D., issued a rebuttal report which addressed my damages opinions as stated in the Bero Report (the “Smith Rebuttal Report”). I address and respond to the Smith Rebuttal Report herein.

As described in the Bero Report and Bero Rebuttal Report, I have not formed any legal opinions about this matter.

B. Basis for my second rebuttal report

The basis for my opinions and information I relied on for damages issues related to Intuitive’s Alleged Wrongdoings and SIS’s Alleged Wrongdoings are set forth in the Bero Report and Bero Rebuttal Report, respectively.⁵ I have now analyzed and considered the

¹ I also provided Updated Bero Report Schedules / Errata Sheet dated February 25, 2023, as described below.

² Compl. I described the parties, case facts and terminology in the Bero Report.

³ Compl. ¶¶ 111-126.

⁴ These counterclaims include: (1) Unfair competition and false advertising – Lanham Act 15 U.S.C. § 1125; (2) Unfair Competition Law – CA. Stat. § 17200; (3) False Advertising – CA. Stat. § 17500; (4) Common Law Unfair Competition; and (5) Tortious interference with contract (collectively, “Intuitive’s Counterclaims”). See Defendant Intuitive Surgical, Inc.’s Answer, Affirmative Defense and Counterclaims ¶¶ 84-109.

⁵ Bero Report 4-6 and Bero Rebuttal Report 1-2.

HIGHLY CONFIDENTIAL – ATTORNEYS’ EYES ONLY

following additional information made available subsequent to the issuance of the Bero Rebuttal Report:

- the Smith Rebuttal Report and the Smith Rebuttal Report’s workpapers;
- additional documents produced / provided by the parties;
- additional expert reports;
- an additional deposition;
- additional discussions with the following SIS personnel (in alphabetical order):
 - Keith Johnson, Executive Vice President, Sales and Clinical Programs;
 - Greg Posdal, President and C.E.O.;
- discussions with Chris Gibson, Rebotix Repair LLC’s COO;
- additional independent research; and
- my skills, knowledge, professional background, education and work experience.

A detailed list of data and other information I have considered in developing this report and my two previous reports is included as **Second Rebuttal Attachment 1**. If additional relevant information becomes available after the issuance of this second rebuttal report, I reserve the right to incorporate such information as necessary. I may also incorporate additional information in response to any expert reports or opinions proffered on Intuitive’s behalf.

C. Expert experience and compensation

I am a certified public accountant, accredited in business valuation, a certified valuation analyst and the Managing Director of The BERO Group. Since 1987, I have analyzed economic damages and accounting and financial issues in a variety of litigation matters concerning areas such as breach of contract, patent infringement, trademark infringement, copyright infringement, trade secrets, anti-trust, dealership disputes and construction disputes. I have testified as an expert more than 170 times. My curriculum vitae, including a list of my testimonial experience in the last four years and publications in the last ten years, is included as **Second Rebuttal Attachment 2**.

HIGHLY CONFIDENTIAL – ATTORNEYS’ EYES ONLY

Compensation to The BERO Group for professional services provided in preparing this report is based on our customary hourly fees as described in the Bero Report. The BERO Group has no financial interest in the outcome of this litigation.

D. Basic damages assumptions

For purposes of this rebuttal report, I assume the parties’ (including third parties) reported revenue, costs and other data are generally accurate and reliable.⁶

II. The Smith Rebuttal Report

The Smith Rebuttal Report includes various criticisms of the Bero Report. Its primary criticism appears to be that the Bero Report’s inclusion of reset X/Xi EndoWrist instrument sales is speculative because no third-party companies have successfully developed a process to reset the use counter of X/Xi EndoWrist instruments.⁷ The Smith Rebuttal Report states that excluding X/Xi EndoWrist sales reduces the Bero Report’s claimed revenue by at least 95%, which implies the Bero Report’s claimed damages are reduced by a similar amount.⁸ I address this criticism first and other criticisms below.

Among other criticisms, the Smith Rebuttal Report claims my lost profits analysis in the Bero Report “suffers from conceptual and methodological flaws that inflate SIS’s purported damages.”⁹ I address some of these claimed “conceptual and methodological flaws” and other criticisms herein. A lack of response to any of the Smith Rebuttal Report’s criticisms does not constitute an agreement with any such criticisms.

The Smith Rebuttal Report also identifies what it refers to as two computational errors in the Bero Report.¹⁰ I have addressed those in my Updated Bero Report Schedules / Errata Sheet dated February 25, 2023. As such, I will not address those herein.

⁶ If the parties’ reported information is incorrect, I reserve the right to update my analyses accordingly.

⁷ Smith Rebuttal Report 12-14. As described in its footnote 15 on page 4, the Smith Rebuttal Report uses the word “reset” instead of “repair.”

⁸ Smith Rebuttal Report 14 and Table 1.

⁹ Smith Rebuttal Report 8.

¹⁰ Smith Rebuttal Report 16-17.

HIGHLY CONFIDENTIAL – ATTORNEYS’ EYES ONLY

III. The Bero Report’s inclusion of damages associated with the X/Xi EndoWrist instruments is assumed, and appears reasonable based on the evidence in the case

The Smith Rebuttal Report states:¹¹

Mr. Bero’s inclusion of sales of reset X/Xi EndoWrist instruments is speculative because, as of the date of this Report, none of the third-party companies has successfully developed a process to reset the use counter of X/Xi EndoWrist instruments.

Based on my experience, damages experts often rely on assumptions for areas outside their expertise. The Bero Report clearly notes it assumes SIS (relying on either Rebotix, Restore or another third-party technology provider) would have been able to reset the X/Xi EndoWrist instruments by various dates, and SIS, Rebotix or Restore would have been able to repair X/Xi EndoWrist instruments as of various dates.¹² The Smith Rebuttal Report ignores this.

The Smith Rebuttal Report also ignores Intuitive’s anti-competitive conduct and how it has affected the ability of third-parties to successfully develop a process to reset the use counter of X/Xi EndoWrist instruments. For example, Rebotix thought about repairing X/Xi EndoWrists as early as 2017.¹³ However, Rebotix’s ability to finance the X/Xi repair business was significantly impacted by Intuitive’s actions, which limited its S/Si sales.¹⁴ But-for Intuitive’s conduct, (assuming encryption was illegal) Rebotix believes it could have begun repairing X/Xi EndoWrists as early as 2019.¹⁵

Similarly, Restore began work on its X/Xi chips in approximately 2020,¹⁶ although its efforts were delayed by Intuitive’s anti-competitive conduct.¹⁷ Restore began funding its X/Xi reverse engineering efforts in late June 2022,¹⁸ and based on its progress as of November 2022, Restore anticipated it will have the technical ability to reset the Xi EndoWrist use counter in “the third and fourth quarter, 2023.”¹⁹ This means it will likely take Restore a little more than 1 year

¹¹ Smith Rebuttal Report 12.

¹² Bero Report 5. Based on SIS’s relationships with Rebotix / Restore prior to the Alleged Wrongdoings and discussion with Kurt Humphrey, SIS’s technical expert.

¹³ Bero Report 30. Deposition of Stan Hamilton 15 (November 4, 2022).

¹⁴ Bero Report 30. Deposition of Stan Hamilton 11-12 and 42-44 (November 4, 2022). Discussion with Chris Gibson.

¹⁵ Bero Report 30. Deposition of Stan Hamilton 15 (November 4, 2022). Discussion with Chris Gibson.

¹⁶ Bero Report 32. Deposition of Kevin May 117-118 (November 3, 2022).

¹⁷ Bero Report 32. Deposition of Kevin May 75-76 (November 3, 2022).

¹⁸ Bero Report 32. Deposition of Kevin May 40 (November 3, 2022). May Dep. Ex. 155 (Restore-00091199-206 at 199).

¹⁹ Bero Report 32. Deposition of Kevin May 60-61 (November 3, 2022).

HIGHLY CONFIDENTIAL – ATTORNEYS’ EYES ONLY

to have a marketable X/Xi. [REDACTED]

[REDACTED]

[REDACTED]

IV. The Bero Report properly analyzed the “but-for” market

The Smith Rebuttal Report states:²¹

A fundamental problem with Mr. Bero’s analysis is that he fails to consider Intuitive’s likely response to SIS’s (and any third party’s) activity in a “but-for” world where Intuitive is unable to sell the da Vinci System as an integrated product. In particular, Mr. Bero does not appear to consider the economic logic that if a firm is not free to maintain quality control and foster investment through contractual restrictions, it likely will try to achieve similar goals in less efficient ways. For example, if Intuitive were not free to protect the safety and welfare of patients, and by extension Intuitive’s reputation and financial viability, through contractual provisions, a rational response would be to change its pricing strategy to achieve as much system integration as possible (e.g., by increasing its prices for da Vinci platforms and lowering its prices for EndoWrist instruments). If Intuitive were to change its strategy to achieve a higher level of system integration in the relevant “but-for” world, it is likely that fewer customers would choose SIS’s reset EndoWrist instruments over Intuitive’s instruments than Mr. Bero assumes. [emphasis added]

A. The Smith Rebuttal Report speculates Intuitive would hypothetically increase da Vinci Surgical System pricing and lower EndoWrist instrument pricing.

The Smith Rebuttal Report provides no apparent Intuitive support or basis for this criticism. It does not cite to any Intuitive information suggesting it contemplated increasing daVinci Surgical System pricing or decreasing EndoWrist instrument pricing due to secondary market competition. Instead, it simply offers this “for example” hypothetical Intuitive response.

The Smith Report provides no support for how much Intuitive’s prices would change and whether Intuitive’s customers would be willing to pay more for da Vinci Surgical Systems. I am

²⁰ Bero Report 32. Based on discussion with Kurt Humphrey. Also, discussion with Chris Gibson.

²¹ Smith Rebuttal Report 10.

HIGHLY CONFIDENTIAL – ATTORNEYS’ EYES ONLY

not aware of any Intuitive documents that suggest Intuitive would have or reasonably could have changed its da Vinci Surgical System pricing, or how any pricing change would affect demand.

I am also not aware this was an action Intuitive considered or the consequences of taking such an action. This hypothetical also appears to run opposite to the only Intuitive document the Smith Rebuttal Report cites in its criticism, from October 1995, which states: “systems will be placed for little or no charge at sites that sign an annual minimum disposables and [Reposable Transmission Unit] purchase contract.”²²

B. The Smith Rebuttal Report’s hypothetical Intuitive pricing approach is not consistent with Intuitive’s contemplated actions

The Smith Rebuttal Report also ignores Intuitive’s documents which suggest its actual or contemplated response actions. For example, in a document titled “Unauthorized Instrument Reprogramming Overview,” Intuitive’s response includes “Trend Analysis, Educate Account, Customer Letter and Terminate Service.”²³ It makes no mention of pricing changes. Instead, this document appears to describe each action from monitoring to see if there is a trend at the customer site for use of repaired instruments to terminating a customer’s sales and service agreement.²⁴ Another Intuitive document titled “Instrument Refurbishment Update” suggests similar actions in addition to “technical opportunities to prevent reprogramming” and “advancing internal programs,”²⁵ which were apparently never pursued.

C. The Smith Rebuttal Report’s hypothetical Intuitive pricing approach fails to account for Intuitive’s identified secondary market benefits.

Another document titled “Secondary Markets” suggests Intuitive and its customers could actually benefit from secondary markets and “Increase da Vinci adoption and customer satisfaction.”²⁶ As described in the Bero Report, Intuitive contemplated what it referred to as “Project Dragon.”²⁷ Intuitive described Project Dragon as “an opportunity for our customers to have improved running costs associated with procedures. We believe a reduction in running cost

²² Smith Rebuttal Report 10, FN 26. Intuitive-00595673-694 at 682-683.

²³ Intuitive-00089767-782 at 771.

²⁴ Intuitive-00089767-782 at 771.

²⁵ Intuitive-00147262-271 at 264.

²⁶ Intuitive-00273300-330 at 301.

²⁷ Intuitive-00273300-330 at 303. Bero Report 28-29.

HIGHLY CONFIDENTIAL – ATTORNEYS’ EYES ONLY

would grow or accelerate our growth in procedures.”²⁸ However, I understand Project Dragon (and similar programs) were abandoned by Intuitive.²⁹ To the extent “running costs” were reduced, the referenced Project Dragon document suggests Intuitive believed it could have potentially sold more instruments than it otherwise did.

The Smith Rebuttal Report does not address or account for the impact or potential Intuitive benefits from secondary markets.

V. The Bero Report conservatively considered SIS costs associated with not owning “intellectual property”

The Smith Rebuttal Report criticizes the Bero Report for “potential costs” based on SIS continuing to offer its services, stating:³⁰

Setting aside Intuitive’s potential change in pricing strategy (as opposed to Mr. Bero’s implicit assumption Intuitive’s behavior would remain unchanged), Mr. Bero’s analysis **does not reflect potential costs stemming from the fact that SIS does not own the “intellectual property” associated with resetting EndoWrist instruments, particularly the chip that would be inserted into the instrument.** In his “in-house repair model,” Mr. Bero assumes that SIS would purchase the chip from Restore Robotics LLC (“Restore”) and/or Rebotix Repairs LLC (“Rebotix”). In his “distributor model,” Mr. Bero assumes that SIS would pay Restore and/or Rebotix for “repair services” that encompass the chip and labor entailed in resetting the EndoWrist instrument. [emphasis added]

The Bero Report properly (and conservatively) considered SIS’s costs. In response to the Smith Rebuttal Report’s criticism, I spoke with Chris Gibson (“Mr. Gibson”), Rebotix Repair LLC’s COO. Mr. Gibson addressed a number of topics associated with Rebotix and SIS’s relationships, SIS’s costs, and the history between the two companies. Mr. Gibson confirmed a number of items addressed in the Bero Report and also clarified that Rebotix’s sales prices to SIS under both SIS’s In-house model and SIS’s Distributor model would have been *lower* than calculated in the Bero Report. In effect, rather than understating SIS’s costs as suggested by the

²⁸ Intuitive-00103407-00103426 at 409.

²⁹ Morales 30(b)(6) Dep. Ex. 143 (Intuitive-00626597-626616 at 598). Bero Report 29.

³⁰ Smith Rebuttal Report 10-11.

HIGHLY CONFIDENTIAL – ATTORNEYS’ EYES ONLY

Smith Rebuttal Report, the Bero Report conservatively overestimated SIS’s costs (and understated lost profits). Mr. Gibson confirmed and/or provided the following information:³¹

- Rebotix stopped working with Restore because Restore wasn’t doing the volume Rebotix expected them to have.³² Rebotix set Restore up initially as a Service Center (akin to what it was going to do with SIS).
- Rebotix was interested in SIS due to its extensive customer relationships including, for example, Vizient, Inc. (“Vizient”), the largest GPO in the U.S., and Banner. Rebotix had a few direct end user relationships, however, expanding direct customer relationships was not Rebotix’s primary business model. SIS had many direct customer relationships and provided Rebotix with an ideal business partner.
- Rebotix and SIS had a strong relationship. They had an initial verbal understanding consistent with the August 22, 2019 Draft Service Center Agreement.³³
- Rebotix’s goal was to have a long-term relationship with SIS due to its national customer accounts.³⁴ Rebotix anticipated a long-term relationship supplying Interceptor chips to SIS (or, as necessary, providing repair services).³⁵
- The intended relationship all along was for SIS to provide the repairs and purchase the Interceptor chips from Rebotix (the “In-house model” described in the Bero Report). Rebotix planned to assist SIS in setting up the repair work, with the expectation that SIS would perform the repair work (i.e., the In-house model) and Rebotix could support repair work if necessary.³⁶
- Rebotix would not have licensed just its intellectual property alone to SIS or others but would have required SIS to purchase the Interceptor chip.

³¹ The following is based on discussion with Mr. Gibson. Other sources are included for certain items.

³² *See also, e.g.*, Bero Report 12.

³³ Gibson Dep. Ex. 13 (REBOTIX061127-138).

³⁴ *See also, e.g.*, Bero Report 11, 30.

³⁵ *See also, e.g.*, Bero Report 11, 30.

³⁶ *See also, e.g.*, Bero Report 11, 27, 29.

HIGHLY CONFIDENTIAL – ATTORNEYS’ EYES ONLY

- The market was excited about a third party EndoWrist (repair) supplier and there was high market demand.³⁷
- 50,000 annual SIS EndoWrist repairs annually is a low estimate.³⁸
- Rebotix “easily” had the capacity to supply 50,000 annual Interceptor chips.³⁹
- Rebotix “easily” had the capacity to supply 50,000 annual EndoWrist instrument repairs.⁴⁰
- EndoWrist repairs (or servicing) was low cost, easily trainable, straightforward and less complicated than other instrument repairs.⁴¹
- Rebotix and SIS both anticipated volume discounts.⁴²
- Volume discounts for thousands of annual units would have been greater than the \$450 Interceptor chip or repair discounts shown in the Draft January 24, 2020 Memorandum of Understanding (“Draft MOU”).⁴³
- The \$450 volume discount per Interceptor chip identified on the Draft MOU would have applied to the \$800 “not to exceed” price identified on the August 22, 2019 draft Service Center Agreement.⁴⁴
- In order to achieve the \$450 or more volume discount on Interceptor chips and/or repairs, Rebotix would have expected volumes of thousands of units annually.

³⁷ See also, e.g., Bero Report 44.

³⁸ See also, e.g., Bero Report **Schedules 2.0 and 3.0**.

³⁹ See also, e.g., Bero Report 5, 45.

⁴⁰ See also, e.g., Bero Report 45.

⁴¹ See also, e.g., Bero Report 27, 45.

⁴² See also, e.g., Bero Report 11, 30.

⁴³ Gibson Dep. Ex. 14 (REBOTIX067735-737). I understand Mr. Gibson testified in his deposition that Rebotix never would have agreed to the Draft MOU (Deposition of Chris Gibson 164-167 (June 22, 2021) (*Rebotix Repair LLC v. Intuitive Surgical, Inc.*, No. 8:20-cv-02274-VMC-TGW (M.D. Fla. filed Sept. 28, 2020))). Based on discussion with Chris Gibson, this is due to two issues. First, and primarily, Rebotix was intent on protecting its Intellectual Property. It would not have licensed its Intellectual Property to SIS after SIS purchased just 300 units. Second, the volume discounts shown appear to have been based on cumulative total combined Interceptor and repair units. Rebotix would not have agreed to a \$450 volume discount after having sold just 300 combined Interceptor and repair units. However, to the extent SIS purchased 300 Interceptor chips (and/or repairs) per order or SIS purchased thousands of Interceptor chips (and/or repairs) annually, Rebotix would have agreed to the \$450 volume discount or more.

⁴⁴ See also, e.g., Bero Report 11. Gibson Dep. Ex. 13 (REBOTIX061127-138) and Gibson Dep. Ex. 14 (REBOTIX067735-737).

HIGHLY CONFIDENTIAL – ATTORNEYS’ EYES ONLY

- The Interceptor chip prices (i.e., SIS costs) would have been, at most, the net \$350 cost (i.e., \$800 less the \$450 volume discount).⁴⁵
- Rebotix’s Interceptor chip prices (net of volume discounts) would have likely been less than \$350 per chip to SIS. They would have likely been \$200 to \$300 per unit at SIS purchase volumes approaching 50,000 annual units (i.e., Interceptor chips and/or repairs combined). The corresponding volume discounts would have been \$500 to \$600 (i.e., \$800 less \$600 volume discount = \$200 Interceptor chip price to SIS).
- While the intention was for SIS to provide repair services (rather than Rebotix), Rebotix repair prices would have similarly been discounted to SIS for volume (i.e., Distributor model). Volume discounts would have applied to the distributor price lists.⁴⁶
- Rebotix repair prices would have been volume discounted for at least as much as the \$450 volume discount per repair identified on the Draft MOU.⁴⁷
- Rebotix’s repair prices (i.e., SIS costs) net of the \$450 per unit volume discount equates to approximately \$590 over time and is reasonable.⁴⁸
- Technicians could achieve a minimum of 10 to 15 repairs per 8-hour shift with no support, and 20 to 25 repairs per 8-hour shift with clerical administrative support.⁴⁹

⁴⁵ **Second Rebuttal Schedule 10.0.** This Rebotix price (i.e., SIS’s cost) is significantly less than the conservative \$533 Interceptor prices (i.e., SIS’s costs) used in the Bero Report. See also **Second Rebuttal Schedules 2.1, 4.1 and 4.4.**

⁴⁶ SIS000047-49. REBOTIX162208-162212 at 212.

⁴⁷ Gibson Dep. Ex. 14 (REBOTIX067735-737). I understand Mr. Gibson testified in his deposition that Rebotix never would have agreed to the Draft MOU (Deposition of Chris Gibson 164-167 (June 22, 2021) (*Rebotix Repair LLC v. Intuitive Surgical, Inc.*, No. 8:20-cv-02274-VMC-TGW (M.D. Fla. filed Sept. 28, 2020))). Based on discussion with Chris Gibson, this is due to two issues. First, and primarily, Rebotix was intent on protecting its Intellectual Property. It would not have licensed its Intellectual Property to SIS after SIS purchased just 300 units. Second, the volume discounts shown appear to have been based on cumulative total combined Interceptor and repair units. Rebotix would not have agreed to a \$450 volume discount after having sold just 300 combined Interceptor and repair units. However, to the extent SIS purchased 300 Interceptor chips (and/or repairs) per order or SIS purchased thousands of Interceptor chips (and/or repairs) annually, Rebotix would have agreed to the \$450 volume discount or more. SIS000047-49. REBOTIX162208-162212 at 212. Second Rebuttal Report **Schedules 12.0 and 12.1.**

⁴⁸ **Second Rebuttal Schedules 3.1, 5.1 and 5.3.** Note this Rebotix price (i.e., SIS’s cost) is significantly less than the conservative approximate \$1,040 Interceptor prices (i.e., SIS’s costs) without any discounts used in the Bero Report. See Bero Report **Schedules 3.1, 5.1 and 5.3.**

⁴⁹ See also, e.g., Bero Report 45.

HIGHLY CONFIDENTIAL – ATTORNEYS’ EYES ONLY

- Rebotix put its X/Xi Interceptor chip development on hold due to Intuitive’s market disruptions. It stopped development for approximately two years.
- Assuming the X/Xi encryption had not changed from the S/Si, Rebotix had the expectation (without Intuitive’s market disruptions) to be able to provide Interceptor chips (and/or repair services) for the X/Xi by sometime in 2019.⁵⁰
- Assuming the X/Xi encryption was legal (i.e., changed as it was from the S/Si), Rebotix likely would have otherwise (without Intuitive’s market disruptions) reasonably been able to provide Interceptor chips (and/or repair services) for the X/Xi EndoWrist instruments by January 1, 2021.⁵¹

A. Incorporating SIS’s costs based on Rebotix’s expected selling prices to SIS results in higher lost profits as shown on Second Rebuttal Schedule 1.0.

Accounting for the expected Rebotix prices (i.e., SIS’s costs) and volume discounts results in higher SIS lost profits. Accordingly, I have updated my lost profits calculations based on these lower SIS costs.

For the In-house model, I use the \$350 (i.e., \$800 less \$450 volume discount) Interceptor price (i.e., SIS’s cost) per unit rather than the initial conservative \$533 cost as addressed above. As noted, at higher volumes, the Interceptor price (i.e., SIS’s costs) would have likely been lower, at approximately \$200 to \$300 per unit. Again, this In-house model was the intended and planned for relationship between Rebotix and SIS.

For the Distributor model, I use the approximate \$590 (i.e., approximately \$1,040 less \$450 discount) repair service price (i.e., SIS’s cost) per unit rather than the initial conservative approximate \$1,040 costs as addressed above. **Table 1** below shows my updated damages summary.⁵²

⁵⁰ See also, e.g., Bero Report 5, 30, 46.

⁵¹ See also, e.g., Bero Report 5, 31-32, 57-58.

⁵² **Second Rebuttal Schedule 1.0.**

HIGHLY CONFIDENTIAL – ATTORNEYS’ EYES ONLY

Table 1: Damages Summary

	Scenario 1		Scenario 2	
<u>Discounted lost profits</u>				
In-house model	\$131,382,634		\$71,856,681 to	\$103,159,956
Distributor model	\$116,476,660		\$63,572,049 to	\$91,324,868
Lanham Act			\$258,367,896 to	\$371,219,363

VI. The Bero Report properly considered SIS’s relationships with Rebotix (and Restore)

The Smith Rebuttal Report states:⁵³

The fact that SIS does not own any “intellectual property” could impact Mr. Bero’s analysis in multiple ways. First, SIS faces risk that **Rebotix or Restore could increase the amount they charge SIS** for the chip/reset services, which would raise SIS’s costs and reduce profits. Second, **Rebotix and/or Restore may license their “intellectual property” with additional distributors**; this could limit SIS’s potential customers or introduce new competitors to SIS. Third, **Rebotix and/or Restore could cut off SIS entirely from reset “services”**; fluctuations in supply of the chips would also potentially harm SIS’s business in selling reset EndoWrist instruments. Although contracts or agreements may help to address these issues, I am not aware of an executed agreement between SIS and Rebotix or between SIS and Restore concerning reset “services.” [emphasis added]

A. The Smith Rebuttal Report speculates on what Rebotix or Restore “could” or “may” have done.

This critique includes hypotheticals about what “could” or “may” have happened since SIS does not own any intellectual property related to EndoWrist repair. These hypotheticals are speculative and unsupported. They are also inconsistent with at least SIS’s relationship with Rebotix.

⁵³ Smith Rebuttal Report 11-12.

HIGHLY CONFIDENTIAL – ATTORNEYS’ EYES ONLY

B. The Smith Rebuttal Report fails to account for SIS’s vendor/customer relationships.

The August 22, 2019 Draft Service Center Agreement specifically defines SIS as being “engaged in the sale and marketing of medical products.”⁵⁴ As noted above, Rebotix was interested in SIS due to its extensive customer relationships including, for example, Vizient and Banner.⁵⁵ The Smith Rebuttal Report fails to account for SIS’s relationships.

The Smith Rebuttal Report ignores that SIS hosted a February 2020 repairs meeting at its Glendale Heights facility⁵⁶ that was attended by multiple representatives of a large hospital system with tens of millions of dollars in annual EndoWrist costs.⁵⁷ The attendees discussed SIS performing repairs of EndoWrists, i.e., with third parties such as Rebotix providing the updated chip and SIS performing the underlying repairs at its facilities.⁵⁸

The Smith Rebuttal Report further ignores that SIS and Vizient, the largest GPO in the U.S., had a relationship dating back to at least 2016, when the parties signed a Supplier Services Agreement for instrument repairs that was effective September 1, 2016.⁵⁹ In September 2019, SIS and Vizient signed an Agreement Amendment specific to EndoWrist repairs.⁶⁰ This Amended Agreement addressed SIS’s intention to repair EndoWrist products, and was for 38 EndoWrist products.⁶¹ The timing of this Amended Agreement also coincided with Vizient’s interest in SIS’s EndoWrist repair business and the meetings it helped set up with its members.⁶² I understand SIS had the customers and relationships Rebotix and Restore desired, including access to Vizient.⁶³ As described in the Bero Report, Rebotix had stopped working with ReStore because Restore wasn’t doing the volume Rebotix expected them to have.⁶⁴

⁵⁴ REBOTIX061127-138 at 128.

⁵⁵ Discussion with Chris Gibson.

⁵⁶ Bero Report 27. Plaintiff’s Response to Intuitive’s Interrogatory No. 5 (August 8, 2022).

⁵⁷ Bero Report 27. Plaintiff’s Response to Intuitive’s Interrogatory No. 5 (August 8, 2022).

⁵⁸ Bero Report 27. Plaintiff’s Response to Intuitive’s Interrogatory No. 5 (August 8, 2022).

⁵⁹ Bero Report 33-34. SIS330591-330634.

⁶⁰ Bero Report 34. SIS0000047-0000049.

⁶¹ Bero Report 34. SIS0000047-0000049. Discussion with Keith Johnson.

⁶² Bero Report 34. Discussion with Keith Johnson.

⁶³ Discussion with Keith Johnson.

⁶⁴ Bero Report 12. Deposition of Chris Gibson 145-146 (June 22, 2021) (*Rebotix Repair LLC v. Intuitive Surgical, Inc.*, No. 8:20-cv-02274-VMC-TGW (M.D. Fla. filed Sept. 28, 2020)). Also, discussions with Keith Johnson and Chris Gibson.

HIGHLY CONFIDENTIAL – ATTORNEYS’ EYES ONLY

C. Rebotix’s goal was a long-term relationship with SIS due to its national customer accounts

Rebotix had no intention to ‘cut off’ or license its intellectual property to others.⁶⁵ Rather, Rebotix’s goal was to have a long-term relationship with SIS due to its national customer accounts.⁶⁶ Rebotix anticipated a long-term relationship supplying Interceptor chips to SIS (or, as necessary, providing repair services).⁶⁷

VII. The Bero Report’s market penetration rate is reasonable and appropriate

The Smith Rebuttal Report states:⁶⁸

Mr. Bero’s final “market penetration” rate (i.e., SIS’s share of total sales of S/Si and X/Xi EndoWrist instruments eligible for reset “services”) is 2 to 12 percent. Mr. Bero compares his “market penetration” rates with three “benchmarks,” claiming they show that his rates “appear [] reasonable relative to other available data.

A. The Smith Rebuttal Report seems to (misleadingly) suggest the Bero Report’s penetration rates (i.e., 2% to 12%) are reliant on three purported “benchmarks”

The Bero Report details the many factors and facts accounted for in projecting the 2% to 12% penetration rates (2% in 2020, 8% in 2021 and 12% in 2022).⁶⁹ Those factors include EndoWrist instruments potentially repairable by SIS, the expiration rate of EndoWrist instruments, market share access (based solely on Vizient market share and not including any of SIS’s other customers or potential customers), the conversion rate of Vizient customers to sign up for the program, the collection rate of converted customers to use the SIS repair program, and the yield rate of collected EndoWrist instruments to be repairable.⁷⁰

The analysis results in SIS repairing an estimated approximate 8,000 EndoWrist instruments in 2020 and up to a maximum of approximately 47,000 EndoWrist instruments in 2023.⁷¹ As described above, according to Chris Gibson, this estimate is low.⁷²

⁶⁵ Discussion with Chris Gibson.

⁶⁶ Discussion with Chris Gibson.

⁶⁷ Discussion with Chris Gibson.

⁶⁸ Smith Rebuttal Report 19.

⁶⁹ See, e.g., Bero Report 47-52.

⁷⁰ See, e.g., Bero Report 47-52.

⁷¹ Bero Report **Schedules 2.0 and 3.0**.

⁷² Discussion with Chris Gibson.

HIGHLY CONFIDENTIAL – ATTORNEYS’ EYES ONLY

The Bero Report compared the penetration rates (i.e., 2% to 12%) developed and underlying the approximate 8,000 to 47,000 annual units to other available comparative data. There were three known sources. The Smith Rebuttal Report refers to these as “benchmarks” implying the Bero Report is reliant on these three comparisons.⁷³ It is not. The Bero Report explicitly lays out the analysis as addressed on pages 47-52 (and noted above) accounting for the numerous relevant factors. The Bero Report simply notes the estimated penetration rates (i.e., 2% to 12%) appear reasonable relative to the other available data.

B. The Bero Report’s 2% to 12% penetration rates appear reasonable relative to Intuitive’s August 2019 estimated 41% to 50% penetration rate

The Smith Rebuttal Report states:⁷⁴

The first of Mr. Bero’s “benchmarks” comes from a 2019 Intuitive presentation that considers “potential Xi refurbishment and **estimated penetration of approximately 41 percent or 50 percent.**” However, Mr. Bero’s reliance on Intuitive’s internal projections to estimate SIS’s “market penetration” rate for the never-initiated instrument refurbishment service is inappropriate for three reasons. He ignores critical components of Intuitive’s calculation: Intuitive’s status as the original equipment manufacturer, and whether Intuitive’s instrument refurbishment procedure was more robust than SIS’s procedure to reset the use counter. First, customers likely would prefer to have the original equipment manufacturer, Intuitive, refurbish an EndoWrist instrument (which Intuitive designed, developed, and manufactured) rather than a third party. Second, Intuitive’s assessment of “[Instrument] Refurbishment Feasibility” contemplated that Intuitive would replace significant portions of the instruments (including the cables, inputs and flush tube) to “survive [additional] lives.” SIS, on the other hand, does not replace any instrument components. Hence, Intuitive’s internal projections of a “penetration rate” are likely to be higher than that which SIS could achieve because SIS does not have Intuitive’s reputation or status as the original equipment manufacturer, nor does SIS replace instrument components. [emphasis added]

⁷³ Smith Rebuttal Report 19-24.

⁷⁴ Smith Rebuttal Report 20-21.

HIGHLY CONFIDENTIAL – ATTORNEYS’ EYES ONLY

Despite the Smith Rebuttal Report’s reference to differences between Intuitive and SIS, the fact remains the Bero Report’s estimated penetration rates are a fraction of Intuitive’s estimated 41% to 50% penetration rates.

C. The Bero Report’s 2% to 12% penetration rates appear reasonable relative to Stryker’s 8.5% to 9% expected penetration rates

The Smith Rebuttal Report states:⁷⁵

Regarding the penetration rate in the Stryker models, **Mr. Bero offers little discussion as to the extent to which Stryker’s forecasts are reliable proxies for SIS**, which does not own the “intellectual property” behind the process to reset the use counters for S/Si EndoWrist instruments, or for the period after 2019. Mr. Bero also does not explain why the discussions between Stryker and Rebotix LLC dissolved, and comments in the models suggest that the models would be subject to change with additional information. Stryker abandoned the contemplated transaction for a company separate from SIS, and the forecasts were developed over five years ago in 2016. **Hence, the assumptions of the Stryker financial models are unreliable as “benchmarks” for Mr. Bero’s damages analysis.** [emphasis added]

The Smith Rebuttal Report appears to (misleadingly) suggest the Bero Report’s penetration rate analysis is somehow based on the Stryker penetration rates. It is not.

As described in the Bero Report, in 2016, Rebotix and Stryker had discussions about Stryker purchasing Rebotix.⁷⁶ I understand Stryker ultimately stopped pursuing an acquisition of Rebotix because of a legal opinion that had nothing to do with Rebotix’s technology.⁷⁷ In 2020, I understand Stryker again considered working with Rebotix on EndoWrists, but ultimately stopped pursuing it because of Covid-19.⁷⁸

Regardless, the 8.5% to 9% Stryker penetration rates are reasonably comparable to the Bero Report’s 2% to 12% penetration rates.

⁷⁵ Smith Rebuttal Report 21-22.

⁷⁶ Bero Report 53. Deposition of Stan Hamilton 35-39 and 126 (June 4, 2021) (*Rebotix Repair LLC v. Intuitive Surgical, Inc.*, No. 8:20-cv-02274-VMC-TGW (M.D. Fla. filed Sept. 28, 2020)).

⁷⁷ Deposition of Stan Hamilton 48 (June 4, 2021) (*Rebotix Repair LLC v. Intuitive Surgical, Inc.*, No. 8:20-cv-02274-VMC-TGW (M.D. Fla. filed Sept. 28, 2020)).

⁷⁸ Deposition of David Fabricant 109-114 (November 8, 2022).

HIGHLY CONFIDENTIAL – ATTORNEYS’ EYES ONLY

D. The Bero Report’s 2% to 12% penetration rates appear reasonable relative to Deutsche Bank’s 4% to 6% penetration rates

The Smith Rebuttal Report states:⁷⁹

Regarding the penetration rate in the Deutsche Bank analyst report, **the report offers no specific sources for its assumptions: the “4 to 6 percent capture rate” proposed by the report was apparently based on “conversations with surgeon and hospital customers.”** Citing to the report’s claim that “each instrument could be repaired three times,” Mr. Bero notes that the penetration rate would be three times higher (12 to 18 percent). In fact, one of Mr. Bero’s own citations contradicts the “three repairs per instrument” assumption: in a 2019 Intuitive internal presentation that Mr. Bero references, Intuitive assumes for its own modeling that “Xi instruments can only be refurbished once.” Rebotix’s own purported testing of the number of uses for EndoWrist instruments has not exceeded 29 uses, which would translate to two resets. Additionally, Iconocare’s 510(k) clearance for resetting Si EndoWrists—the only clearance for resetting I am aware of—is limited to one reset. **As with his second “benchmark”, Mr. Bero’s third “benchmark” lacks reliable support.** [emphasis added]

The Smith Rebuttal Report appears to (again misleadingly) suggest the Bero Report’s penetration rate analysis is somehow based on the Deutsche Bank penetration rates. It is not.

Regardless, the Deutsche Bank’s 4% to 6% penetration rates are reasonably comparable to the Bero Report’s 2% to 12% penetration rates. If the Bero Report incorporated an assumption EndoWrist’s could be reset more than once, the Bero Report’s penetration rates would, if anything, have been higher.

E. The Smith Rebuttal Report’s reference to Vizient, if anything, highlights the Bero Report’s conservative penetration rates

The Smith Rebuttal Report states:⁸⁰

In Mr. Bero’s “but-for” world, SIS would capture at most 11.6 percent of the total market for resettable EndoWrist instruments although SIS only provides “service” to hospitals in Vizient’s network. For Mr. Bero’s estimate of SIS’s “market penetration” rate to be in line with his “benchmarks” (as Mr. Bero asserts), there

⁷⁹ Smith Rebuttal Report 22-23.

⁸⁰ Smith Rebuttal Report 23-24.

HIGHLY CONFIDENTIAL – ATTORNEYS’ EYES ONLY

would have to be little to no sales of reset EndoWrist instruments outside of SIS’s sales to hospitals in Vizient’s network. **If SIS itself can achieve an overall “market penetration” rate of 11.6 percent when it has access to only 55 percent of resettable EndoWrist instruments, then— under the assumption that the number of reset EndoWrist units per hospital is the same among Vizient and non-Vizient hospitals—the overall “market penetration” rate would be equal to SIS’s assumed “penetration rate” within Vizient hospitals—21.2 percent.** This value is higher than even the upper end of the estimate in the Deutsche Bank report assuming three resets per instrument (12 percent to 18 percent) and more than double the upper end of Stryker’s estimate (8.5 to 9.0 percent). [emphasis added]

If anything, this highlights the conservative nature of the Bero Report’s penetration rates. The Bero Report’s analysis does not include non-Vizient customers.⁸¹ Vizient represents a 55% market share.⁸² GPO’s and hospital systems’ interest in SIS’s repair program was “monumental.”⁸³ SIS had also presented and generated interest with hospital systems beyond Vizient healthcare providers.⁸⁴ As the Smith Rebuttal Report notes, including non-Vizient hospitals would have resulted in an overall market penetration of 21.2%.⁸⁵

To the extent non-Vizient hospital / customers were included in the Bero Report’s analysis, the penetration rates would have been higher resulting in higher lost profits.

F. The Bero Report’s 60% expiration rate is reasonable

The Smith Rebuttal Report criticizes the Bero Report’s use of 60% expiration rate, suggesting a lower (unexplained) 50% rate.⁸⁶ The Smith Rebuttal Report states:⁸⁷

By focusing on the “top 5” X/Xi instruments to calculate his expiration rate and applying that rate across all EndoWrist instruments in his analysis, Mr. Bero uses an aggressive expiration rate that inflates his damages estimate when a more appropriate alternative is available within the source that he relies on. Mr. Bero acknowledges that the “Top 5” instruments account for a disproportionately high share of expired core instruments. To the

⁸¹ Bero Report 49-50.

⁸² Bero Report 49-50.

⁸³ Bero Report 24. Also, for example, discussion with Chris Gibson.

⁸⁴ Bero Report 23-25, 50

⁸⁵ Smith Rebuttal Report 23.

⁸⁶ Smith Rebuttal Report 25.

⁸⁷ Smith Rebuttal Report 25.

HIGHLY CONFIDENTIAL – ATTORNEYS’ EYES ONLY

extent that the “Top 5” instruments are used more frequently than other EndoWrist instruments, one may expect that the expiration rate for these instruments would be relatively higher than the overall expiration rate across all instruments. Indeed, when I calculate the expiration rate of X/Xi core instruments (not exclusive to the “top 5”) using Mr. Bero’s methodology, I find that the expiration rate would be 50 percent instead of 60 percent. [emphasis added]

Using a 60% expiration rate is reasonable. As noted in the Bero Report, and as shown on Bero Report **Schedule 7.0**, the estimated expiration rate for the Top 5 instruments increased from approximately 60% in 2018 to approximately 74% in 2021. These Top 5 instruments are shown on Morales Dep. Exhibit 141 (Intuitive-00603992) and are repairable by SIS.⁸⁸ As also shown on Bero Report **Schedule 7.0**, the estimated expiration rates from 2018 through 2021 suggest an expiration rate higher than 60%.

To support its claim the expiration rate should be 50%, the Smith Rebuttal Report relies on its calculation of the expiration rate for the approximate 15 X/Xi “core” instruments.⁸⁹ However, the basis for this calculation is not clear. Morales Dep. Exhibit 141 (Intuitive-00603992) indicates approximately 105,000 and 143,000 expired “core” instruments in 2018 and 2019, respectively, for a total of approximately 248,000 expired “core” instruments. The Smith Rebuttal Report indicates it divided this approximate 248,000 expired “core” instrument units “by the number of Intuitive 2018-2019 sales of core instruments identified in the same exhibit.”⁹⁰

My team and I have reviewed Morales Dep. Exhibit 141 (Intuitive-00603992) and the Smith Rebuttal Report’s identified workpapers and have been unable to determine where or how its 2018 and 2019 X/Xi total sales of expired “core” instrument was derived. One Smith Rebuttal Report workpaper indicates approximately 208,000 and 288,000 X/Xi “core” instruments were sold in 2018 and 2019, respectively, for a total of 496,000 in combined “core” instruments sold.⁹¹ However, the underlying data appears to be inaccessible. The 2018 and 2019 unit sales of X/Xi “core” instruments the Smith Rebuttal Report appears to rely on are higher

⁸⁸ SIS000047-49.

⁸⁹ Smith Rebuttal Report 25-26 and FN 84. *See also*, Morales Dep. 41-43.

⁹⁰ Smith Rebuttal Report 26 FN 84.

⁹¹ Smith Rebuttal Report Workpaper “Bero Sensitivities” at tab “Core Instrument Expiration.”

HIGHLY CONFIDENTIAL – ATTORNEYS’ EYES ONLY

than Intuitive’s 2018 and 2019 unit sales of 189,000 and 266,000, respectively, for the relevant 38 instruments SIS can repair.⁹²

The Smith Rebuttal Report does not identify what constitutes the approximate 15 X/Xi “core” instruments, Morales Dep. Exhibit 141 (Intuitive-00603992) does not appear to indicate or describe the 15 X/Xi “core” instruments and it is not apparent how many of these approximate 15 X/Xi “core” instruments SIS can repair.

G. The Bero Report’s conversion rates of 15% in Year 1, 50% in Year 2, and 70% in Year 3 appear reasonable

The Smith Rebuttal Report states:⁹³

Mr. Bero estimates that up to 70 percent of Vizient’s members will “convert” to SIS repair” services and relies on the expert opinions of Jean Sargent. Ms. Sargent’s assessment is based on her industry “experience with Vizient and other GPOs,” and she does not cite to independent sources or present corroborating evidence to support her claim. [emphasis added]

The Smith Rebuttal Report makes no mention and provides no support for any alternative conversion rates. The Bero Report uses conversion rates of 15% in Year 1, 50% in Year 2 and 70% in Year 3.⁹⁴ Based on my experience, damage experts often rely on other experts for opinions and knowledge outside the damages expert’s area of expertise. The Bero Report clearly states it relies on SIS’s industry expert, Jean Sargent, for the conversion rates.⁹⁵ The 70% is also consistent with the testimony of Restore’s CEO, who testified he expected “70 to 80 plus percent” of hospitals would have used its services to repair EndoWrists.⁹⁶ To the extent the higher 80% or more conversion rates were included in the Bero Report’s analysis, the penetration rates would have been higher resulting in higher lost profits.

⁹² **Second Rebuttal Schedule 13.0.**

⁹³ Smith Rebuttal Report 26.

⁹⁴ Bero Report 50-51.

⁹⁵ Bero Report 50-51.

⁹⁶ Bero Report 31. Deposition of Clifton Parker 166-167 (October 25, 2022).

HIGHLY CONFIDENTIAL – ATTORNEYS’ EYES ONLY

H. The Bero Reports assumption FDA approval was not needed appears reasonable.

The Smith Rebuttal Report states:⁹⁷

...without 510(k) clearance from the Food and Drug Administration (“FDA”), hospitals and surgeons would be reluctant (or potentially unwilling) to use SIS’s reset “services.” For example, hospital administrators at Valley Medical Center, Larkin Community Hospital, and Franciscan Alliance stated that their hospitals do not purchase medical equipment that required FDA clearance and did not have it. Surgeon testimony also confirms that they expect that the medical devices that they use in surgery to have been cleared by the FDA. **Neither Mr. Bero nor Ms. Sargent discuss how FDA clearance would factor into the decisions of hospitals to purchase and surgeons to use SIS’s reset EndoWrist instruments, which would affect Mr. Bero’s assumed “conversion rate.”** [emphasis added]

As noted earlier, based on my experience, damages experts often rely on assumptions for areas outside their expertise. The Bero Report clearly states it assumes SIS would not need FDA approval to make the EndoWrist repairs at issue (citing discussions with Keith Johnson and Greg Posdal and the Deposition of Imron Zafar (November 1, 2022) Ex. 113 at 3).⁹⁸

I. The Bero Report’s collection rate of 70% is reasonable

The Smith Rebuttal Report states:⁹⁹

Mr. Bero uses a collection rate of 70 percent based on an Intuitive presentation in 2020 that reports results from a “small scale” pilot refurbishment program for 6 Xi instruments. However, the number that Mr. Bero relies on is Intuitive’s target collection rate; in its own financial analysis, **Intuitive assumed a collection rate of 40 percent**, which more closely aligns with the realized collection rates from the pilot program. Todd Tourand, Intuitive’s Director of Portfolio Management, cited low yield from collection efforts as one of the reasons Intuitive did not pursue the refurbishment program commercially beyond the pilot. Intuitive consistently assumed a 40 percent collection rate in its 2020 “Reclamation and Refurbishment

⁹⁷ Smith Rebuttal Report 26-27.

⁹⁸ Bero Report 5. Discussions with Keith Johnson and Greg Posdal. *See also*, Deposition of Imron Zafar (November 1, 2022) Ex. 113 at 3.

⁹⁹ Smith Rebuttal Report 28.

HIGHLY CONFIDENTIAL – ATTORNEYS’ EYES ONLY

Cost” models that were developed during the pilot. [emphasis added]

The Smith Rebuttal Report ignores the Bero Report’s reference to SIS’s industry expert, Jean Sargent. Ms. Sargent noted a higher 75% collection rate would be reasonable for an expensive instrument such as the EndoWrist.¹⁰⁰ Intuitive targeted a greater than 70% collection rate for its contemplated EndoWrist refurbishment program in a September 2020 document.¹⁰¹

The Expert Report of Jean Sargent (“Sargent Report”) states:¹⁰²

Given the ease of this collection process *and what I understand to be the substantial per-instrument cost savings of 40% or more, this collection process would likely be at the high end of general industry collection rates for instrument repairs, which in my experience would be approximately 75%.* [emphasis added]

The Pilot Study targeted a collection rate of greater than 70%.¹⁰³ The Pilot Study’s collection rate is later assumed to be 40%.¹⁰⁴ However, the Pilot Study appeared to focus on Intuitive’s ability to save costs on EndoWrist instruments,¹⁰⁵ versus addressing the “monumental” market interest (by Intuitive customers) for lower priced EndoWrist instruments.¹⁰⁶ In contrast to SIS providing substantial cost savings to hospitals, the Pilot Study’s participants received “no financial incentives.”¹⁰⁷ Of the 17 hospitals approached to participate, only 3 sites actually participated.¹⁰⁸ The Pilot Study also recognized that “Potential for 3rd party collections is more effective/efficient; can up yields with training.”¹⁰⁹

As described in the Bero Report, SIS has 50 years of experience servicing surgical instruments and equipment¹¹⁰ and “the interest in saving and reducing costs on robotic surgery in

¹⁰⁰ Bero Report 51. Discussion with Jean Sargent.

¹⁰¹ Bero Report 51. 30(b)(6) Deposition of Colin Morales (November 1, 2022) at Ex. 143 (Intuitive 00626597-626616 at 604).

¹⁰² Sargent Report 18.

¹⁰³ Morales 30(b)(6) Dep. Ex. 143 (Intuitive-00626597-626616 at 604).

¹⁰⁴ Morales 30(b)(6) Dep. Ex. 143 (Intuitive-00626597-626616 at 603).

¹⁰⁵ See, e.g., Morales 30(b)(6) Dep. Ex. 143 (Intuitive-00626597-626616 at 610-613).

¹⁰⁶ Bero Report 24-25.

¹⁰⁷ Morales 30(b)(6) Dep. Ex. 143 (Intuitive-00626597-626616 at 603).

¹⁰⁸ Morales 30(b)(6) Dep. Ex. 143 (Intuitive-00626597-626616 at 603).

¹⁰⁹ Morales 30(b)(6) Dep. Ex. 143 (Intuitive-00626597-626616 at 604).

¹¹⁰ Bero Report 7. Compl. ¶ 1.

HIGHLY CONFIDENTIAL – ATTORNEYS’ EYES ONLY

the industry is something I’ve never seen before in my 25 years of being in the surgical business.”¹¹¹

The Smith Rebuttal Report reduces the 70% collection rate used in the Bero Report to 40% in its Tables 3 (lost profits damages) and Table 4 (Lanham Act damages) to reflect what it refers to as Intuitive’s “assumed” 40 percent collection rate.¹¹² For the reasons described herein and since a 70% collection rate appears reasonable, I disagree with these adjustments.

VIII. The Bero Report’s Disgorgement Damages pertaining to SIS’s claims under the Lanham Act are appropriate.

The Smith Rebuttal Report states:¹¹³

I understand that Mr. Bero’s Lanham Act claim is based on one letter sent to Marin General Hospital by Intuitive regarding its utilization of a third-party reset service. However, Mr. Bero does not offer a disgorgement amount associated with sales to only that customer. Instead, he claims that all of the instrument resets included in his lost profits damages calculation also represent disgorgement damages for Intuitive. Mr. Bero provides no explanation of how that single letter that allegedly included a false claim would cause all of SIS’s past and future lost sales, which seems entirely inconsistent with the assumptions of his lost profits analysis. That is, Mr. Bero assumes that SIS’s lost profits were caused by instrument encryption and provisions in Intuitive’s contracts with hospitals, but they also all were caused by a letter to a single hospital. [emphasis added]

The Smith Rebuttal Report fails to acknowledge the Lanham Act allegations in the Complaint.¹¹⁴ It fails to acknowledge the Bero Report’s description of the Alleged Wrongdoings,¹¹⁵ Disgorgement analysis,¹¹⁶ or its use of and reliance on the Marin General Hospital letter.¹¹⁷

¹¹¹ Bero Report 25. 30(b)(6) Deposition of Keith Johnson 44 (October 27, 2022).

¹¹² Smith Rebuttal Report 29-32.

¹¹³ Smith Rebuttal Report 31.

¹¹⁴ Complaint ¶¶ 122-126.

¹¹⁵ Bero Report 1-2.

¹¹⁶ Bero Report 1, 4, 5, 58.

¹¹⁷ Bero Report 59.

HIGHLY CONFIDENTIAL – ATTORNEYS’ EYES ONLY

A. The Smith Rebuttal Report apparently is unaware of the Lanham Act allegations in the Complaint

The Complaint’s disgorgement damages allegations under the Lanham Act is not simply based on one letter sent to Marin General Hospital. Rather, the Complaint alleges:¹¹⁸

122. SIS incorporates all of the above paragraphs as though fully set forth herein.

123. Intuitive, in connection with the sale of its EndoWrist instruments, asserted false or misleading descriptions of facts or representations in its correspondence with its and SIS’s customers and such misrepresentations were likely to cause consumer confusion or inaccurately describe the nature, characteristics, or qualities of its and SIS’s commercial activities in violation of Section 43 of the Lanham Act, 15 U.S.C. § 1125

124. Intuitive has at least misrepresented that SIS’s services are contrary to FDA approvals of the EndoWrist products and are in violation of intellectual property rights. Intuitive sent such correspondence to multiple SIS customers and potential customers. Intuitive made such statements knowingly, willfully, and/or recklessly that such statements were misleading. These misleading statements affected the purchasing decisions of such customers

125. Intuitive’s misrepresentations were made to SIS’s customers, and upon information and belief, a significant number of Intuitive customers that have, or had, Intuitive Si robots [emphasis added]

The Bero Report describes the Alleged Wrongdoing in three paragraphs on the first two pages of the Bero Report.¹¹⁹ The Bero Report cites the Marin General Hospital letter to support the date the Lanham Act damages should begin, rather than limiting disgorgement damages only to Marin General Hospital as the Smith Rebuttal Report proposes.¹²⁰ As the Bero Report makes clear, I was asked to calculate disgorgement of Intuitive’s profits under the Lanham Act based on the lost SIS repair units underlying Scenario 2 – Unenforceable Contracts lost profits.¹²¹

¹¹⁸ Complaint ¶¶ 122-125.

¹¹⁹ Bero Report 1-2.

¹²⁰ Bero Report 59.

¹²¹ Bero Report 1, 4, 5, 58.

HIGHLY CONFIDENTIAL – ATTORNEYS’ EYES ONLY

The Smith Rebuttal Report, however, apparently is unaware of the Complaint’s Lanham Act allegations, the Bero Report’s description of the Alleged Wrongdoings, or the Bero Report’s use of and reliance on the Marin General Hospital letter.

IX. The Smith Rebuttal Report makes unsupported deductions in its Lanham Act analyses.

The Smith Rebuttal Report makes no reference to the Lanham Act. It does not cite the Lanham Act as “Materials Considered” in its Exhibit B.

As described in the Bero Report, under the Lanham Act, I understand a plaintiff is entitled to recover:¹²²

...(1) **defendant’s profits**, (2) any damages sustained by the plaintiff, and (3) the costs of the action. The court shall assess such profits and damages or cause the same to be assessed under its direction. **In assessing profits the plaintiff shall be required to prove defendant’s sales only; defendant must prove all elements of cost or deduction claimed.** In assessing damages the court may enter judgment, according to the circumstances of the case, for any sum above the amount found as actual damages, not exceeding three times such amount. If the court shall find that the amount of the recovery based on profits is either inadequate or excessive the court may in its discretion enter judgment for such sum as the court shall find to be just, according to the circumstances of the case. Such sum in either of the above circumstances shall constitute compensation and not a penalty. The court in exceptional cases may award reasonable attorney fees to the prevailing party. [emphasis added]

As noted in the Bero Report, Intuitive’s profits that SIS would be entitled to under the Lanham Act are Intuitive’s sales on the Scenario 2 – Unenforceable Contracts. I understand, per above (and consistent with my experience), it is the defendant’s burden to prove its costs or deductions to those sales.

¹²² 15 USC 1117: Recovery for violation of rights; (a) Profits; damages and costs; attorney fees (house.gov). Bero Report 58.

HIGHLY CONFIDENTIAL – ATTORNEYS’ EYES ONLY

A. The Smith Rebuttal Report primarily reduces disgorgement damages by eliminating X/Xi EndoWrist sales

The Smith Rebuttal Report reduces disgorgement damages primarily by eliminating X/Xi EndoWrist instrument sales.¹²³ While the Smith Rebuttal Report eliminates X/Xi EndoWrist instrument sales, to my knowledge, Dr. Smith is not providing legal opinions on whether or not the X/Xi EndoWrist instrument sales are, in fact, subject to disgorgement.

X. Conclusion

My second rebuttal report and analyses contained herein are based upon information that is presently known and available to me. As additional information is made available, I may update my rebuttal report and analyses accordingly. In preparing for trial, I may prepare demonstrative exhibits based upon information included in this second rebuttal report, the Bero Report, the Bero Rebuttal Report or additional information that becomes available hereafter.

Respectfully submitted,



Richard F. Bero, CPA, CVA
March 1, 2023

¹²³ Smith Rebuttal Report 31-32. The Smith Rebuttal Report presents its adjustments on Table 4 (Smith Rebuttal Report 32). It first adjusts for what it refers to “corrections for computational and methodological errors,” then adjusts for the “removal of X/Xi EndoWrist instrument sales.” Regardless of the first adjustment, the “removal of X/Xi EndoWrist instrument sales” is the primary reduction. In other words, without the first adjustment, and just applying the second “removal of X/Xi EndoWrist instrument sales” would reduce the Smith Rebuttal Report’s claimed disgorgement by at least 95%, as described on page 14 of the Smith Rebuttal Report and shown on its Table 1, where X/Xi sales account for at least 95% of SIS’s lost revenue, which is the revenue to be disgorged.

Data and Other Information Considered - as of March 1, 2023

Second Rebuttal Attachment 1

DATA AND OTHER INFORMATION CONSIDERED - AS OF THE DECEMBER 2, 2022 BERO REPORT:

LEGAL FILINGS:

Surgical Instrument Service Company, Inc. v. Intuitive Surgical, Inc. (Case No. 3:21-cv-03496-VC):

Complaint dated May 10, 2021
Defendant Intuitive Surgical, Inc.'s Notice of Motion, Motion and Memorandum of Points and Authorities in Support of its Motion to Dismiss the Complaint filed August 6, 2021
Declaration of Karen Hoffman Lent in Support of Defendant's Request for Judicial Notice in Support of Intuitive Surgical, Inc.'s Motion to Dismiss the Complaint with Exhibit 1 filed August 6, 2021
Request for Judicial Notice in Support of Intuitive Surgical, Inc.'s Motion to Dismiss the Complaint filed August 6, 2021
[Proposed Order] Granting Request for Judicial Notice filed August 6, 2021
Defendant Intuitive Surgical, Inc.'s Notice of Motion, Motion and Memorandum of Point and Authorities in Support of Motion to Stay filed August 13, 2021
[Proposed] Order Granting Defendant Intuitive Surgical Inc.'s Stay filed August 13, 2021
Declaration of Karen Hoffman Lent in Support of Defendant's Notice of Motion, Motion, and Memorandum of Points and Authorities in Support of Motion to Stay with Exhibits 1-4 filed August 13, 2021
Plaintiff Surgical Instrument Service Company, Inc.'s Opposition to Defendant's Motion to Dismiss filed August 20, 2021
Plaintiff's Initial Disclosures dated August 26, 2021
Intuitive's Initial Disclosures dated August 26, 2021
Plaintiff Surgical Instrument Service Company, Inc.'s Opposition to Defendant's Motion to Stay filed August 27, 2021
Declaration of Joshua Van Hoven in Support of Plaintiff's Opposition to Defendant's Motion to Stay with Exhibits 1 and 2 filed August 27, 2021
Declaration of Gregory J. Posdal filed August 27, 2021
Defendant Intuitive Surgical, Inc.'s Reply Memorandum of Law in Support of its Motion to Dismiss the Complaint filed September 3, 2021
Defendant Intuitive Surgical, Inc.'s Reply Memorandum of Law in Support of its Motion to Stay filed September 3, 2021
Declaration of Karen Hoffman Lent in Support of Defendant's Reply Memorandum of Law in Support of its Motion to Stay with Exhibit 1 filed September 3, 2021
Order Granting in Part and Denying in Part Motion to Dismiss filed November 23, 2021
Defendant Intuitive Surgical, Inc.'s Answer, Affirmative Defense and Counterclaims with Exhibits 1-7 filed December 14, 2021
Plaintiff/Counterclaim Defendant Surgical Instrument Service Company, Inc.'s Answer to Defendant/Counterclaim Plaintiff's Counterclaims filed January 10, 2022
Stipulated Protective Order filed with Exhibit A signed by Richard Bero, Beth Bergman, Joseph Laur, Ammar Susnerwala and Nick Romans filed March 30, 2022
Joint Stipulation and [Proposed] Order to Modify Schedule filed April 11, 2022

Interrogatories:

Defendant/Counterclaimant Intuitive Surgical, Inc.'s Objections and Responses to Plaintiff Surgical Instrument Service Co., Inc.'s First Set of Interrogatories dated April 29, 2022
Plaintiff Surgical Instrument Service Company, Inc.'s Answer and Objection to Defendant's Interrogatories First Set - Nos. 1-3 dated May 20, 2022
Plaintiff Surgical Instrument Service Company, Inc.'s Answer and Objections to Defendant's Interrogatories Second Set - Nos. 4-18 dated August 8, 2022

Restore Robotics, et al. v. Intuitive Surgical, Inc. (Case No. 5:19-cv-00055-TKW-MJF):

Defendant's Answer, Affirmative Defense and Counterclaims filed September 30, 2019
Defendant's First Amended Counterclaims with Exhibits 1-3 filed November 28, 2019
Plaintiffs Restore Robotics LLC and Restore Robotics Repairs LLC's Answer to Defendant's Amended Counterclaims filed December 12, 2019
Second Amended Complaint with Exhibits 1-5 filed March 29, 2021
Defendant's Answer and Affirmative Defense filed April 12, 2021

Rebotix Repair LLC v. Intuitive Surgical, Inc. (Case No. 8:20-cv-02274-VMC-TGW):

Complaint filed September 28, 2020
Defendant's Answer, Affirmative Defenses and Counterclaims with Exhibits A-E filed April 2, 2021
Rebotix's Answer and Affirmative Defenses to Intuitive's Counterclaims filed April 23, 2021

EXPERT REPORTS:

Surgical Instrument Service Company, Inc. v. Intuitive Surgical, Inc. (Case No. 3:21-cv-03496-VC):

Expert Report of Jean Sargent dated December 2, 2022

Data and Other Information Considered - as of March 1, 2023

Second Rebuttal Attachment 1

Restore Robotics, et al. v. Intuitive Surgical, Inc. (Case No. 5:19-cv-00055-TKW-MJF):

Expert Report of Heather Rosecrans dated August 20, 2021
Expert Report of John Bomalaski dated August 20, 2021
Expert Report of Dr. Robert D. Howe dated August 20, 2021
Expert Report of Sara Parikh, Ph.D. dated August 20, 2021
Expert Report of Professor Christina DePasquale dated August 20, 2021
Expert Report of Loren K. Smith, Ph.D. dated August 20, 2021
Expert Rebuttal Report of Loren K. Smith, Ph.D. dated September 27, 2021
Rebuttal Expert Report of Christina DePasquale dated October 7, 2021
Supplemental Expert Report of Christina DePasquale dated October 28, 2021

Any additional documents cited therein.

Rebotix Repair LLC v. Intuitive Surgical, Inc. (Case No. 8:20-cv-02274-VMC-TGW):

Expert Report of Dr. John Bomalaski dated July 26, 2021
Expert Report of Robert Howe dated July 26, 2021
Expert Report of Kurt Humphrey dated July 26, 2021
Expert Report of Russell Lamb dated July 26, 2021
Expert Report of Gwen Mandel dated July 26, 2021
Expert Report of Robert Mills dated July 26, 2021
Expert Report of Sara Parikh dated July 26, 2021
Expert Report of Heather Rosecrans dated July 26, 2021
Expert Report of Joshua Sharlin dated July 26, 2021
Expert Report of Loren K. Smith, Ph.D. dated July 26, 2021
Amended Expert Report of Sara Parikh dated August 5, 2021
Expert Report of Larry Chiagouris dated August 30, 2021
Rebuttal Report of Robert Mills dated August 30, 2021
Expert Report of Kim Parnell dated August 30, 2021
Rebuttal Expert Report of Heather Rosecrans dated August 30, 2021
Expert Damages Rebuttal Report of Loren K. Smith, Ph.D. dated August 30, 2021
Expert Antitrust Merits Report of Loren K. Smith, Ph.D. dated August 30, 2021
Expert Report of Lawrence Stevens dated August 30, 2021
Supplemental Expert Report of Russell Lamb dated September 22, 2021
Supplemental Expert Report of Robert Mills dated September 22, 2021

Any additional documents cited therein.

DEPOSITIONS:

Restore Robotics, et al. v. Intuitive Surgical, Inc. (Case No. 5:19-cv-00055-TKW-MJF):

Mark Johnson dated April 29, 2021 with Exhibits 0001-0009
Todd Pope dated April 30, 2021 with Exhibits 1-7
30(b)(6) Restore Robotics LLC and Restore Robotics Repairs LLC through Clifton Earl Parker, and Clifton Parker Individually dated May 4, 2021 with Exhibits 1-7
David Robinson dated May 5, 2021
Kevin May dated May 6, 2021 with Exhibits 1-24
John "Jake" Joseph Colletti Jr., dated May 7, 2021 with Exhibits 1-13
Greg Posdal dated May 10, 2021 with Exhibits 1-6
Mills Vautrot dated May 11, 2021 with Exhibits 1-12
West E. Gordon dated May 13, 2021 with Exhibits 1-17

Data and Other Information Considered - as of March 1, 2023

Second Rebuttal Attachment 1

Sherry Harvey dated May 14, 2021 with Exhibits 1-7
Cario Wasfy dated May 18, 2021 with Exhibits 1-23
Dave Rosa dated May 19, 2021 with Exhibits 1-9
Robert DeSantis dated May 20, 2021 with Exhibits 1-9
Kyle Marks dated May 21, 2021 with Exhibits 1-8
Tyler McDonald dated May 21, 2021 with Exhibits 1-17
Ronald Lee Blair Jr. dated May 24, 2021 with Exhibits 1-3
Eugene Otto Dickens M.D., dated May 27, 2021 with Exhibits 1-2
Amie Renee Reed dated May 27, 2021 with Exhibits 1-3
Kevin May (Vol. II) dated June 8, 2021 with Exhibits 1-6
Michael Madewell dated June 11, 2021 with Exhibits 1-21

Rebotix Repair LLC v. Intuitive Surgical, Inc. (Case No. 8:20-cv-02274-VMC-TGW):

Myriam Curet M.D., dated May 7, 2021 with Exhibits 1-6
Glenn Vavoso dated May 14, 2021 with Exhibits 1-39
Ronald Lee Blair, Jr. dated May 24, 2021 with Exhibits 1-22
Edward W. Harrich dated May 24, 2021 with Plaintiff's Exhibits 1-9, Defendant's Exhibits DF1-DF5
Katie Scoville dated May 26, 2021 with Exhibits 1-13
Robert DeSantis dated May 27, 2021 with Exhibits 1-29
Stacey Donovan dated May 27, 2021 with Exhibits P1-P9, D1-D3
30(b)(6) Rebotix Repair, LLC through Glenn Papit dated June 2, 2021 with Exhibits 1-24
Stan (Lay) Hamilton dated June 4, 2021 with Exhibits 1-10
David Mixner dated June 10, 2021 with Exhibits 1-18
Chris Gibson dated June 22, 2021 with Exhibits 1-22

In Re: Da Vinci Surgical Robot Litigation - All Cases:

Judith Schimmel dated September 22, 2022 with Exhibits 1-20
Sandra Guerro dated September 23, 2022 with Exhibits 21-46
Mark Early dated October 6, 2022 with Exhibits 28, 30, 59-81
Disha Peswani dated October 6, 2022 with Exhibits 1-17
Margaret Nixon dated October 7, 2022 with Exhibits 18-32
John Wagner dated October 11, 2022 with Exhibits 54, 56, 104-116
Shreya Purohit dated October 12, 2022 with Exhibits 33-53
John Francis M.D. dated October 14, 2022 with Exhibits 54-55
Ryan Shaw dated October 19, 2022 with Exhibits 56-74
Gayle Perry dated October 20, 2022 with Exhibits 75-79, 81-84
Ricardo Estape, M.D. dated October 22, 2022 with Exhibits 118-120, Estape 01, 34, 61, 95
Clifton Parker dated October 25, 2022 with Exhibits 121-134
30(b)(6) Nickola (Nicky) Goodson dated October 27, 2022 with Exhibits 85-106
30(b)(6) Keith Johnson dated October 27, 2022 with Exhibits 135-140
Keith Johnson (Individually) dated October 27, 2022 with Exhibits 141-144
Imron Zafar dated November 1, 2022 with Exhibits 1-5, 111-113
Mario Lowe dated November 3, 2022 with Exhibits 81-83, 144
Kevin May dated November 3, 2022 with Exhibits 154-156, Plaintiff's Exhibit 1
John Sampson dated November 3, 2022 with Exhibits 184-193
Stan Hamilton dated November 4, 2022 with Exhibits 157, 158, 160, 204

Data and Other Information Considered - as of March 1, 2023

Second Rebuttal Attachment 1

Sharathchandra (Shark) Somayaji dated November 4, 2022 with Exhibits 201, 203, 205-208, 211-213, 216-218, 220, 223-224, 227-230
Todd Tourand dated November 4, 2022 with Exhibits 39, 200, 202, 209, 210, 214, 215, 219, 221, 222, 225, 226
30 (b)(6) Marshall Mohr dated November 7, 2022 with Exhibits 231-236
30(b)(1) Grant DuQue (Personal) dated November 8, 2022 with Exhibits 238, 240-241, 243-244, 246-249, 257-258, 263
30(b)(6) Grant DuQue dated November 8, 2022 with Exhibits 264, 266-269
David Fabricant dated November 8, 2022 with Exhibits 239, 239A-239D, 242, 242A, 245, 245A, 250-253, 253A, 254-256, 259, 261-262
Catherine Mohr M.D. dated November 9, 2022 with Exhibits 270-285
30(b)(1) Colin Morales (Personal) dated November 9, 2022 with Exhibits 120-134
30(b)(6) Colin Morales dated November 9, 2022 with Exhibits 135-143
Dan Jones dated November 10, 2022 with Exhibits 286-294
Rick Ferreira dated November 10, 2022 with Exhibits 207-220, 295-296
30 (b)(6) Nickola (Nicky) Goodson dated November 16, 2022 with Exhibit 297

Surgical Instrument Service Company, Inc. v. Intuitive Surgical, Inc.:

30(b)(1) Jose Gonzales (Personal) dated October 17, 2022 with Exhibits 39, 45, 82, 83
30(b)(6) Jose Gonzales dated October 17, 2022 with Exhibits 84-99, 117
30(b)(6) Greg Posdal dated November 1, 2022 with Exhibits 145-146, Previously Marked Exhibits 136, 138
30(b)(1) Greg Posdal (Personal) dated November 1, 2022 with Exhibits 147-148, Previously Marked Exhibits 107, 143

DISCUSSIONS WITH:

SIS personnel:

Keith Johnson, Executive Vice President, Sales and Clinical Programs
Greg Posdal, President and C.E.O
Jean Sargent, industry expert

DOCUMENTS WITH BATES STAMPS:

ALPIN00001-00005	Intuitive-00223902-00223935	Intuitive-00602325	Restore-00001939	SIS091827-091828	SIS196155
BB001260	Intuitive-00223937-00223970	Intuitive-00602576-00602578	Restore-00002260-00002265	SIS091833	SIS196156
BB002642-002644	Intuitive-00223998-00224033	Intuitive-00602603	Restore-00002891-00002915	SIS091834	SIS196158
BSWH-0000446-0000448	Intuitive-00230855	Intuitive-00603164	Restore-00003932-00003942	SIS091839	SIS196159
CCSC-I 000038-000051	Intuitive-00230856	Intuitive-00603510	Restore-00006083-00006084	SIS091840-091841	SIS196209
CMR-00001108-00001111	Intuitive-00231004	Intuitive-00603990-00603991	Restore-00009387	SIS091842-091844	SIS196210
Intuitive 00398790-00398858	Intuitive-00234762-00234838	Intuitive-00604054-00604055	Restore-00012292	SIS091846-091913	SIS196219
Intuitive-00000157-00000209	Intuitive-00240550-00240638	Intuitive-00604123	Restore-00013682-00013692	SIS092142	SIS196220
Intuitive-00000256	Intuitive-00241336-00241370	Intuitive-00604127	Restore-00022922	SIS092353-092356	SIS196226
Intuitive-00000257	Intuitive-00246469-00246491	Intuitive-00604145	Restore-00055932-00055939	SIS092357-092359	SIS196227
Intuitive-00000258	Intuitive-00254135	Intuitive-00605636	SIS000001	SIS092410-092477	SIS196228
Intuitive-00000259	Intuitive-00254875-00254877	Intuitive-00620200	SIS000022	SIS092637-092638	SIS196230-196231
Intuitive-00000260	Intuitive-00255397	Intuitive-00624829	SIS000023	SIS092666-092668	SIS196232
Intuitive-00000261	Intuitive-00258654	Intuitive-00626145	SIS000024	SIS092675	SIS196235
Intuitive-00000276	Intuitive-00261446-00261486	Intuitive-00646018-00646041	SIS000025	SIS092916-092917	SIS196236
Intuitive-00000316	Intuitive-00265324-00265336	Intuitive-00670355	SIS000026	SIS093097	SIS196239
Intuitive-00001087-00001146	Intuitive-00266133	Intuitive-00671020-00671035	SIS000028-000029	SIS093099-093101	SIS196240
Intuitive-00001237-00001311	Intuitive-00268606-00268612	Intuitive-00674398	SIS000033-000034	SIS093168-093170	SIS196251
Intuitive-00001639	Intuitive-00268762-00268767	Intuitive-00685424	SIS000035-000045	SIS093171-093176	SIS196252
Intuitive-00001788-00001851	Intuitive-00270554-00270572	Intuitive-00686044	SIS000047-000049	SIS093361-093364	SIS196253
Intuitive-00002050-00002092	Intuitive-00273157	Intuitive-00686068	SIS000050	SIS093423-093425	SIS196254
Intuitive-00002138	Intuitive-00273226-00273228	Intuitive-00686068	SIS000051	SIS093436-093438	SIS196255
Intuitive-00002937-00002944	Intuitive-00273229-00273259	Intuitive-00688902	SIS000051-000054	SIS093894	SIS196256

Data and Other Information Considered - as of March 1, 2023

Second Rebuttal Attachment 1

Intuitive-00003494	Intuitive-00273264-00273294	Intuitive-00689957	SIS000056	SIS093980-093981	SIS196258
Intuitive-00003866-00003869	Intuitive-00273300	Intuitive-00695006	SIS000057-000058	SIS093984	SIS196259
Intuitive-00004126-00004172	Intuitive-00273715	Intuitive-00695144	SIS000059-000060	SIS094006-094008	SIS196260
Intuitive-00004412-00004420	Intuitive-00278244-00278245	Intuitive-00695231-00695234	SIS000061	SIS094014-094016	SIS196273
Intuitive-00004661	Intuitive-00279920-00279922	Intuitive-00695236-00695237	SIS000097-000112	SIS094023-094090	SIS196274
Intuitive-00004692-00004704	Intuitive-00279923-00279957	Intuitive-00695243-00695245	SIS000118-000137	SIS094101-094103	SIS196288
Intuitive-00004811	Intuitive-00279958-00279983	Intuitive-00700899-00700909	SIS000138-000157	SIS094111	SIS196289-196290
Intuitive-00004968-00004986	Intuitive-00282732-00282736	Intuitive-00701320-00701322	SIS000158-000165	SIS094176	SIS196291
Intuitive-00005049	Intuitive-00285709-00285741	Intuitive-00701343	SIS000173-000181	SIS094245	SIS196292
Intuitive-00005051-00005067	Intuitive-00288971-00288972	Intuitive-00701739	SIS000183-000198	SIS094284	SIS196309
Intuitive-00005135-00005147	Intuitive-00288975-00288976	Intuitive-00701743-00701744	SIS000202-000204	SIS094291	SIS196310
Intuitive-00005309-00005328	Intuitive-00292437-00292461	Intuitive-00702284	SIS000213-000215	SIS094448-094450	SIS196311
Intuitive-00005955-00005989	Intuitive-00292544-00292628	Intuitive-00752495	SIS000216-000217	SIS094462-094463	SIS196315
Intuitive-00008839-00008905	Intuitive-00293271-00293356	Intuitive-00784942-00784972	SIS000218-000220	SIS094498-094501	SIS196316
Intuitive-00009073-00009076	Intuitive-00293400-00293606	Intuitive-00807510-00807557	SIS000224-000225	SIS094524-094525	SIS196317
Intuitive-00009517-00009561	Intuitive-00296258-00296294	Intuitive-00808372-00808551	SIS000226-000227	SIS094530	SIS196318
Intuitive-00009716-00009717	Intuitive-00296295-00296298	Intuitive-00810697	SIS000228-000229	SIS094531	SIS196319
Intuitive-00009824-00009880	Intuitive-00313683-00313684	Intuitive-00817085-00817118	SIS000239-000240	SIS094572-094573	SIS196320
Intuitive-00010119	Intuitive-00313685-00313730	Intuitive-00834771	SIS000241-000260	SIS094574	SIS196321
Intuitive-00010179	Intuitive-00323352	Intuitive-00834793	SIS000261-000268	SIS094618-094622	SIS196322-196323
Intuitive-00011483	Intuitive-00323856-00323930	Intuitive-00834845	SIS000274-000282	SIS094631-094635	SIS196327
Intuitive-00011487	Intuitive-00333561-00333572	Intuitive-00846238	SIS000293-000294	SIS094779-094781	SIS196328
Intuitive-00012397-00012400	Intuitive-00335054	Intuitive-00849019	SIS000302-000317	SIS094825	SIS196329
Intuitive-00012401-00012543	Intuitive-00338790-00338805	Intuitive-00882424	SIS000319-000321	SIS094857-094871	SIS196330-196332
Intuitive-00014019	Intuitive-00354548-00354590	Intuitive-00897681-00897695	SIS000322-000325	SIS094955-094969	SIS196333
Intuitive-00014395-00014396	Intuitive-00356654-00356745	Intuitive-00902243	SIS000355-000357	SIS095191-095192	SIS196334-196335
Intuitive-00015314-00015351	Intuitive-00363883-00363901	Intuitive-00945455	SIS000392-000394	SIS095220-095223	SIS196336-196337
Intuitive-00015458-00015493	Intuitive-00363903-00363918	Intuitive-00982519	SIS000395-000414	SIS095278-095280	SIS196338
Intuitive-00018120	Intuitive-00364420-00364444	Intuitive-00986625	SIS000415-000422	SIS095294-095296	SIS196340-196342
Intuitive-00019774-00019775	Intuitive-00364863-00364874	Intuitive-01011044-01011053	SIS000433	SIS095312	SIS196343
Intuitive-00019946-00020046	Intuitive-00365857-00365897	Intuitive-01024426-01024427	SIS000437-000439	SIS095344	SIS196344
Intuitive-00020363-00020372	Intuitive-00366044-00366053	Intuitive-01032092	SIS000440-000444	SIS095440	SIS196362-196366
Intuitive-00021011	Intuitive-00367019-00367063	Intuitive-01034247	SIS000449	SIS095539-095540	SIS196367
Intuitive-00024105	Intuitive-00367171-00367172	Intuitive-01069706-01069707	SIS000450-000451	SIS095555-095622	SIS196368
Intuitive-00024910-00024941	Intuitive-00367339-00367344	Intuitive-01071172-01071202	SIS000455	SIS095665-095666	SIS196369-196370
Intuitive-00025115-00025121	Intuitive-00367339-00367344	Intuitive-01085248	SIS000459 001	SIS095669-095725	SIS235009-235017
Intuitive-00027482-00027488	Intuitive-00367345	Intuitive-01087438	SIS000463-000465	SIS095923-095928	SIS235018-235028
Intuitive-00028665-00028668	Intuitive-00367522-00367534	Intuitive-01101507	SIS000473-000476	SIS095938-095940	SIS235244-235253
INTUITIVE-00028864	Intuitive-00367724-00367726	Intuitive-01101508	SIS000477	SIS096017-096021	SIS235254-235256
Intuitive-00028874-00028963	Intuitive-00367727	Intuitive-01115600	SIS000481-000484	SIS096161-096164	SIS235283-235298
Intuitive-00029346-00029347	Intuitive-00367733-00367790	Intuitive-01126654-01126655	SIS000491	SIS096196-096197	SIS235301-235305
Intuitive-00030279-00030285	Intuitive-00367806-00367807	Intuitive-01132295	SIS000492-000495	SIS096225	SIS236038-236053
Intuitive-00030451-00030517	Intuitive-00367808-00367812	Intuitive-01134566	SIS000506-000525	SIS096226	SIS236058-236082
Intuitive-00032916-00032917	Intuitive-00367902	Intuitive-01141301-01141305	SIS000526-000533	SIS096236-096237	SIS236083-236088
Intuitive-00033512-00033513	Intuitive-00367961	Intuitive-01155852	SIS000561	SIS096271	SIS236829
Intuitive-00033514-00033539	Intuitive-00369327-00369328	Intuitive-01156820	SIS000568	SIS096296	SIS236830-236844
Intuitive-00033815-00033870	Intuitive-00369329-00369347	Intuitive-01182910	SIS000569-000570	SIS096605	SIS236845-236848
Intuitive-00033957-00034025	Intuitive-00372053-00372055	Intuitive-01197005	SIS000580	SIS096629-096633	SIS236911-236957
Intuitive-00034599-00034621	Intuitive-00372699-00372703	INTUITIVE-01215093	SIS000582-000587	SIS096683-096685	SIS236958-237033
Intuitive-00034748-00034749	Intuitive-00373839-00373841	Intuitive-01219019	SIS000593 001	SIS096761	SIS237071-237074
Intuitive-00034750-00034774	Intuitive-00373885-00373887	Intuitive-01236912	SIS000597	SIS096786	SIS237075-237100
Intuitive-00035386	Intuitive-00376786-00376808	Intuitive-01240518-01240523	SIS000598	SIS096963-096966	SIS237101-237106
Intuitive-00036783-00036788	Intuitive-00389936	Intuitive-01261766	SIS000600-000604	SIS097025-097028	SIS237108-237131
Intuitive-00038260-00038278	Intuitive-00390869	Intuitive-01405182-01405188	SIS000611-000613	SIS097031	SIS237186-237204
Intuitive-00040518	Intuitive-00390870-00390906	Intuitive-01405189-01405190	SIS000631-000632	SIS097037-097104	SIS237205-237209

Data and Other Information Considered - as of March 1, 2023

Second Rebuttal Attachment 1

Intuitive-00042816-00042851	Intuitive-00394297	Intuitive-01740518-01740520	SIS000633-000634	SIS097107-097109	SIS237343-237360
Intuitive-00042937-00042972	Intuitive-00397354-00397395	Intuitive-02025757-02025759	SIS000635-000639	SIS097110-097112	SIS237364-237373
Intuitive-00043100	Intuitive-00412740-00412762	Intuitive-02026480	SIS000652-000655	SIS097113-097114	SIS250885
Intuitive-00043101-00043148	Intuitive-00421009-00421014	Intuitive-02046270	SIS000656-001	SIS097119	SIS251593
Intuitive-00043879-00043885	Intuitive-00421106-00421118	Intuitive-02067634	SIS000660-000661	SIS097122-097123	SIS276305
Intuitive-00044517	Intuitive-00421796-00421808	Intuitive-02068980	SIS000662	SIS097126-097128	SIS299535-299561
Intuitive-00044524-00044526	Intuitive-00423683-00423683	Intuitive-02069208	SIS000663	SIS097139	SIS299583-299593
Intuitive-00044528-00044530	Intuitive-00423684-00423736	Intuitive-02069211	SIS000663-000664	SIS097141	SIS319267
Intuitive-00045350-00045354	Intuitive-00439319-00439321	Intuitive-02069286	SIS000665-000667	SIS097217-097218	SIS319315-319322
Intuitive-00045861-00045898	Intuitive-00439677-00439679	Intuitive-02069694	SIS000672	SIS097220-097231	SIS319323-19329
Intuitive-00046428	Intuitive-00463328-00463403	Intuitive-02069746	SIS001621	SIS097269	SIS320176-320188
Intuitive-00047082	Intuitive-00465615-00465616	Intuitive-02069760	SIS001648	SIS097270	SIS320189-320201
Intuitive-00047105-00047314	Intuitive-00466686	Intuitive-02069764	SIS001685	SIS097273	SIS320922-320935
Intuitive-00047998-00048207	Intuitive-00471993-00471997	Intuitive-02069774	SIS001685-001690	SIS097281	SIS320936-320949
Intuitive-00048514-00048542	Intuitive-00471998-00472003	Intuitive-02069795	SIS001957-001960	SIS097322	SIS320950-320963
Intuitive-00049014-00049016	Intuitive-00473788-00473819	INTUITIVE-02070399	SIS003653-003670	SIS106475	SIS321287-321299
Intuitive-00049089-00049102	Intuitive-00478297-00478298	Intuitive-553115-553161	SIS003902	SIS106484	SIS321300-321312
Intuitive-00050362-00050388	Intuitive-00478439-00478444	Intuitive-00028864	SIS003913	SIS106485-106486	SIS327571-327577
Intuitive-00050419	Intuitive-00478797-00479033	Intuitive-00049995	SIS003926	SIS106491-106492	SIS327578-327591
Intuitive-00054857-00054896	Intuitive-0049128-0049132	Intuitive-00104210	SIS003937	SIS106493	SIS327606-327612
Intuitive-00070364-00070421	Intuitive-00506505-00506641	Intuitive-00994761	SIS00568591-00568634	SIS106493-106498	SIS327613-327620
Intuitive-00073538-00073559	Intuitive-00512348-00512353	Intuitive-00995697	SIS007986	SIS116933-116940	SIS327621-327628
Intuitive-00075214-00075252	Intuitive-00515818-00515856	MEDIVISION001731-001732	SIS009366	SIS116993	SIS327629-327636
Intuitive-00076261	Intuitive-00519980-00520005	MEDLINE0040518 - 0040544	SIS009428	SIS117733-117749	SIS327637
Intuitive-00086011-00086082	Intuitive-00538914-00538929	REBOTIX000685-000687	SIS009443	SIS117894-117911	SIS328154
Intuitive-00086194-00086283	Intuitive-00544903-00545124	REBOTIX000835-000845	SIS009514	SIS117912-117929	SIS328322-328333
Intuitive-00088621	Intuitive-00552533-00552535	REBOTIX001387-001425	SIS009617-009619	SIS118397-118409	SIS328334
Intuitive-00089621	Intuitive-00552745-00552759	REBOTIX004379-004388	SIS010151	SIS118410-118422	SIS328335
Intuitive-00089767-00089782	Intuitive-00552993-00553014	REBOTIX0164822	SIS010152	SIS118423-118435	SIS328336
Intuitive-00091257-00091351	Intuitive-00553115-00553161	REBOTIX0173140	SIS010200	SIS118436-118448	SIS328337
Intuitive-00098205	Intuitive-00553825-00553834	REBOTIX0173144	SIS010237	SIS118449-118461	SIS328338
Intuitive-00098209	Intuitive-00554106-00554113	REBOTIX0173188	SIS010270	SIS118462-118474	SIS328339
Intuitive-00098287-00098354	Intuitive-00555435	REBOTIX0173204	SIS010341	SIS118878	SIS328340
Intuitive-00098370	Intuitive-00555864-00555866	REBOTIX0174292	SIS010342	SIS118879-118880	SIS328341
Intuitive-00098680	Intuitive-0055790	REBOTIX0174307	SIS010343	SIS119199-119206	SIS328342
Intuitive-00098681	Intuitive-00559343-00559456	REBOTIX0174757	SIS010648-010665	SIS119299	SIS328343
Intuitive-00100251-00100269	Intuitive-00559695-00559706	REBOTIX0174771	SIS010691-010707	SIS119300-119310	SIS328344
Intuitive-00102909	Intuitive-00559824-00559939	REBOTIX040273-040276	SIS010912	SIS119311	SIS328345
Intuitive-00102938	Intuitive-00562853-00562855	REBOTIX040277	SIS010923	SIS119312-119313	SIS328346
Intuitive-00102938-00102989	Intuitive-00563445	REBOTIX040446-040450	SIS011151-011165	SIS126698-126705	SIS328348
Intuitive-00103402-00103405	Intuitive-00563940-00563948	REBOTIX041613-041620	SIS011187-011202	SIS127642	SIS329815
Intuitive-00103407-00103426	Intuitive-00564534-00564535	REBOTIX045504-045510	SIS011228-011243	SIS132796	SIS329816-329817
Intuitive-00103427	Intuitive-00565670-00565671	REBOTIX048125-048125	SIS011268-011283	SIS135949-135967	SIS329827-329828
Intuitive-00103456-00103478	Intuitive-00566055-00566082	REBOTIX049817	SIS032473-032488	SIS136056-136064	SIS329829-329830
Intuitive-00103571-00103596	Intuitive-00566149-00566153	REBOTIX050132-050133	SIS032622-032689	SIS136259-136274	SIS329848
Intuitive-00103598	Intuitive-00566507-00566543	REBOTIX050420	SIS032716-032718	SIS136648	SIS329849
Intuitive-00103786	Intuitive-00566601-00566643	REBOTIX050423	SIS032770	SIS136691	SIS329850-329865
Intuitive-00103787-00103836	Intuitive-00568626	REBOTIX050721	SIS032896-032898	SIS138226-138234	SIS329885-329893
Intuitive-00104130-00104131	Intuitive-00569180-00569182	REBOTIX050854	SIS032899-032955	SIS139358-139376	SIS329894-329902
Intuitive-00104183-00104205	Intuitive-00569308-00569310	REBOTIX051079	SIS032956-032959	SIS139407-139415	SIS330591-330634
INTUITIVE-00104210	Intuitive-00569531-00569541	REBOTIX051537-051538	SIS032969-032972	SIS139456-139464	SIS336456-336474
Intuitive-00104535-00104537	Intuitive-00571075	REBOTIX053473	SIS033073-033142	SIS139559-139567	SIS336744-336759
Intuitive-00104562-00104563	Intuitive-00571076-00571080	REBOTIX054164-054165	SIS033151-033220	SIS139980-139998	SIS336761
Intuitive-00104566-00104570	Intuitive-00578133-00578202	REBOTIX054166	SIS033364-033365	SIS140013-140030	SIS336984-337014
Intuitive-00104928-00104953	Intuitive-00579633-00579645	REBOTIX054249-054249	SIS033371-033438	SIS142445	SIS340585-340599

Data and Other Information Considered - as of March 1, 2023

Second Rebuttal Attachment 1

Intuitive-00105904-00106106	Intuitive-00581597	REBOTIX054620-054620	SIS033590-033593	SIS142683-142698	SIS341124
Intuitive-00106127-00106128	Intuitive-00581618	REBOTIX054897	SIS033653	SIS142726-142742	SIS341132
Intuitive-00106653-00106658	Intuitive-00581814-00581883	REBOTIX055131	SIS033654	SIS142766-142782	SIS343965
Intuitive-00110242-00110243	Intuitive-00582105-00582117	REBOTIX055134	SIS033655-033660	SIS142937-142939	SIS343965-343971
Intuitive-00110255-00110258	Intuitive-00582618-00582629	REBOTIX055331	SIS033663	SIS143176	SIS343965-343971
Intuitive-00111192-00111193	Intuitive-00583337-00583347	REBOTIX055419	SIS033664-033665	SIS143178	SIS344662-344670
Intuitive-00113020-00113020	Intuitive-00583659-00583707	REBOTIX055424	SIS033654	SIS143365-143366	SIS346078-346080
Intuitive-00114808-00114839	Intuitive-00585561-00585659	REBOTIX055565	SIS038107-038109	SIS143367-143374	SIS346124-346129
Intuitive-00115483-00115501	Intuitive-00586241-00586249	REBOTIX055566	SIS038110-038112	SIS143466-143477	SIS346133
Intuitive-00115576-00115578	Intuitive-00586668-00586708	REBOTIX056297	SIS038113-038169	SIS143490	SIS346146
Intuitive-00115682-00115689	Intuitive-00593443-00593480	REBOTIX056325	SIS038223-038290	SIS143895-143964	SIS346147
Intuitive-00118636-00118706	Intuitive-00593897-00593981	REBOTIX056326	SIS038293-038362	SIS145108	SIS346180-346195
Intuitive-00121229-00121230	Intuitive-00594517-00594542	REBOTIX056394	SIS043777-043778	SIS146228-146234	SIS346200-346215
Intuitive-00122488-00122603	Intuitive-00594883-00594902	REBOTIX056408	SIS045193-045194	SIS146768	SIS346248
Intuitive-00124485-00124487	Intuitive-00594904-00594949	REBOTIX057417-057417	SIS045195-045198	SIS146838	SIS346265
Intuitive-00128685	Intuitive-00595404	REBOTIX057473	SIS045199-045200	SIS146989	SIS346266
Intuitive-00128687-00128691	Intuitive-00595405	REBOTIX058675	SIS045201-045203	SIS148945	SIS346267
Intuitive-00128700-00128728	Intuitive-00595406	REBOTIX059010-059013	SIS045227	SIS149741	SIS346306-346322
Intuitive-00129015	Intuitive-00595407	REBOTIX059648-059651	SIS045231-045232	SIS158253-158271	SIS346641-346657
Intuitive-00133628-00133630	Intuitive-00595408	REBOTIX059927	SIS045332-045337	SIS161609	SIS346820
Intuitive-00136727-00136727	Intuitive-00595409	REBOTIX060483	SIS045701-045719	SIS161610	SIS346866-346874
Intuitive-00136728-00136735	Intuitive-00595410	REBOTIX061037	SIS045720-045736	SIS161611	SIS347987
Intuitive-00138863-00138863	Intuitive-00595411	REBOTIX062113	SIS047175-047180	SIS161612	SIS347997
Intuitive-00138864-00138892	Intuitive-00595412	REBOTIX062114	SIS047433-047435	SIS161613	SIS356339
Intuitive-00138893-00138902	Intuitive-00595413	REBOTIX062280	SIS048559-048561	SIS161614	SIS356362-356406
Intuitive-00139149-00139150	Intuitive-00595414	REBOTIX062408	SIS059789	SIS163317-163341	SIS356407-356411
Intuitive-00139238	Intuitive-00595415	REBOTIX062427	SIS063100-063101	SIS166875-166876	SIS356412-356437
Intuitive-00139709-00139741	Intuitive-00595416	REBOTIX062442	SIS063495	SIS166877	SIS356438-356439
Intuitive-00139742-00139756	Intuitive-00595417	REBOTIX063037	SIS063496-063510	SIS166890-166892	SIS356440-356478
Intuitive-00139764	Intuitive-00595418	REBOTIX063142	SIS063511	SIS166893-166895	SIS356479-356503
Intuitive-00139765-00139801	Intuitive-00595419	REBOTIX063807	SIS065442-065443	SIS167696	SIS356504-356505
Intuitive-00140459	Intuitive-00595420	REBOTIX065420	SIS065604-065606	SIS167697	SIS356506-356613
Intuitive-00141202	Intuitive-00595421	REBOTIX065762	SIS065608-065609	SIS167787-167788	SIS356614-356735
Intuitive-00141567-00141568	Intuitive-00595422	REBOTIX065982	SIS068983-068985	SIS167789-167790	SIS356736-356856
Intuitive-00143279-00143310	Intuitive-00595423	REBOTIX067626	SIS069084-069102	SIS167798-167800	SIS356857-356987
Intuitive-00145425-00145437	Intuitive-00595424	REBOTIX068401	SIS069104-069122	SIS167801-167804	SIS356988-357133
Intuitive-00146235-00146236	Intuitive-00595425	REBOTIX068496	SIS069981	SIS167809-167810	SIS357134-357135
Intuitive-00146237-00146302	Intuitive-00595426	REBOTIX068513	SIS069989-070019	SIS167815-167816	SIS357136-357137
Intuitive-00146467-00146480	Intuitive-00595427	REBOTIX068620	SIS070033-070062	SIS167817	SIS357138-357139
Intuitive-00146892-00146903	Intuitive-00595428	REBOTIX068802	SIS070291-070306	SIS167818	SIS357140-357141
Intuitive-00147161-00147220	Intuitive-00595429	REBOTIX068949	SIS070308-070323	SIS167819-167821	SIS357142-357143
Intuitive-00147262-00147271	Intuitive-00595430	REBOTIX071552	SIS070435-070436	SIS167822-167823	SIS357144-357145
Intuitive-00147286-00147287	Intuitive-00595431	REBOTIX071632	SIS070437	SIS168991-169009	SIS357146-357147
Intuitive-00147459-00147494	Intuitive-00595432	REBOTIX071979	SIS070460	SIS169233-169280	SIS357148-357149
Intuitive-00147651-00147662	Intuitive-00595433	REBOTIX073495	SIS070464	SIS175955-175963	SIS357150-357151
Intuitive-00154125-00154126	Intuitive-00595434	REBOTIX073787	SIS070473-070475	SIS175964-175972	SIS357152-357153
Intuitive-00156362-00156365	Intuitive-00595435	REBOTIX078175-078179	SIS070495-070497	SIS175973-175981	SIS357154-357158
Intuitive-00157064-00157065	Intuitive-00595436	REBOTIX078553-078574	SIS070498-070554	SIS175982-175990	SIS357159-357176
Intuitive-00157098-00157099	Intuitive-00595437	REBOTIX081801-081815	SIS070555-070558	SIS175991-175999	SIS357177-357178
Intuitive-00165844-00165844	Intuitive-00595438	REBOTIX081841	SIS070804	SIS176000-176008	SIS357186-357198
Intuitive-00173065	Intuitive-00595439	REBOTIX081842-081843	SIS070870	SIS191424-191425	SIS357199-357233
Intuitive-00173701	Intuitive-00595440	REBOTIX084000-084002	SIS070871-070872	SIS191426	SIS357234-357261
Intuitive-00173706	Intuitive-00595441	REBOTIX101177-101184	SIS070883	SIS191465-191466	SIS357262-357267
Intuitive-00174591-00174604	Intuitive-00595442	REBOTIX103066-103075	SIS070988	SIS191467	SIS357268
Intuitive-00185828	Intuitive-00595443	REBOTIX140009-140013	SIS070994	SIS191494-191495	SIS357269-357272

Data and Other Information Considered - as of March 1, 2023

Second Rebuttal Attachment 1

Intuitive-00186899	Intuitive-00595444	REBOTIX140015-140019	SIS071129-071130	SIS191496	SIS357273
Intuitive-00187238-00187248	Intuitive-00595445	REBOTIX143364-143367	SIS073497	SIS192056	SIS357274-357277
Intuitive-00192940-00192960	Intuitive-00595446	REBOTIX143532-143533	SIS075739	SIS194492-194495	SIS357278-357279
Intuitive-00194074-00194089	Intuitive-00595447	REBOTIX144717-144721	SIS075742-075743	SIS194501-194504	SIS357280-357283
Intuitive-00194765-00194772	Intuitive-00595448	REBOTIX144993-145008	SIS075744-075746	SIS195959-195960	SIS357284-357285
Intuitive-00203904-00203907	Intuitive-00595449	REBOTIX145062-145084	SIS080897	SIS195961-195963	SIS357286-357291
Intuitive-00203908-00203910	Intuitive-00595450	REBOTIX162208-162212	SIS081049-081065	SIS195964-195966	SIS357292
Intuitive-00203911-00203932	Intuitive-00595451	REBOTIX162404-162424	SIS081069-081083	SIS195967-195971	SIS357293-357298
Intuitive-00210269	Intuitive-00595452	REBOTIX164558-164560	SIS081102-081117	SIS195972-195975	SIS357299-357301
Intuitive-00211776-00211778	Intuitive-00595453	REBOTIX164733-164733	SIS081197	SIS196006	SIS357302-357308
Intuitive-00213893-Intuitive-00213893	Intuitive-00595454	REBOTIX165105-165108	SIS081200	SIS196007	STRREB00000187-00000190
Intuitive-00214265-00214265	Intuitive-00595455	REBOTIX165260	SIS081282-081284	SIS196008	STRREB00000215-00000217
Intuitive-00214266-00214278	Intuitive-00595456	REBOTIX165487-165492	SIS087771	SIS196009	STRREB00000218-00000219
Intuitive-00214279	Intuitive-00595457	REBOTIX165540	SIS088060	SIS196010-196013	STRREB00000259
Intuitive-00214280	Intuitive-00595458	REBOTIX165571-165573	SIS088061-088063	SIS196027-196028	STRREB00000260-00000273
Intuitive-00215018-00215029	Intuitive-00595459	REBOTIX165623	SIS090681-090683	SIS196029	STRREB00000276-00000277
Intuitive-00215503-00215511	Intuitive-00595460	REBOTIX165846-165851	SIS090943-090944	SIS196055-196056	STRREB00000278
Intuitive-00215547-00215558	Intuitive-00595461	REBOTIX166019	SIS090945-090952	SIS196057	STRREB000001682
Intuitive-00215972-00215983	Intuitive-00595462	REBOTIX171110-171113	SIS090989	SIS196058	STRREB000001810
Intuitive-00216481-00216492	Intuitive-00595463	REBOTIX174692-174696	SIS091197	SIS196059	STRREB000001827
Intuitive-00216786-00216798	Intuitive-00595673-00595694	REBOTIX174971-174976	SIS091199	SIS196071	STRREB000002039
Intuitive-002175344	Intuitive-00596101	REBOTIX174977-174982	SIS091221-091235	SIS196072-196074	STRREB000002553-00002555
Intuitive-00218424-00218431	Intuitive-00596102-00596106	REBOTIX175080-175083	SIS091241-091257	SIS196075	STRREB000003853
Intuitive-00221189-00221219	Intuitive-00596789	REBOTIX175326	SIS091755	SIS196084	STRREB00004528-00004531
Intuitive-00221603-00221626	Intuitive-00601505-00601511	REBOTIX175328	SIS091769	SIS196085	
Intuitive-00221661-00221669	Intuitive-00601672-00601675	Restore-00000970-00001005	SIS091779	SIS196086	
Intuitive-00222027-00222038	Intuitive-00602098	Restore-00001538-00001578	SIS091796-091797	SIS196087-196091	

DOCUMENTS WITHOUT BATES STAMPS:

SIS Financial Statements:

2019 income statement.xls
Apr 2018 Income Statement.xls

SIS Sales by Customer:

Annual Sales by Hosp.xls

SIS Tax Returns:

Tax Return - Surgical Instrument Service Co. - 2019 Client Copy
Copy of State Tax Research (003)
Dept_Summary (1)
Dept_Summary
Vizient_Membership_Eligibility-2022-11-26T21_40_59
Vizient_Public_Sector_Eligibility-2022-11-26T21_43_04

INDEPENDENT RESEARCH:

Intuitive Surgical, Inc. Form 10-K for the fiscal year ended December 31, 2017
Intuitive Surgical, Inc. Annual Report 2018 with Form 10-K for the fiscal year ended December 31, 2018
Intuitive Surgical, Inc. Annual Report 2019 with Form 10-K for the fiscal year ended December 31, 2019
Intuitive Surgical, Inc. Form 10-K for the fiscal year ended December 31, 2020
Intuitive Surgical, Inc. Form 10-K for the fiscal year ended December 31, 2021

New Membership Agreement Between Vizient and the Children's Hospital Association Expands Services to Include Supply Chain Analytics Solutions

Data and Other Information Considered - as of March 1, 2023

Second Rebuttal Attachment 1

Vizient Announces 11 Member Agreements for Q1 2022
Vizient Announces 15 New, Renewed or Expanded Member Agreements in Q1
Vizient Announces 21 New, Renewed or Expanded Member agreements in Q2
Vizient Announces 35 New, Renewed or Expanded Member Agreements in Q3 and Q4 of 2020
Vizient Announces 97 New, Renewed or Expanded Member Agreements in 2021
Vizient Announces New Member Agreement with The University of Texas System
Vizient Announces New Membership Agreement with Leading Academic Health System
Vizient Announces New Membership Agreement with SSM Health

da Vinci Surgical System EndoWrist/Single-Site Instrument & Accessory Catalog (May 2014)
Da Vinci Xi X Instrument & Accessory Catalog (January 2019)
Da Vinci Xi/Xi Instrument & Accessory Catalog (October 2021)

WEBSITES:

<https://www.aha.org/statistics/fast-facts-us-hospitals>
<https://bmpmedical.com/reasons-to-switch-to-single-use-medical-devices-and-disposable-medical-supplies/>
<https://www.carevoyance.com/blog/acute-care-hospitals>
<https://www.cdc.gov/oralhealth/infectioncontrol/faqs/single-use-devices.html>
<https://www.definitivehc.com/blog/how-many-hospitals-are-in-the-us>
<https://www.definitivehc.com/blog/top-10-gpos-by-staffed-beds>
<https://www.fda.gov/media/150141/download>
<https://www.fda.gov/medical-devices/reprocessing-reusable-medical-devices/what-are-reusable-medical-devices>
<https://www.fda.gov/medical-devices/products-and-medical-procedures/reprocessing-reusable-medical-devices>
<https://healthtrustpg.com/about-healthtrust/>
<https://investors.premierinc.com/events-and-reports/reports/default.aspx?section=report>
<https://investors.premierinc.com/news/press-release-details/2016/Premier-Inc-and-Banner-Health-Expand-Partnership/default.aspx>
<https://www.justice.gov/atr/horizontal-merger-guidelines-08192010>
<https://premierinc.com/about>
<https://rebotixrepair.com>
<https://newsroom.vizientinc.com/en-US/releases/vizient-announces-11-member-agreements-for-q1-2022>
<https://supplychainassociation.org/about-us/what-is-gpo>
<https://web.archive.org/web/20191108191050/https://www.vizientinc.com/what-we-do>
<https://www.yankeealliance.com/content/premier-certified-sponsor-affiliates>
<https://www.vizientinc.com>
Moore, Eric J., "Robotic Surgery," Britannica (<https://www.britannica.com/science/robotic-surgery>)
15 USC 1117: Recovery for violation of rights (a) Profits; damages and costs; attorney fees (house.gov)

OTHER:

American Institute of Certified Public Accountants (AICPA) Practice 06-4 (2006)
Association of International Certified Public Accountants (AICPA) Forensic & Valuation Services Practice Aid – Calculating Lost Profits (2018)
The Comprehensive Guide to Economic Damages: Volume One (2020 6th ed., BVR Publications)

DATA AND OTHER INFORMATION CONSIDERED - RECEIVED AFTER THE BERO REPORT DATED DECEMBER 2, 2022:

ADDITIONAL LEGAL FILING:

Intuitive Surgical, Inc. Responses to Rebotix Repair, LLC's Data Questions dated July 9, 2021

Data and Other Information Considered - as of March 1, 2023

Second Rebuttal Attachment 1

ADDITIONAL EXPERT REPORT:

Expert Report of Loren K. Smith, Ph.D. dated December 2, 2022

ADDITIONAL BATES DOCUMENTS:

Intuitive-00000316.xlsm
Intuitive-00595406.XLSX
Intuitive-00595407.xlsx
Intuitive-00595408.xlsx
Intuitive-00595409.xlsx
Intuitive-00595410.xlsx
Intuitive-00595411.xlsx
Intuitive-00595412.xlsx
Intuitive-00595413.xlsx
Intuitive-00595415.xlsx
Intuitive-00595416.XLSX
Intuitive-00595417.xlsx
Intuitive-00595418.xlsx
Intuitive-00595419.xlsx
Intuitive-00595420.xlsx
Intuitive-00595421.xlsx
Intuitive-00595422.xlsx
Intuitive-00595423.xlsx
Intuitive-00595424.xlsx
Intuitive-00595425.xlsx
Intuitive-00595426.xlsx
Intuitive-00595427.xlsx
Intuitive-00595428.xlsx
Intuitive-00595434.xlsx
Intuitive-00595435.xlsx
Intuitive-00595436.xlsx
Intuitive-00695144.xlsx
Intuitive-00695232.xlsx
Intuitive-00695233.xlsx
Intuitive-00695234.xlsx
Intuitive-00701322.xlsx
REBOTIX000253-000263
REBOTIX144629-144633
SIS000046
SIS001637.xlsx
SIS001703-001716
SIS009067-009112
SIS048254
SIS048255.xlsx
SIS337172.xlsx

Data and Other Information Considered - as of March 1, 2023

Second Rebuttal Attachment 1

ADDITIONAL NON-BATES DOCUMENTS:

Smith Workpapers:

0. Master Script.R
Disgorgement Tables.xlsx
Figures - Trend Charts.xlsx
Lost Profits Table.xlsx
Matching Checks.xlsx

DATA AND OTHER INFORMATION CONSIDERED - RECEIVED AFTER THE BERO REBUTTAL REPORT DATED JANUARY 18, 2023:

ADDITIONAL EXPERT REPORTS:

SIS v. Intuitive - Expert Report of Dr. Russell L. Lamb dated December 2, 2022
Expert Antitrust Mertis Rebuttal Report of Loren K. Smith, Ph.D. dated January 18, 2023
Expert Damages Rebuttal Report of Loren K. Smith Ph.D., dated January 18, 2023

ADDITIONAL DISCUSSIONS WITH:

SIS personnel:

Keith Johnson, Executive Vice President, Sales and Clinical Programs
Greg Posdal, President and C.E.O
Chris Gibson, Rebotix's COO

ADDITIONAL BATES DOCUMENTS:

Intuitive-00103407.pdf
Intuitive-00367019.pdf
Intuitive-00566055.pdf
Intuitive-00595405
Intuitive-00595406
Intuitive-00595407
Intuitive-00595408
Intuitive-00595409
Intuitive-00595410
Intuitive-00595411
Intuitive-00595412
Intuitive-00595413
Intuitive-00595415
Intuitive-00595416
Intuitive-00595417
Intuitive-00595418
Intuitive-00595419
Intuitive-00595420
Intuitive-00595421
Intuitive-00595422
Intuitive-00595423
Intuitive-00595424
Intuitive-00595425
Intuitive-00595426

Data and Other Information Considered - as of March 1, 2023

Second Rebuttal Attachment 1

Intuitive-00595427
Intuitive-00595428
Intuitive-00595434
Intuitive-00595435
Intuitive-00595436
Intuitive-00595673.pdf
Intuitive-00603990.pdf
Intuitive-00603992 (1).xlsx
Intuitive-00603992 (2)
Intuitive-00626145.xlsx
Intuitive-00695144
Intuitive-00695232
Intuitive-00695233
Intuitive-00695234
Intuitive-00701322
Intuitive-00706090
Intuitive-02025757_HIGHLY CONFIDENTIAL
Intuitive-02025758_HIGHLY CONFIDENTIAL
Intuitive-02025759_HIGHLY CONFIDENTIAL

Rebotix061127.pdf
REBOTIX162404.pdf
REBOTIX175326_Highly Confiden ial.xlsx

SIS000093.pdf

ADDITIONAL NON-BATES DOCUMENTS:

Letters from The Food and Drug Administration (FDA) to Iconocare Health regarding K210478 dated Sept. 30, 2022 and Nov. 15, 2022

Smith Workpapers:

Bero Sensitivi ies

ADDITIONAL DEPOSITION:

Rebotix Repair LLC v. Intuitive Surgical, Inc. (Case No. 8:20-cv-02274-VMC-TGW):

Deposition of Anthony McGrogan dated June 7, 2021

ADDITIONAL INDEPENDENT RESEARCH:

FDA Clearance to Remanufacture Da Vinci Robotic Instruments Could Present Hospitals with Substan ial Savin.pdf

Any additional documents, websites, or other information referenced throughout this report.

SECOND REBUTTAL ATTACHMENT 2



RICHARD F. BERO, CPA, CVA

N27 W23960 Paul Road, Suite 202, Pewaukee, WI 53072

Phone – (262) 522-7922 Fax – (262) 436-2444

rbero@berogroup.com

PROFESSIONAL EXPERIENCE:

The BERO Group / Corporate Financial Advisors, LLC

Managing Director

Waukesha, Wisconsin

December 1995-Present

Mr. Bero founded Corporate Financial Advisors in 1995 and served as Managing Director. The BERO Group evolved from Corporate Financial Advisors and Mr. Bero serves as Managing Director. Mr. Bero provides financial and accounting consulting services and expert testimony pertaining to valuation issues and financial damages issues.

Coopers & Lybrand

Manager – Litigation & Claims Services

Milwaukee, Wisconsin

1994-1995

Mr. Bero was the Manager and Practice Leader of the Coopers & Lybrand Milwaukee Litigation & Claims Services practice.

Peterson Consulting Limited Partnership

Executive Consultant

Milwaukee, Wisconsin

Chicago, Illinois

1989-1994

1987-1989

Mr. Bero provided litigation and business dispute support services to trial attorneys and corporate counsel.

EDUCATION:

University of Wisconsin–Madison

Bachelor of Business Administration

Accounting and Finance

1986

ACTIVITIES/OTHER:

Intellectual Property Valuation Instructor – National Association of Certified Valuation Analysts
Licensing Executives Society – Co-Chair Wisconsin Chapter – 2006-2008
Intellectual Property Owners Association – Damages Committee Member – 2004-present
National Association of Certified Valuation Analysts, CVA
Wisconsin Institute of Certified Public Accountants:
Board of Directors – 2000-2002
Chairman CPA's In Industry – Committee 1997-1999
Outstanding Committee Chairperson Award – 1997-1998
American Institute of Certified Public Accountants
Becker CPA Review – Instructor 1995-1998

EXPERT WITNESS TESTIMONY – LAST FOUR YEARS:

MCP IP, LLC v. .30-06 Outdoors, LLC; and Daibow, Inc.
United States District Court – Southern District of Ohio
Case No. 2:21-cv-00581-ALM-CMV (filed 2/9/21)
February 2023 (Hearing Testimony)

Crystal Lagoons U.S. Corp. and Crystal Lagoons Technology Inc. v. Cloward H2O LLC and Pacific Aquascape International, Inc.
United States District Court – District of Utah
Case No. 2:19-cv-00796-BSJ (filed 10/21/19)
December 2022 (Deposition Testimony)

Hangzhou Chic Intelligent Technology Co., Ltd., and Unicorn Global, Inc. v. The Partnership and Unincorporated Associations Identified on Schedule "A"
United States District Court – Northern District of Illinois
Case No. 1:20-cv-04806 (filed 8/17/20)
December 2022 (Hearing Testimony)
February 2022 (Deposition Testimony)

Condair Group AG v. Dri-Steem Corporation
United States District Court – U.S. District of Minnesota
Case No. 0:21-cv-00863 (filed 3/29/21)
September 2022 (Deposition Testimony)

Don Lee Farms, a division of Goodman Food Products, Inc., v. Beyond Meat Inc., et al.
State of California – Los Angeles County
Case No. BC662838 (filed 5/25/17)
April 2022 (Deposition Testimony)

G.W. Lisk Company, Inc. v. Power Packer North America, Inc. d/b/a GITS Manufacturing Company
United States District Court – Southern District of Iowa
Case No. 4:17-cv-00273 (filed 7/21/17)
April 2022 (Deposition Testimony)

Sartin et al. v. Chula Vista Inc. et al.
United States District Court – Eastern District of Wisconsin
Case No. 2:18-cv-01890-WED (filed 11/30/18)
October 2021 (Deposition Testimony)

Cyntec Company, Ltd. v. Chilisin Electronics Corp. and Chilisin America Ltd.
United States District Court – Northern District of California
Case No. 4:18-cv-00939-PJH (filed 2/14/18)
August 2021 (Trial Testimony)
June 2020 (Deposition Testimony)

Wudi Industrial (Shanghai) Co., Ltd. v. Wai L. Wong
United States District Court – Eastern District of Virginia
Case No. 1:20-cv-00908-CMH-MSN (filed 8/7/20)
April 2021 (Deposition Testimony)

Vermeer Corporation v. The Toro Company
United States District Court – Southern District of Iowa
Case Nos. 4:17-cv-0076, 4:19-cv-00050 (filed 2/28/17; 2/12/19)
October 2020 (Deposition Testimony)

AOS Holding Company and A.O. Smith Corporation v. Bradford White Corporation
United States District Court – District of Delaware
Case No. 1:18-cv-00412-LPS (filed 3/16/18)
August 2020 (Trial Testimony)
November 2019 (Deposition Testimony)

RAM Group, Inc. v. H5G, LLC
State of Wisconsin – Milwaukee County
Case No. 2018CV010102 (filed 12/10/18)
June 2020 (Deposition Testimony)

Dimensions Events LLC v. Danziger USA
Chicago Rabbinical Council (DT #17-09)
May 2019 (Arbitration Hearing Testimony)
May 2019 (Deposition Testimony)

Smart Solar, Inc. d/b/a Smart Living Home & Garden v. Sky Billiards, Inc. d/b/a Best Choice Products
United States District Court – Northern District of Illinois
Case No.: 1:17-cv-04211 (filed 6/2/17)
April 2019 (Deposition Testimony)

Gold & Levy d/b/a Rosseto v. Cal-Mil Plastic Products, Inc., et al.
United States District Court – Northern District of Illinois
Case No.: 1:17-cv-00786-JBG-YBK (filed 1/31/17)
December 2018 (Deposition Testimony)

PUBLICATIONS:

The Comprehensive Guide to Economic Damages, “Patent Infringement Damages: Lost Profits and Royalties”, “Design Patent Damages” and “Trade Secret Damages” (Chapters 28, 29 and 30, 2020 6th ed., Business Valuation Resources, LLC)

Bero, Richard. *The Litigator’s Damages Blueprint: The Pragmatic Solution*. Wisconsin: 422 Doty, LLC, 2019

The Comprehensive Guide to Economic Damages, “Patent Infringement Damages: Lost Profits and Royalties” and “Trade Secret Damages” (Chapters 26 and 27, 2018 5th ed., BVR Publications)

The Comprehensive Guide to Economic Damages, “Patent Infringement Damages: Lost Profits and Royalties” (Chapter 26, 2016 4th ed., BVR Publications)

The Comprehensive Guide to Lost Profits and Other Commercial Damages, “Patent Infringement Damages: Lost Profits and Royalties” (Chapter 25, 2014 3rd ed., BVR Publications)

April 2011 – CCH Business Valuation Alert, “The *Uniloc* Case: 25 Percent Rule of Thumb Rejected”

The Comprehensive Guide to Lost Profits, “Lost Profits Damages in Patent Infringement Lawsuits” (Chapter 19, 2011 ed., BVR Publications)

August 2009 – IP Law360 – “Demand for the Patented Product – Lower Bar?”

The Comprehensive Guide to Lost Profits, “Lost Profits Damages in Patent Infringement Lawsuits” (Chapter 12, 2009 ed., BVR Publications)

October 2008 – AIPLA White Paper – “Constructing Royalty Rates”

February 2008 – IP Law360 – “IP Litigation in China and the U.S.”

Global Intellectual Property Asset Management Report, “Intellectual Property Metrics Today: It Can Be Done” (June 2005 and July 2005)

Proving and Pricing Construction Claims, “Claims for Lost Profit” (Chapter 14, 2nd ed., 1996, Wiley Law Publications)

PRESENTATIONS:

December 2022	Business Valuation Resources, LLC Commercial Success – Using Economic Analysis to Show Patentability Co-Presenter: Shane Brunner, Michael Best & Friedrich LLP
---------------	--

November 2021	Business Valuation Resources, LLC BVR's Special Series on New Economic Damages Guide Patent Royalty Damages – What’s the Approach? Co-Presenter: John L. Abramic, Steptoe & Johnson LLP
---------------	--

May 2021	Business Valuation Resources, LLC National Economic Damages Virtual Conference 2021 (Day 1) Patent Infringement Damages Co-Presenter: Autumn N. Nero, Perkins Coie LLP
November 2020	American Intellectual Property Law Association Damages Subcommittee – Speaker Series Webinar Part II The Pragmatic Solution©
May 2020	American Intellectual Property Law Association Damages Subcommittee – Speaker Series Webinar Part I The Pragmatic Solution©
February 2020	Marquette Law School Guest Instructor – IP Litigation Class Milwaukee, Wisconsin
May 2019	Milwaukee Bar Association The Pragmatic Solution© Co-Presenter: Shane Brunner, Milwaukee Best & Friedrich LLP Milwaukee, Wisconsin
July 2018	Intellectual Property Owners Association – IP Chat Channel Webinar What’s Next for Design Patent Damages? The DOJ Test on Trial Co-Presenters: James Dottavio, Ford Motor Company and Elizabeth Ferrill, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
September 2016	Wisconsin Intellectual Property Law Association Patent and IP Damages Update Milwaukee, Wisconsin
December 2015	WestLegalEdcenter Webinar Recent Patent Royalty Damages Decisions – Update & Discussion
October 2015	WestLegalEdcenter Webinar Recent Patent Royalty Damages Decisions – Update & Discussion
October 2015	Milwaukee Bar Association VirnetX and Ericsson – The Latest on Apportionment and Comparable Licenses Milwaukee, Wisconsin
July 2015	Hot Topics in Patent Royalty Damages Webinar Business Valuation Resources’ 2015 Special Series on Intellectual Property
April 2014	Michigan Intellectual Property Law Association Hot Topics in Patent Damages Troy, Michigan
May 2013	Hot Topics in Patent Royalty Damages Business Valuation Resources Online Symposium on Economic Damages: Part 3 Chicago, Illinois

September 2011	WestLegalEdcenter Webinar Recent Patent Damages Decisions – What is the Effect
August 2011	WestLegalEdcenter Webinar Constructing Royalty Rate Damages
January 2011	The Evolution of the Entire Market Value Rule Business Valuation Resources Webinar Series on Advanced Topics in Lost Profits Damages Chicago, Illinois
September 2010	Patent Damages: Managing the Risks and Contingent Costs Business Valuation Resources / Morningstar Summit on Best Practices in Valuing Intellectual Property Chicago, Illinois
March 2010	Tianjin Bar Association Damage Analysis Techniques and Considerations in U.S. Patent Litigations Tianjin, China
March 2010	Beijing Lawyers Association Damage Analysis Techniques and Considerations in U.S. Patent Litigations Beijing, China
December 2009	Milwaukee Bar Association Constructing Royalty Rate Damages Milwaukee, Wisconsin
October 2009	Michigan Intellectual Property Law Association Constructing Royalty Rate Damages Detroit, Michigan
June 2009	Licensing Executive Society – Chicago Chapter Constructing Royalty Rates Chicago, Illinois
March 2009	Milwaukee Bar Association Patent Infringement Damages – Working Effectively With Your Damages Expert Milwaukee, Wisconsin
January 2009	Wisconsin Intellectual Property Law Association Constructing Royalty Rates Milwaukee, Wisconsin
November 2008	Licensing Executive Society – Minnesota Chapter Constructing Royalty Rates Minneapolis, Minnesota
October 2008	American Intellectual Property Law Association – Annual Meeting Constructing Royalty Rates Washington, D.C.

October 2008	Minnesota Intellectual Property Law Association Constructing Royalty Rates Minneapolis, Minnesota
June 2008	Presentation to Judges and IP attorneys in China The Development of Patent Damages Shenzhen, China
May 2008	Licensing Executive Society International – Spring Conference Avoiding Intellectual Property Hurdles in the U.S. - The View from China Roundtable Moderator Chicago, Illinois
March 2008	Marquette Law School Royalty Damages in Patent Litigation Guest Instructor – IP Litigation Class Milwaukee, Wisconsin
October 2007	Guarding the Treasure: IP Valuation & Remedies Panelist Sponsored by Foley & Lardner New York, New York
October 2007	Shanghai Bar Association Patent Litigation & Valuation – Real World Examples in the U.S. Shanghai, China
October 2007	Shenzhen Society of Certified Public Appraisers Intellectual Property, Valuation and Damages Analysis – Real World Examples in the U.S. Shenzhen, China
May 2007	Shanghai Intellectual Property Service Center Intellectual Property in the U.S.: Opportunities, Valuation & Litigation Shanghai, China
May 2007	Shenzhen Bar Association Managing and Understanding the Value of IP – Real World Examples in the U.S. Shenzhen, China
October 2006	China Hi-Tech Fair 2006 Protection of Chinese Intellectual Property in the U.S. Patent Damages & Ways to Avoid Infringement Shenzhen, China
August 2006	Nanshan Sub-Bureau of Intellectual Property Administration Intellectual Property Value Issues in the United States an Overview for Chinese Businesses Shenzhen, China

March 2006	Milwaukee Bar Association Hindsight is 20/20: Developing & Presenting Damages in Intellectual Property Litigation and Complex Litigation Milwaukee, Wisconsin
December 2005	Wisconsin Intellectual Property Law Association Intellectual Property Damages Update & Discussion Pewaukee, Wisconsin
October 2005	Licensing Executives Society – Annual Meeting Facilitator: Advanced Practices Working Session III: To Sue or Not? How to Decide Phoenix, Arizona
September 2005	Digital Fabrication 2005 Seminar Panel Discussion: Intellectual Property Baltimore, Maryland
September 2005	Intellectual Property Owner’s Annual Meeting Patent Infringement Damages Update and Discussion Seattle, Washington
April 2005	Licensing Executives Society – Wisconsin Chapter What’s Reasonable: Royalty Damages in Patent Litigation Fond Du Lac, Wisconsin

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Second Rebuttal Schedules Index

Schedule #	Title
Second Rebuttal Schedule 1.0	Damages Summary
Second Rebuttal Schedule 2.0	Scenario 1 - Discounted Lost Profits: In-house Model
Second Rebuttal Schedule 2.1	Scenario 1 - Undiscounted Lost Profits: In-house Model
Second Rebuttal Schedule 2.2	Scenario 1 - Lost EndoWrist Repair Units
Second Rebuttal Schedule 3.0	Scenario 1 - Discounted Lost Profits: Distributor Model
Second Rebuttal Schedule 3.1	Scenario 1 - Undiscounted Lost Profits: Distributor Model
Second Rebuttal Schedule 4.0	Scenario 2 - Discounted Lost Profits: In-house Model (2 Year X/Xi Delay)
Second Rebuttal Schedule 4.1	Scenario 2 - Undiscounted Lost Profits: In-house Model (2 Year X/Xi Delay)
Second Rebuttal Schedule 4.2	Scenario 2 - Lost EndoWrist Repair Units (2 Year X/Xi Delay)
Second Rebuttal Schedule 4.3	Scenario 2 - Discounted Lost Profits: In-house Model (1 Year X/Xi Delay)
Second Rebuttal Schedule 4.4	Scenario 2 - Undiscounted Lost Profits: In-house Model (1 Year X/Xi Delay)
Second Rebuttal Schedule 4.5	Scenario 2 - Lost EndoWrist Repair Units (1 Year X/Xi Delay)
Second Rebuttal Schedule 5.0	Scenario 2 - Discounted Lost Profits: Distributor Model (2 Year X/Xi Delay)
Second Rebuttal Schedule 5.1	Scenario 2 - Undiscounted Lost Profits: Distributor Model (2 Year X/Xi Delay)
Second Rebuttal Schedule 5.2	Scenario 2 - Discounted Lost Profits: Distributor Model (1 Year X/Xi Delay)
Second Rebuttal Schedule 5.3	Scenario 2 - Undiscounted Lost Profits: Distributor Model (1 Year X/Xi Delay)
Second Rebuttal Schedule 6.0	Intuitive's U.S. EndoWrist Instrument Units - Actual and Forecasted: 2014 - 2025
Second Rebuttal Schedule 7.0	Estimated EndoWrist Expiration Rates: 2018 - 2021
Second Rebuttal Schedule 8.0	Potential EndoWrist Instrument Units, Net Sales Dollars and Average Selling Price by System (Using Intuitive Sales Volumes and September 2019 Vizient Amended Agreement Prices): 2018 - June 2022
Second Rebuttal Schedule 8.1	Potential EndoWrist Instrument Units, Net Sales Dollars and ASP by Product (Instrument Number) - da Vinci S/Si (Using Intuitive Sales Volumes and September 2019 Vizient Amended Agreement Prices): 2018 - June 2022
Second Rebuttal Schedule 8.2	Potential EndoWrist Instrument Units, Net Sales Dollars and ASP by Product (Instrument Number) - da Vinci X/Xi (Using Intuitive Sales Volumes and September 2019 Vizient Amended Agreement Prices): 2018 - June 2022
Second Rebuttal Schedule 9.0	SIS's Estimated EndoWrist Instrument Repair Cost: 2020 - June 2022
Second Rebuttal Schedule 9.1	Intuitive's "Top 5" X/Xi EndoWrist Instrument Units: 2018 - June 2022

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Second Rebuttal Schedules Index

Schedule #	Title
Second Rebuttal Schedule 10.0	SIS's Estimated Interceptor Chip Cost (Based on Rebotix's Sales to Restore)
Second Rebuttal Schedule 10.1	Rebotix Sales to SIS: June 27, 2019 - November 21, 2019
Second Rebuttal Schedule 11.0	Potential EndoWrist Instrument Units, Costs and Costs per Unit by System (Using Intuitive Sales Volumes and Rebotix Pricing): 2018 - June 2022
Second Rebuttal Schedule 11.1	Potential EndoWrist Instrument Units, Costs and Costs per Unit by Product (Instrument Number) - da Vinci S/Si (Using Intuitive Sales Volumes and Rebotix Pricing): 2018 - June 2022
Second Rebuttal Schedule 11.2	Potential EndoWrist Instrument Units, Costs and Costs per Unit by Product (Instrument Number) - da Vinci X/Xi (Using Intuitive Sales Volumes and Rebotix Pricing): 2018 - June 2022
Second Rebuttal Schedule 12.0	SIS's EndoWrist Instrument Sales Prices and Costs (from Rebotix) - da Vinci S/Si
Second Rebuttal Schedule 12.1	SIS's EndoWrist Instrument Sales Prices and Costs (from Rebotix) - da Vinci X/Xi
Second Rebuttal Schedule 12.2	SIS's EndoWrist Instrument Sale Price vs Intuitive Sales Price - da Vinci S/Si
Second Rebuttal Schedule 13.0	Intuitive's EndoWrist Instrument Units, Net Sales Dollars and Average Selling Price by System: 2014 - June 2022
Second Rebuttal Schedule 13.1	Intuitive's EndoWrist Instrument Units and Net Sales Dollars by Product (Instrument Number) - da Vinci S/Si: 2014 - June 2022
Second Rebuttal Schedule 13.2	Intuitive's EndoWrist Instrument Units and Net Sales Dollars by Product (Instrument Number) - da Vinci X/Xi: 2014 - June 2022
Second Rebuttal Schedule 14.0	SIS's EndoWrist Instrument Repair Summary
Second Rebuttal Schedule 15.0	SIS's Financial Statements: 2019 - October 2021
Second Rebuttal Schedule 15.1	SIS's Detailed SGA: 2019 - October 2021
Second Rebuttal Schedule 16.0	Intuitive EndoWrist Instrument Average Selling Price, Units and Net Sales Dollars: 2020 - 2025
Second Rebuttal Schedule 16.1	Lanham Act Based on Scenario 2 - Unenforceable Contracts(2 Year X/Xi Delay): 2020 - 2025
Second Rebuttal Schedule 16.2	Lanham Act Based on Scenario 2 - Unenforceable Contracts(1 Year X/Xi Delay): 2020 - 2025

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Damages Summary

Second Rebuttal Schedule 1.0

	2020	2021	2022	2023	2024 (discounted)	2025 (discounted)	Total
Lost profits							
<u>Scenario 1 - Illegal Encryption</u>							
[A] In-house model	\$6,235,557	\$21,765,377	\$30,999,702	\$35,400,982	\$28,213,690	\$8,767,326	\$131,382,634
[B] Distributor model	\$5,573,947	\$19,392,500	\$27,440,979	\$31,335,614	\$24,973,286	\$7,760,334	\$116,476,660
<u>Scenario 2 - Unenforceable Contracts</u>							
<u>2 Year X/Xi delay</u>							
[C] In-house model	\$958,569	\$1,359,572	\$7,179,842	\$25,377,682	\$28,213,690	\$8,767,326	\$71,856,681
[D] Distributor model	\$837,634	\$1,179,972	\$6,357,184	\$22,463,639	\$24,973,286	\$7,760,334	\$63,572,049
<u>1 Year X/Xi delay</u>							
[E] In-house model	\$958,569	\$7,481,387	\$22,338,002	\$35,400,982	\$28,213,690	\$8,767,326	\$103,159,956
[F] Distributor model	\$837,634	\$6,643,796	\$19,774,204	\$31,335,614	\$24,973,286	\$7,760,334	\$91,324,868
Lanham Act							
[G] Scenario 2 - 2 year X/Xi delay	\$3,274,156	\$4,775,564	\$25,742,312	\$91,369,970	\$101,623,818	\$31,582,076	\$258,367,896
[H] Scenario 2 - 1 year X/Xi delay	\$3,274,156	\$26,905,717	\$80,352,656	\$127,480,940	\$101,623,818	\$31,582,076	\$371,219,363

NOTES / SOURCES:

Note: Any minor differences are due to rounding.

[A] Per Second Rebuttal Schedule 2.0.

[B] Per Second Rebuttal Schedule 3.0.

[C] Per Second Rebuttal Schedule 4.0.

[D] Per Second Rebuttal Schedule 5.0.

[E] Per Second Rebuttal Schedule 4.3.

[F] Per Second Rebuttal Schedule 5.2.

[G] Per Second Rebuttal Schedule 16.1.

[H] Per Second Rebuttal Schedule 16.2.

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Scenario 1 - Discounted Lost Profits: In-house Model

Second Rebuttal Schedule 2.0

	2020	2021	2022	2023	2024	2025	Total
<u>Lost EndoWrist repair units</u>							
[A] da Vinci S/Si	1,273	1,796	921	431	170	35	4,626
[B] da Vinci X/Xi	7,209	27,763	40,968	47,407	40,179	14,008	177,534
[C] Total	8,482	29,559	41,889	47,838	40,349	14,043	182,160
<u>Lost revenues</u>							
[A] da Vinci S/Si	\$1,829,301	\$2,605,996	\$1,320,714	\$618,054	\$243,780	\$50,190	\$6,668,035
[B] da Vinci X/Xi	\$10,193,526	\$39,562,275	\$58,666,176	\$67,886,824	\$57,536,328	\$20,059,456	\$253,904,585
[C] Total	\$12,022,827	\$42,168,271	\$59,986,890	\$68,504,878	\$57,780,108	\$20,109,646	\$260,572,620
<u>Incremental costs</u>							
[A] da Vinci S/Si	\$870,732	\$1,246,424	\$637,332	\$298,252	\$117,640	\$24,220	\$3,194,600
[B] da Vinci X/Xi	\$4,916,538	\$19,156,470	\$28,349,856	\$32,805,644	\$27,803,868	\$9,693,536	\$122,725,912
[C] Total	\$5,787,270	\$20,402,894	\$28,987,188	\$33,103,896	\$27,921,508	\$9,717,756	\$125,920,512
<u>Lost profits (undiscounted)</u>							
[A] da Vinci S/Si	\$958,569	\$1,359,572	\$683,382	\$319,802	\$126,140	\$25,970	\$3,473,435
[B] da Vinci X/Xi	\$5,276,988	\$20,405,805	\$30,316,320	\$35,081,180	\$29,732,460	\$10,365,920	\$131,178,673
[C] Total	\$6,235,557	\$21,765,377	\$30,999,702	\$35,400,982	\$29,858,600	\$10,391,890	\$134,652,108
[D] Discount %					12%	12%	
[E] Discount period					0.5	1.5	
[F] Discount factor	1.00000	1.00000	1.00000	1.00000	0.94491	0.84367	
[G] Discounted lost profits	\$6,235,557	\$21,765,377	\$30,999,702	\$35,400,982	\$28,213,690	\$8,767,326	\$131,382,634

NOTES / SOURCES:

Note: Any minor differences are due to rounding.

[A] Per Second Rebuttal Schedule 2.1.

[B] Per Second Rebuttal Schedule 2.1.

[C] = [A] + [B]

[D] For the GICS 35101010, Health Care Equipment & Supplies, Duff and Phelps - Cost of Capital Composite, September 30, 2022, the average SIC/GICS Composite WACC (weighted average cost of capital) is 9.2% and median WACC is 8.9%. For the small composite, the WACC is 11.1% to 11.2% (CRSP Decile). For purposes of my analysis I use 12%, which is conservative. Note: The projections after 2022 do not include growth, therefore the discount rate would likely be less.

[E] Calculated using the mid-year convention to January 1, 2024, the approximate date of trial.

[F] = $(1 + [H])^{-[I]}$, rounded to 5 decimals.

[G] = Lost profits (undiscounted) per [C] * [F]

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Scenario 1 - Undiscounted Lost Profits: In-house Model

Second Rebuttal Schedule 2.1

		2020	2021	2022	2023	2024	2025	Total
da Vinci S/Si								
[A] Lost EndoWrist repair units		1,273	1,796	921	431	170	35	4,626
<u>Per unit</u>								
[B] Average selling price		\$1,437	\$1,451	\$1,434	\$1,434	\$1,434	\$1,434	\$1,441
<u>Incremental costs per unit</u>								
[C] Repair costs		\$148	\$155	\$156	\$156	\$156	\$156	\$153
[D] Chip costs		\$350	\$350	\$350	\$350	\$350	\$350	\$350
[E] Vizient admin fees - % of sales	4%	\$57	\$58	\$57	\$57	\$57	\$57	\$57
[F] Additional SGA - % of sales	9%	\$129	\$131	\$129	\$129	\$129	\$129	\$130
[G] Total incremental costs		\$684	\$694	\$692	\$692	\$692	\$692	\$691
[H] Lost profits per unit		\$753	\$757	\$742	\$742	\$742	\$742	\$751
[I] Lost revenues		\$1,829,301	\$2,605,996	\$1,320,714	\$618,054	\$243,780	\$50,190	\$6,668,035
<u>Incremental costs</u>								
[J] Repair costs		\$188,404	\$278,380	\$143,676	\$67,236	\$26,520	\$5,460	\$709,676
[K] Chip costs		\$445,550	\$628,600	\$322,350	\$150,850	\$59,500	\$12,250	\$1,619,100
[L] Vizient admin fees - 4% of sales		\$72,561	\$104,168	\$52,497	\$24,567	\$9,690	\$1,995	\$265,478
[M] Additional SGA - % of sales		\$164,217	\$235,276	\$118,809	\$55,599	\$21,930	\$4,515	\$600,346
[N] Total incremental costs		\$870,732	\$1,246,424	\$637,332	\$298,252	\$117,640	\$24,220	\$3,194,600
[O] Lost profits - undiscounted		\$958,569	\$1,359,572	\$683,382	\$319,802	\$126,140	\$25,970	\$3,473,435
da Vinci X/Xi								
[A] Lost EndoWrist repair units		7,209	27,763	40,968	47,407	40,179	14,008	177,534
<u>Per unit</u>								
[B] Average selling price		\$1,414	\$1,425	\$1,432	\$1,432	\$1,432	\$1,432	\$1,430
<u>Incremental costs per unit</u>								
[C] Repair costs		\$148	\$155	\$156	\$156	\$156	\$156	\$156
[D] Chip costs		\$350	\$350	\$350	\$350	\$350	\$350	\$350
[E] Vizient admin fees - % of sales	4%	\$57	\$57	\$57	\$57	\$57	\$57	\$57
[F] Additional SGA - % of sales	9%	\$127	\$128	\$129	\$129	\$129	\$129	\$129
[G] Total incremental costs		\$682	\$690	\$692	\$692	\$692	\$692	\$691
[H] Lost profits per unit		\$732	\$735	\$740	\$740	\$740	\$740	\$739
[I] Lost revenues		\$10,193,526	\$39,562,275	\$58,666,176	\$67,886,824	\$57,536,328	\$20,059,456	\$253,904,585
<u>Incremental costs</u>								
[J] Repair costs		\$1,066,932	\$4,303,265	\$6,391,008	\$7,395,492	\$6,267,924	\$2,185,248	\$27,609,869
[K] Chip costs		\$2,523,150	\$9,717,050	\$14,338,800	\$16,592,450	\$14,062,650	\$4,902,800	\$62,136,900
[L] Vizient admin fees - 4% of sales		\$410,913	\$1,582,491	\$2,335,176	\$2,702,199	\$2,290,203	\$798,456	\$10,119,438
[M] Additional SGA - % of sales		\$915,543	\$3,553,664	\$5,284,872	\$6,115,503	\$5,183,091	\$1,807,032	\$22,859,705
[N] Total incremental costs		\$4,916,538	\$19,156,470	\$28,349,856	\$32,805,644	\$27,803,868	\$9,693,536	\$122,725,912
[O] Lost profits - undiscounted		\$5,276,988	\$20,405,805	\$30,316,320	\$35,081,180	\$29,732,460	\$10,365,920	\$131,178,673

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Scenario 1 - Undiscounted Lost Profits: In-house Model

Second Rebuttal Schedule 2.1

NOTES / SOURCES:

Note: Any minor differences are due to rounding.

[A] Per Second Rebuttal Schedule 2.2.

[B] Per Second Rebuttal Schedule 8.0. For purposes of my analysis, the ASP after 2022 is the same as 2022.

[C] Per Second Rebuttal Schedule 9.0. For purposes of my analysis, the cost per unit after 2022 is the same as 2022.

[D] Per Second Rebuttal Schedule 10.0.

[E] = [B] * 4%. Per SIS169233-169280 at 238-239, SIS would have paid Vizient a GPO administrative fee of 4% of net sales. Per SIS319315, SIS would have paid Yankee a 3% administrative fee. SIS would not have paid an administrative fee for non-Vizient and non-Yankee customers. For purposes of my analysis, I assume all sales would have been subject to a 4% administrative fee, consistent with the Vizient Agreement.

[F] = [B] * 9% per Second Rebuttal Schedule 15.1.

[G] = [C] + [D] + [E] + [F]

[H] = [B] - [G]

[I] = [A] * [B]

[J] = [A] * [C]

[K] = [A] * [D]

[L] = [A] * [E]

[M] = [A] * [F]

[N] = [J] + [K] + [L] + [M]

[O] = [I] - [N]

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Scenario 1 - Lost EndoWrist Repair Units

Second Rebuttal Schedule 2.2

	2020	2021	2022	2023	2024	2025	Total
<u>EndoWrist instruments potentially repairable by SIS - units</u>							
[A] da Vinci S/Si	52,970	22,411	8,214	3,839	1,928	1,077	90,439
[A] da Vinci X/Xi	299,954	346,579	365,304	422,719	455,982	437,186	2,327,724
[A] Total	352,924	368,990	373,518	426,558	457,910	438,263	2,418,163
[B] Expiration rate of new sales units	60%	60%	60%	60%	60%	60%	60%
<u>Expired EndoWrist instrument - units</u>							
[C] da Vinci S/Si	31,782	13,447	4,928	2,303	1,157	646	54,263
[C] da Vinci X/Xi	179,972	207,947	219,182	253,631	273,589	262,312	1,396,633
[C] Total	211,754	221,394	224,110	255,934	274,746	262,958	1,450,896
[D] SIS market share rate	55%	55%	55%	55%	55%	55%	55%
<u>SIS market share units</u>							
[E] da Vinci S/Si	17,480	7,396	2,710	1,267	636	355	29,844
[E] da Vinci X/Xi	98,985	114,371	120,550	139,497	150,474	144,272	768,149
[E] Total	116,465	121,767	123,260	140,764	151,110	144,627	797,993
<u>SIS conversion factor</u>							
[F] da Vinci S/Si	15%	50%	70%	70%	70%	70%	
[F] da Vinci X/Xi	15%	50%	70%	70%	70%	70%	
<u>SIS converted units</u>							
[G] da Vinci S/Si	2,622	3,698	1,897	887	445	249	9,798
[G] da Vinci X/Xi	14,848	57,186	84,385	97,648	105,332	100,990	460,389
[G] Total	17,470	60,884	86,282	98,535	105,777	101,239	470,187
[H] Collection rate of SIS converted units	70%	70%	70%	70%	70%	70%	70%
<u>SIS collected units</u>							
[I] da Vinci S/Si	1,835	2,589	1,328	621	312	174	6,859
[I] da Vinci X/Xi	10,394	40,030	59,070	68,354	73,732	70,693	322,273
[I] Total	12,229	42,619	60,398	68,975	74,044	70,867	329,132
[J] Repair yield of SIS would-have-been units	69.35%	69.35%	69.35%	69.35%	69.35%	69.35%	69.35%
<u>Would-have-been Lost EndoWrist repair units</u>							
[K] da Vinci S/Si	1,273	1,796	921	431	216	121	4,758
[K] da Vinci X/Xi	7,209	27,763	40,968	47,407	51,137	49,029	223,513
[K] Total	8,482	29,559	41,889	47,838	51,353	49,150	228,271
[L] Market penetration (% of total units)	2%	8%	11%	11%	11%	11%	9%

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Scenario 1 - Lost EndoWrist Repair Units

Second Rebuttal Schedule 2.2

	2020	2021	2022	2023	2024	2025	Total
<u>Actual conversion rate</u>							
[M] da Vinci S/Si					15%	50%	
[M] da Vinci X/Xi					15%	50%	
<u>Actual EndoWrist repair units</u>							
[N] da Vinci S/Si					46	86	132
[N] da Vinci X/Xi					10,958	35,021	45,979
[N] Total					11,004	35,107	46,111
<u>Lost EndoWrist repair units</u>							
[O] da Vinci S/Si	1,273	1,796	921	431	170	35	4,626
[O] da Vinci X/Xi	7,209	27,763	40,968	47,407	40,179	14,008	177,534
[O] Total	8,482	29,559	41,889	47,838	40,349	14,043	182,160

NOTES / SOURCES:

Note: Any minor differences are due to rounding.

[A] Per Second Rebuttal Schedule 6.0.

[B] Per Second Rebuttal Schedule 7.0.

[C] = [A] * [B]

[D] Per <https://web.archive.org/web/20191108191050/https://www.vizientinc.com/what-we-do> as of November 8, 2019, "50% of the nation's acute care providers are Vizient members." Per <https://www.vizientinc.com/> as of November 29, 2022, Vizient has ">60% of acute care hospitals in the U.S." For purposes of my analysis, I use 55%. See discussion in my report.

[E] = [C] * [D]

[F] Per discussion with Keith Johnson and Greg Posdal, SIS anticipated a quick ramp up in 2020, both in sales and in-house repair capabilities. According to Jean Sargent there would have been a transition timeframe conversion for this type of program. In 2020, or Year 1, 30% of Vizient's acute care providers would have reasonably converted. In 2021, or Year 2, and thereafter, 70% would have reasonably converted. I apply a 15% conversion factor in 2020, or Year 1 (i.e. mid-point between 0% January 1 and 30% December 31st). I apply a 50% conversion factor in 2021, or Year 2 (i.e., mid-point between 30% January 1 and 70% December 31st). I apply a 70% conversion factor in 2022, or Year 3, and thereafter. Per May Dep. 113-114 (November 3, 2022), if the Xi had the same security measures as the Si, Restore would have been able to repair the Xi's as of January 2020.

[G] = [E] * [F]

[H] Per Morales 30(b)(6) Dep. Ex. 143 (Intuitive-00626597-626616 at 604), where Intuitive targets a collection rate of 70%. See *a/so*, Intuitive-00620200 where Intuitive assumes a collection rate of 70%. See *a/so*, Morales 30(b)(6) Dep. Ex. 141 (at pdf page 1), where Intuitive targets a collection rate of 80%. Per discussion with Jean Sargent, I understand for an expensive instrument such as an EndoWrist, a 75% collection rate would be reasonable.

[I] = [G] * [H]

[J] Deposition of Clifton Parker 43-45, 178-179 (October 25, 2022). Per Restore-00094918-00094956 at 922 (Parker Dep. Ex. 121), 215 out of 310 instruments (approximately 69.35%) collected in a 2-week sample that had lives on them passed Restore's inspection (i.e., were repairable). Note: Per Morales 30(b)(6) Dep. Ex. 143 (Intuitive-00626597-626616 at 609), where Intuitive realized a yield of 85%. See *a/so*, Morales 30(b)(6) Dep. Ex. 143 (Intuitive-00626597-626616 at 612), where Intuitive targeted a yield of 85% to 95%. Second Rebuttal Schedule 14.0 shows the repair yield of SIS collectable units was approximately 88%. For purposes of my analysis, I use approximately 69.35%.

Scenario 1 - Lost EndoWrist Repair Units

Second Rebuttal Schedule 2.2

2020	2021	2022	2023	2024	2025	Total
------	------	------	------	------	------	-------

[K] = [I] * [J]

[L] = [K] / [A]

[M] Assuming trial is resolved in or about January 1, 2024, SIS would then begin ramping up. For the Actual EndoWrist repair units, I use the Year 1, Year 2 and Year 3 market conversion rates addressed at [F] above. Currently, I assume Year 1 is 2024 and the first year SIS will begin selling its repair program again. Per May Dep. 60 (November 3, 2022), Restore will have the technical capability to change the usage limitations of the EndoWrist X/Xi's in the third or fourth quarter of 2023. For purposes of this analysis, I assume the conversion rate for the S/Si and X/Xi would be the same starting January 1, 2024.

[N] = [E] * [H] * [J] * [M]

[O] = [K] - [N]

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Scenario 1 - Discounted Lost Profits: Distributor Model

Second Rebuttal Schedule 3.0

	2020	2021	2022	2023	2024	2025	Total
<u>Lost EndoWrist repair units</u>							
[A] da Vinci S/Si	1,273	1,796	921	431	170	35	4,626
[B] da Vinci X/Xi	7,209	27,763	40,968	47,407	40,179	14,008	177,534
[C] Total	8,482	29,559	41,889	47,838	40,349	14,043	182,160
<u>Lost revenues</u>							
[A] da Vinci S/Si	\$1,829,301	\$2,605,996	\$1,320,714	\$618,054	\$243,780	\$50,190	\$6,668,035
[B] da Vinci X/Xi	\$10,193,526	\$39,562,275	\$58,666,176	\$67,886,824	\$57,536,328	\$20,059,456	\$253,904,585
[C] Total	\$12,022,827	\$42,168,271	\$59,986,890	\$68,504,878	\$57,780,108	\$20,109,646	\$260,572,620
<u>Incremental costs</u>							
[A] da Vinci S/Si	\$991,667	\$1,426,024	\$713,775	\$334,025	\$131,750	\$27,125	\$3,624,366
[B] da Vinci X/Xi	\$5,457,213	\$21,349,747	\$31,832,136	\$36,835,239	\$31,219,083	\$10,884,216	\$137,577,634
[C] Total	\$6,448,880	\$22,775,771	\$32,545,911	\$37,169,264	\$31,350,833	\$10,911,341	\$141,202,000
<u>Lost profits (undiscounted)</u>							
[A] da Vinci S/Si	\$837,634	\$1,179,972	\$606,939	\$284,029	\$112,030	\$23,065	\$3,043,669
[B] da Vinci X/Xi	\$4,736,313	\$18,212,528	\$26,834,040	\$31,051,585	\$26,317,245	\$9,175,240	\$116,326,951
[C] Total	\$5,573,947	\$19,392,500	\$27,440,979	\$31,335,614	\$26,429,275	\$9,198,305	\$119,370,620
[D] Discount %					12%	12%	
[E] Discount period					0.5	1.5	
[F] Discount factor	1.00000	1.00000	1.00000	1.00000	0.94491	0.84367	
[G] Discounted lost profits	\$5,573,947	\$19,392,500	\$27,440,979	\$31,335,614	\$24,973,286	\$7,760,334	\$116,476,660

NOTES / SOURCES:

Note: Any minor differences are due to rounding.

[A] Per Second Rebuttal Schedule 3.1.

[B] Per Second Rebuttal Schedule 3.1.

[C] = [A] + [B]

[D] For the GICS 35101010, Health Care Equipment & Supplies, Duff and Phelps - Cost of Capital Composite, September 30, 2022, the average SIC/GICS Composite WACC (weighted average cost of capital) is 9.2% and median WACC is 8.9%. For the small composite, the WACC is 11.1% to 11.2% (CRSP Decile). For purposes of my analysis I use 12%, which is conservative. Note: The projections after 2022 do not include growth, therefore the discount rate would likely be less.

[E] Calculated using the mid-year convention to January 1, 2024, the approximate date of trial.

[F] = $(1 + [H])^{-[I]}$, rounded to 5 decimals.

[G] = Lost profits (undiscounted) per [C] * [F]

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Scenario 1 - Undiscounted Lost Profits: Distributor Model

Second Rebuttal Schedule 3.1

		2020	2021	2022	2023	2024	2025	Total
da Vinci S/Si								
[A] Lost EndoWrist repair units		1,273	1,796	921	431	170	35	4,626
Per unit								
[B] Average selling price		\$1,437	\$1,451	\$1,434	\$1,434	\$1,434	\$1,434	\$1,441
Incremental costs per unit								
[C] Repair costs (including chip costs)		\$593	\$605	\$589	\$589	\$589	\$589	\$596
[D] Vizient admin fees - % of sales	4%	\$57	\$58	\$57	\$57	\$57	\$57	\$57
[E] Additional SGA - % of sales	9%	\$129	\$131	\$129	\$129	\$129	\$129	\$130
[F] Total incremental costs		\$779	\$794	\$775	\$775	\$775	\$775	\$783
[G] Lost profits per unit		\$658	\$657	\$659	\$659	\$659	\$659	\$658
[H] Lost revenues		\$1,829,301	\$2,605,996	\$1,320,714	\$618,054	\$243,780	\$50,190	\$6,668,035
Incremental costs								
[I] Repair costs (including chip costs)		\$754,889	\$1,086,580	\$542,469	\$253,859	\$100,130	\$20,615	\$2,758,542
[J] Vizient admin fees - 4% of sales		\$72,561	\$104,168	\$52,497	\$24,567	\$9,690	\$1,995	\$265,478
[K] Additional SGA - % of sales		\$164,217	\$235,276	\$118,809	\$55,599	\$21,930	\$4,515	\$600,346
[L] Total incremental costs		\$991,667	\$1,426,024	\$713,775	\$334,025	\$131,750	\$27,125	\$3,624,366
[M] Lost profits - undiscounted		\$837,634	\$1,179,972	\$606,939	\$284,029	\$112,030	\$23,065	\$3,043,669
da Vinci X/Xi								
[A] Lost EndoWrist repair units		7,209	27,763	40,968	47,407	40,179	14,008	177,534
Per unit								
[B] Average selling price		\$1,414	\$1,425	\$1,432	\$1,432	\$1,432	\$1,432	\$1,430
Incremental costs per unit								
[C] Repair costs (including chip costs)		\$573	\$584	\$591	\$591	\$591	\$591	\$589
[D] Vizient admin fees - % of sales	4%	\$57	\$57	\$57	\$57	\$57	\$57	\$57
[E] Additional SGA - % of sales	9%	\$127	\$128	\$129	\$129	\$129	\$129	\$129
[F] Total incremental costs		\$757	\$769	\$777	\$777	\$777	\$777	\$775
[G] Lost profits per unit		\$657	\$656	\$655	\$655	\$655	\$655	\$655
[H] Lost revenues		\$10,193,526	\$39,562,275	\$58,666,176	\$67,886,824	\$57,536,328	\$20,059,456	\$253,904,585
Incremental costs								
[I] Repair costs (including chip costs)		\$4,130,757	\$16,213,592	\$24,212,088	\$28,017,537	\$23,745,789	\$8,278,728	\$104,598,491
[J] Vizient admin fees - 4% of sales		\$410,913	\$1,582,491	\$2,335,176	\$2,702,199	\$2,290,203	\$798,456	\$10,119,438
[K] Additional SGA - % of sales		\$915,543	\$3,553,664	\$5,284,872	\$6,115,503	\$5,183,091	\$1,807,032	\$22,859,705
[L] Total incremental costs		\$5,457,213	\$21,349,747	\$31,832,136	\$36,835,239	\$31,219,083	\$10,884,216	\$137,577,634
[M] Lost profits - undiscounted		\$4,736,313	\$18,212,528	\$26,834,040	\$31,051,585	\$26,317,245	\$9,175,240	\$116,326,951

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Scenario 1 - Undiscounted Lost Profits: Distributor Model

Second Rebuttal Schedule 3.1

NOTES / SOURCES:

Note: Any minor differences are due to rounding.

[A] Per Second Rebuttal Schedule 2.2.

[B] Per Second Rebuttal Schedule 8.0. For purposes of my analysis, the ASP after 2022 is the same as 2022.

[C] Per Second Rebuttal Schedule 11.0. For purposes of my analysis, the cost per unit after 2022 is the same as 2022.

[D] = [B] * 4%. Per SIS169233-169280 at 238-239, SIS would have paid Vizient a GPO administrative fee of 4% of net sales. Per SIS319315, SIS would have paid Yankee a 3% administrative fee. SIS would not have paid an administrative fee for non-Vizient and non-Yankee customers. For purposes of my analysis, I assume all sales would have been subject to a 4% administrative fee, consistent with the Vizient Agreement.

[E] = [B] * 9% per Second Rebuttal Schedule 15.1.

[F] = [C] + [D] + [E]

[G] = [B] - [F]

[H] = [A] * [B]

[I] = [A] * [C]

[J] = [A] * [D]

[K] = [A] * [E]

[L] = [I] + [J] + [K]

[M] = [H] - [L]

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Scenario 2 - Discounted Lost Profits: In-house Model (2 Year X/Xi Delay)

Second Rebuttal Schedule 4.0

	2020	2021	2022	2023	2024	2025	Total
<u>Lost EndoWrist repair units</u>							
[A] da Vinci S/Si	1,273	1,796	921	431	170	35	4,626
[B] da Vinci X/Xi	0	0	8,779	33,862	40,179	14,008	96,828
[C] Total	1,273	1,796	9,700	34,293	40,349	14,043	101,454
<u>Lost revenues</u>							
[A] da Vinci S/Si	\$1,829,301	\$2,605,996	\$1,320,714	\$618,054	\$243,780	\$50,190	\$6,668,035
[B] da Vinci X/Xi	\$0	\$0	\$12,571,528	\$48,490,384	\$57,536,328	\$20,059,456	\$138,657,696
[C] Total	\$1,829,301	\$2,605,996	\$13,892,242	\$49,108,438	\$57,780,108	\$20,109,646	\$145,325,731
<u>Incremental costs</u>							
[A] da Vinci S/Si	\$870,732	\$1,246,424	\$637,332	\$298,252	\$117,640	\$24,220	\$3,194,600
[B] da Vinci X/Xi	\$0	\$0	\$6,075,068	\$23,432,504	\$27,803,868	\$9,693,536	\$67,004,976
[C] Total	\$870,732	\$1,246,424	\$6,712,400	\$23,730,756	\$27,921,508	\$9,717,756	\$70,199,576
<u>Lost profits (undiscounted)</u>							
[A] da Vinci S/Si	\$958,569	\$1,359,572	\$683,382	\$319,802	\$126,140	\$25,970	\$3,473,435
[B] da Vinci X/Xi	\$0	\$0	\$6,496,460	\$25,057,880	\$29,732,460	\$10,365,920	\$71,652,720
[C] Total	\$958,569	\$1,359,572	\$7,179,842	\$25,377,682	\$29,858,600	\$10,391,890	\$75,126,155
[D] Discount %					12%	12%	
[E] Discount period					0.5	1.5	
[F] Discount factor	1.00000	1.00000	1.00000	1.00000	0.94491	0.84367	
[G] Discounted lost profits	\$958,569	\$1,359,572	\$7,179,842	\$25,377,682	\$28,213,690	\$8,767,326	\$71,856,681

NOTES / SOURCES:

Note: Any minor differences are due to rounding.

[A] Per Second Rebuttal Schedule 4.1.

[B] Per Second Rebuttal Schedule 4.1.

[C] = [A] + [B]

[D] For the GICS 35101010, Health Care Equipment & Supplies, Duff and Phelps - Cost of Capital Composite, September 30, 2022, the average SIC/GICS Composite WACC (weighted average cost of capital) is 9.2% and median WACC is 8.9%. For the small composite, the WACC is 11.1% to 11.2% (CRSP Decile). For purposes of my analysis I use 12%, which is conservative. Note: The projections after 2022 do not include growth, therefore the discount rate would likely be less.

[E] Calculated using the mid-year convention to January 1, 2024, the approximate date of trial.

[F] = $(1 + [H])^{-[I]}$, rounded to 5 decimals.

[G] = Lost profits (undiscounted) per [C] * [F]

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Scenario 2 - Undiscounted Lost Profits: In-house Model (2 Year X/Xi Delay)

Second Rebuttal Schedule 4.1

		2020	2021	2022	2023	2024	2025	Total
da Vinci S/Si								
[A] Lost EndoWrist repair units		1,273	1,796	921	431	170	35	4,626
<u>Per unit</u>								
[B] Average selling price		\$1,437	\$1,451	\$1,434	\$1,434	\$1,434	\$1,434	\$1,441
<u>Incremental costs per unit</u>								
[C] Repair costs		\$148	\$155	\$156	\$156	\$156	\$156	\$153
[D] Chip costs		\$350	\$350	\$350	\$350	\$350	\$350	\$350
[E] Vizient admin fees - % of sales	4%	\$57	\$58	\$57	\$57	\$57	\$57	\$57
[F] Additional SGA - % of sales	9%	\$129	\$131	\$129	\$129	\$129	\$129	\$130
[G] Total incremental costs		\$684	\$694	\$692	\$692	\$692	\$692	\$691
[H] Lost profits per unit		\$753	\$757	\$742	\$742	\$742	\$742	\$751
[I] Lost revenues		\$1,829,301	\$2,605,996	\$1,320,714	\$618,054	\$243,780	\$50,190	\$6,668,035
<u>Incremental costs</u>								
[J] Repair costs		\$188,404	\$278,380	\$143,676	\$67,236	\$26,520	\$5,460	\$709,676
[K] Chip costs		\$445,550	\$628,600	\$322,350	\$150,850	\$59,500	\$12,250	\$1,619,100
[L] Vizient admin fees - 4% of sales		\$72,561	\$104,168	\$52,497	\$24,567	\$9,690	\$1,995	\$265,478
[M] Additional SGA - % of sales		\$164,217	\$235,276	\$118,809	\$55,599	\$21,930	\$4,515	\$600,346
[N] Total incremental costs		\$870,732	\$1,246,424	\$637,332	\$298,252	\$117,640	\$24,220	\$3,194,600
[O] Lost profits - undiscounted		\$958,569	\$1,359,572	\$683,382	\$319,802	\$126,140	\$25,970	\$3,473,435
da Vinci X/Xi								
[A] Lost EndoWrist repair units		0	0	8,779	33,862	40,179	14,008	96,828
<u>Per unit</u>								
[B] Average selling price		\$1,414	\$1,425	\$1,432	\$1,432	\$1,432	\$1,432	\$1,432
<u>Incremental costs per unit</u>								
[C] Repair costs		\$148	\$155	\$156	\$156	\$156	\$156	\$156
[D] Chip costs		\$350	\$350	\$350	\$350	\$350	\$350	\$350
[E] Vizient admin fees - % of sales	4%	\$57	\$57	\$57	\$57	\$57	\$57	\$57
[F] Additional SGA - % of sales	9%	\$127	\$128	\$129	\$129	\$129	\$129	\$129
[G] Total incremental costs		\$682	\$690	\$692	\$692	\$692	\$692	\$692
[H] Lost profits per unit		\$732	\$735	\$740	\$740	\$740	\$740	\$740
[I] Lost revenues		\$0	\$0	\$12,571,528	\$48,490,384	\$57,536,328	\$20,059,456	\$138,657,696
<u>Incremental costs</u>								
[J] Repair costs		\$0	\$0	\$1,369,524	\$5,282,472	\$6,267,924	\$2,185,248	\$15,105,168
[K] Chip costs		\$0	\$0	\$3,072,650	\$11,851,700	\$14,062,650	\$4,902,800	\$33,889,800
[L] Vizient admin fees - 4% of sales		\$0	\$0	\$500,403	\$1,930,134	\$2,290,203	\$798,456	\$5,519,196
[M] Additional SGA - % of sales		\$0	\$0	\$1,132,491	\$4,368,198	\$5,183,091	\$1,807,032	\$12,490,812
[N] Total incremental costs		\$0	\$0	\$6,075,068	\$23,432,504	\$27,803,868	\$9,693,536	\$67,004,976
[O] Lost profits - undiscounted		\$0	\$0	\$6,496,460	\$25,057,880	\$29,732,460	\$10,365,920	\$71,652,720

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Scenario 2 - Undiscounted Lost Profits: In-house Model (2 Year X/Xi Delay)

Second Rebuttal Schedule 4.1

NOTES / SOURCES:

Note: Any minor differences are due to rounding.

[A] Per Second Rebuttal Schedule 4.2.

[B] Per Second Rebuttal Schedule 8.0. For purposes of my analysis, the ASP after 2022 is the same as 2022.

[C] Per Second Rebuttal Schedule 9.0. For purposes of my analysis, the cost per unit after 2022 is the same as 2022.

[D] Per Second Rebuttal Schedule 10.0.

[E] = [B] * 4%. Per SIS169233-169280 at 238-239, SIS would have paid Vizient a GPO administrative fee of 4% of net sales. Per SIS319315, SIS would have paid Yankee a 3% administrative fee. SIS would not have paid an administrative fee for non-Vizient and non-Yankee customers. For purposes of my analysis, I assume all sales would have been subject to a 4% administrative fee, consistent with the Vizient Agreement.

[F] = [B] * 9% per Second Rebuttal Schedule 15.1.

[G] = [C] + [D] + [E] + [F]

[H] = [B] - [G]

[I] = [A] * [B]

[J] = [A] * [C]

[K] = [A] * [D]

[L] = [A] * [E]

[M] = [A] * [F]

[N] = [J] + [K] + [L] + [M]

[O] = [I] - [N]

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Scenario 2 - Lost EndoWrist Repair Units (2 Year X/Xi Delay)

Second Rebuttal Schedule 4.2

	2020	2021	2022	2023	2024	2025	Total
<u>EndoWrist instruments potentially repairable by SIS - units</u>							
[A] da Vinci S/Si	52,970	22,411	8,214	3,839	1,928	1,077	90,439
[A] da Vinci X/Xi	0	0	365,304	422,719	455,982	437,186	1,681,191
[A] Total	52,970	22,411	373,518	426,558	457,910	438,263	1,771,630
[B] Expiration rate of new sales units	60%	60%	60%	60%	60%	60%	60%
<u>Expired EndoWrist instrument - units</u>							
[C] da Vinci S/Si	31,782	13,447	4,928	2,303	1,157	646	54,263
[C] da Vinci X/Xi	0	0	219,182	253,631	273,589	262,312	1,008,714
[C] Total	31,782	13,447	224,110	255,934	274,746	262,958	1,062,977
[D] SIS market share rate	55%	55%	55%	55%	55%	55%	55%
<u>SIS market share units</u>							
[E] da Vinci S/Si	17,480	7,396	2,710	1,267	636	355	29,844
[E] da Vinci X/Xi	0	0	120,550	139,497	150,474	144,272	554,793
[E] Total	17,480	7,396	123,260	140,764	151,110	144,627	584,637
<u>SIS conversion factor</u>							
[F] da Vinci S/Si	15%	50%	70%	70%	70%	70%	
[F] da Vinci X/Xi			15%	50%	70%	70%	
<u>SIS converted units</u>							
[G] da Vinci S/Si	2,622	3,698	1,897	887	445	249	9,798
[G] da Vinci X/Xi	0	0	18,083	69,749	105,332	100,990	294,154
[G] Total	2,622	3,698	19,980	70,636	105,777	101,239	303,952
[H] Collection rate of SIS market share units	70%	70%	70%	70%	70%	70%	70%
<u>SIS collected units</u>							
[I] da Vinci S/Si	1,835	2,589	1,328	621	312	174	6,859
[I] da Vinci X/Xi	0	0	12,658	48,824	73,732	70,693	205,907
[I] Total	1,835	2,589	13,986	49,445	74,044	70,867	212,766
[J] Repair yield of SIS would-have-been units	69.35%	69.35%	69.35%	69.35%	69.35%	69.35%	69.35%
<u>Would-have-been Lost EndoWrist repair units</u>							
[K] da Vinci S/Si	1,273	1,796	921	431	216	121	4,758
[K] da Vinci X/Xi	0	0	8,779	33,862	51,137	49,029	142,807
[K] Total	1,273	1,796	9,700	34,293	51,353	49,150	147,565
[L] Market penetration (% of total units)	2%	8%	3%	8%	11%	11%	8%

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Scenario 2 - Lost EndoWrist Repair Units (2 Year X/Xi Delay)

Second Rebuttal Schedule 4.2

	2020	2021	2022	2023	2024	2025	Total
<u>Actual conversion rate</u>							
[M] da Vinci S/Si					15%	50%	
[M] da Vinci X/Xi					15%	50%	
<u>Actual EndoWrist repair units</u>							
[N] da Vinci S/Si					46	86	132
[N] da Vinci X/Xi					10,958	35,021	45,979
[N] Total					11,004	35,107	46,111
<u>Lost EndoWrist repair units</u>							
[O] da Vinci S/Si	1,273	1,796	921	431	170	35	4,626
[O] da Vinci X/Xi	0	0	8,779	33,862	40,179	14,008	96,828
[O] Total	1,273	1,796	9,700	34,293	40,349	14,043	101,454

NOTES / SOURCES:

Note: Any minor differences are due to rounding.

[A] Per Second Rebuttal Schedule 6.0. Note: Per Parker Dep. 143-144 (October 25, 2022), in a but for world (a world without Intuitive's anticompetitive behaviors), Restore would have begun repairing X/Xi EndoWrists by January 2022. For purposes of my analysis, I assume X/Xi EndoWrist repairs start on January 1, 2022.

[B] Per Second Rebuttal Schedule 7.0.

[C] = [A] * [B]

[D] Per <https://web.archive.org/web/20191108191050/https://www.vizientinc.com/what-we-do> as of November 8, 2019, "50% of the nation's acute care providers are Vizient members." Per <https://www.vizientinc.com/> as of November 29, 2022, Vizient has ">60% of acute care hospitals in the U.S." For purposes of my analysis, I use 55%. See discussion in my report.

[E] = [C] * [D]

[F] Per discussion with Jean Sargent, I understand the conversion rate would have been at 30% at the end of year 1, 70% at the end of year 2 and 70% thereafter, recognizing SIS would not have gotten all hospitals. For purposes of my analysis, I use an average of 15% in year 1, 50% in year 2 and 70% thereafter. Also, per discussions with Greg Posdal and Keith Johnson, I understand SIS believed its ramp up period would have been one year.

[G] = [E] * [F]

[H] Per Morales 30(b)(6) Dep. Ex. 143 (Intuitive-00626597-626616 at 604), where Intuitive targets a collection rate of 70%. See *a/so*, Intuitive-00620200 where Intuitive assumes a collection rate of 70%. See *a/so*, Morales 30(b)(6) Dep. Ex. 141 (at pdf page 1), where Intuitive targets a collection rate of 80%. Per discussion with Jean Sargent, I understand for an expensive instrument such as an EndoWrist, a 75% collection rate would be reasonable.

[I] = [G] * [H]

[J] Deposition of Clifton Parker 43-45, 178-179 (October 25, 2022). Per Restore-00094918-00094956 at 922 (Parker Dep. Ex. 121), 215 out of 310 instruments (approximately 69.35%) collected in a 2-week sample that had lives on them passed Restore's inspection (i.e., were repairable). Note: Per Morales 30(b)(6) Dep. Ex. 143 (Intuitive-00626597-626616 at 609), where Intuitive realized a yield of 85%. See also, Morales 30(b)(6) Dep. Ex. 143 (Intuitive-00626597-626616 at 612), where Intuitive targeted a yield of 85% to 95%. Second Rebuttal Schedule 14.0 shows the repair yield of SIS collectable units was approximately 88%. For purposes of my analysis, I use approximately 69.35%.

[K] = [I] * [J]

Scenario 2 - Lost EndoWrist Repair Units (2 Year X/Xi Delay)

Second Rebuttal Schedule 4.2

2020	2021	2022	2023	2024	2025	Total
------	------	------	------	------	------	-------

[L] = [K] / [A]

[M] Assuming trial is resolved in or about January 1, 2024, SIS would then begin ramping up. For the Actual EndoWrist repair units, I use the Year 1, Year 2 and Year 3 market conversion rates addressed at [F] above. Currently, I assume Year 1 is 2024 and the first year SIS will begin selling its repair program again. Per May Dep. 60 (November 3, 2022), Restore will have the technical capability to change the usage limitations of the EndoWrist X/Xi's in the third or fourth quarter of 2023. For purposes of this analysis, I assume the conversion rate for the S/Si and X/Xi would be the same starting January 1, 2024.

[N] = [E] * [H] * [J] * [M]

[O] = [K] - [N]

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Scenario 2 - Discounted Lost Profits: In-house Model (1 Year X/Xi Delay)

Second Rebuttal Schedule 4.3

	2020	2021	2022	2023	2024	2025	Total
<u>Lost EndoWrist repair units</u>							
[A] da Vinci S/Si	1,273	1,796	921	431	170	35	4,626
[B] da Vinci X/Xi	0	8,329	29,263	47,407	40,179	14,008	139,186
[C] Total	1,273	10,125	30,184	47,838	40,349	14,043	143,812
<u>Lost revenues</u>							
[A] da Vinci S/Si	\$1,829,301	\$2,605,996	\$1,320,714	\$618,054	\$243,780	\$50,190	\$6,668,035
[B] da Vinci X/Xi	\$0	\$11,868,825	\$41,904,616	\$67,886,824	\$57,536,328	\$20,059,456	\$199,256,049
[C] Total	\$1,829,301	\$14,474,821	\$43,225,330	\$68,504,878	\$57,780,108	\$20,109,646	\$205,924,084
<u>Incremental costs</u>							
[A] da Vinci S/Si	\$870,732	\$1,246,424	\$637,332	\$298,252	\$117,640	\$24,220	\$3,194,600
[B] da Vinci X/Xi	\$0	\$5,747,010	\$20,249,996	\$32,805,644	\$27,803,868	\$9,693,536	\$96,300,054
[C] Total	\$870,732	\$6,993,434	\$20,887,328	\$33,103,896	\$27,921,508	\$9,717,756	\$99,494,654
<u>Lost profits (undiscounted)</u>							
[A] da Vinci S/Si	\$958,569	\$1,359,572	\$683,382	\$319,802	\$126,140	\$25,970	\$3,473,435
[B] da Vinci X/Xi	\$0	\$6,121,815	\$21,654,620	\$35,081,180	\$29,732,460	\$10,365,920	\$102,955,995
[C] Total	\$958,569	\$7,481,387	\$22,338,002	\$35,400,982	\$29,858,600	\$10,391,890	\$106,429,430
[D] Discount %					12%	12%	
[E] Discount period					0.5	1.5	
[F] Discount factor	1.00000	1.00000	1.00000	1.00000	0.94491	0.84367	
[G] Discounted lost profits	\$958,569	\$7,481,387	\$22,338,002	\$35,400,982	\$28,213,690	\$8,767,326	\$103,159,956

NOTES / SOURCES:

Note: Any minor differences are due to rounding.

[A] Per Second Rebuttal Schedule 4.4.

[B] Per Second Rebuttal Schedule 4.4.

[C] = [A] + [B]

[D] For the GICS 35101010, Health Care Equipment & Supplies, Duff and Phelps - Cost of Capital Composite, September 30, 2022, the average WACC (weighted average cost of capital) is 9.2% and median WACC is 8.9%. For the small composite, the WACC is 11.1% to 11.2% (CRSP Decile). For purposes of my analysis I use 12%, which is conservative. Note: The projections after 2022 do not include growth, therefore the discount rate would likely be less.

[E] Calculated using the mid-year convention to January 1, 2024, the approximate date of trial.

[F] = $(1 + [H])^{-[I]}$, rounded to 5 decimals.

[G] = Lost profits (undiscounted) per [C] * [F]

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Scenario 2 - Undiscounted Lost Profits: In-house Model (1 Year X/Xi Delay)

Second Rebuttal Schedule 4.4

		2020	2021	2022	2023	2024	2025	Total
da Vinci S/Si								
[A] Lost EndoWrist repair units		1,273	1,796	921	431	170	35	4,626
<u>Per unit</u>								
[B] Average selling price		\$1,437	\$1,451	\$1,434	\$1,434	\$1,434	\$1,434	\$1,441
<u>Incremental costs per unit</u>								
[C] Repair costs		\$148	\$155	\$156	\$156	\$156	\$156	\$153
[D] Chip costs		\$350	\$350	\$350	\$350	\$350	\$350	\$350
[E] Vizient admin fees - % of sales	4%	\$57	\$58	\$57	\$57	\$57	\$57	\$57
[F] Additional SGA - % of sales	9%	\$129	\$131	\$129	\$129	\$129	\$129	\$130
[G] Total incremental costs		\$684	\$694	\$692	\$692	\$692	\$692	\$691
[H] Lost profits per unit		\$753	\$757	\$742	\$742	\$742	\$742	\$751
[I] Lost revenues		\$1,829,301	\$2,605,996	\$1,320,714	\$618,054	\$243,780	\$50,190	\$6,668,035
<u>Incremental costs</u>								
[J] Repair costs		\$188,404	\$278,380	\$143,676	\$67,236	\$26,520	\$5,460	\$709,676
[K] Chip costs		\$445,550	\$628,600	\$322,350	\$150,850	\$59,500	\$12,250	\$1,619,100
[L] Vizient admin fees - 4% of sales		\$72,561	\$104,168	\$52,497	\$24,567	\$9,690	\$1,995	\$265,478
[M] Additional SGA - % of sales		\$164,217	\$235,276	\$118,809	\$55,599	\$21,930	\$4,515	\$600,346
[N] Total incremental costs		\$870,732	\$1,246,424	\$637,332	\$298,252	\$117,640	\$24,220	\$3,194,600
[O] Lost profits - undiscounted		\$958,569	\$1,359,572	\$683,382	\$319,802	\$126,140	\$25,970	\$3,473,435
da Vinci X/Xi								
[A] Lost EndoWrist repair units		0	8,329	29,263	47,407	40,179	14,008	139,186
<u>Per unit</u>								
[B] Average selling price		\$1,414	\$1,425	\$1,432	\$1,432	\$1,432	\$1,432	\$1,432
<u>Incremental costs per unit</u>								
[C] Repair costs		\$148	\$155	\$156	\$156	\$156	\$156	\$156
[D] Chip costs		\$350	\$350	\$350	\$350	\$350	\$350	\$350
[E] Vizient admin fees - % of sales	4%	\$57	\$57	\$57	\$57	\$57	\$57	\$57
[F] Additional SGA - % of sales	9%	\$127	\$128	\$129	\$129	\$129	\$129	\$129
[G] Total incremental costs		\$682	\$690	\$692	\$692	\$692	\$692	\$692
[H] Lost profits per unit		\$732	\$735	\$740	\$740	\$740	\$740	\$740
[I] Lost revenues		\$0	\$11,868,825	\$41,904,616	\$67,886,824	\$57,536,328	\$20,059,456	\$199,256,049
<u>Incremental costs</u>								
[J] Repair costs		\$0	\$1,290,995	\$4,565,028	\$7,395,492	\$6,267,924	\$2,185,248	\$21,704,687
[K] Chip costs		\$0	\$2,915,150	\$10,242,050	\$16,592,450	\$14,062,650	\$4,902,800	\$48,715,100
[L] Vizient admin fees - 4% of sales		\$0	\$474,753	\$1,667,991	\$2,702,199	\$2,290,203	\$798,456	\$7,933,602
[M] Additional SGA - % of sales		\$0	\$1,066,112	\$3,774,927	\$6,115,503	\$5,183,091	\$1,807,032	\$17,946,665
[N] Total incremental costs		\$0	\$5,747,010	\$20,249,996	\$32,805,644	\$27,803,868	\$9,693,536	\$96,300,054
[O] Lost profits - undiscounted		\$0	\$6,121,815	\$21,654,620	\$35,081,180	\$29,732,460	\$10,365,920	\$102,955,995

Scenario 2 - Undiscounted Lost Profits: In-house Model (1 Year X/Xi Delay)

Second Rebuttal Schedule 4.4

NOTES / SOURCES:

Note: Any minor differences are due to rounding.

[A] Per Second Rebuttal Schedule 4.5.

[B] Per Second Rebuttal Schedule 8.0. For purposes of my analysis, the ASP after 2022 is the same as 2022.

[C] Per Second Rebuttal Schedule 9.0. For purposes of my analysis, the cost per unit after 2022 is the same as 2022.

[D] Per Second Rebuttal Schedule 10.0.

[E] = [B] * 4%. Per SIS169233-169280 at 238-239, SIS would have paid Vizient a GPO administrative fee of 4% of net sales. Per SIS319315, SIS would have paid Yankee a 3% administrative fee. SIS would not have paid an administrative fee for non-Vizient and non-Yankee customers. For purposes of my analysis, I assume all sales would have been subject to a 4% administrative fee, consistent with the Vizient Agreement.

[F] = [B] * 9% per Second Rebuttal Schedule 15.1.

[G] = [C] + [D] + [E] + [F]

[H] = [B] - [G]

[I] = [A] * [B]

[J] = [A] * [C]

[K] = [A] * [D]

[L] = [A] * [E]

[M] = [A] * [F]

[N] = [J] + [K] + [L] + [M]

[O] = [I] - [N]

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Scenario 2 - Lost EndoWrist Repair Units (1 Year X/Xi Delay)

Second Rebuttal Schedule 4.5

	2020	2021	2022	2023	2024	2025	Total
<u>EndoWrist instruments potentially repairable by SIS - units</u>							
[A] da Vinci S/Si	52,970	22,411	8,214	3,839	1,928	1,077	90,439
[A] da Vinci X/Xi	0	346,579	365,304	422,719	455,982	437,186	2,027,770
[A] Total	52,970	368,990	373,518	426,558	457,910	438,263	2,118,209
[B] Expiration rate of new sales units	60%	60%	60%	60%	60%	60%	60%
<u>Expired EndoWrist instrument - units</u>							
[C] da Vinci S/Si	31,782	13,447	4,928	2,303	1,157	646	54,263
[C] da Vinci X/Xi	0	207,947	219,182	253,631	273,589	262,312	1,216,661
[C] Total	31,782	221,394	224,110	255,934	274,746	262,958	1,270,924
[D] SIS market share rate	55%	55%	55%	55%	55%	55%	55%
<u>SIS market share units</u>							
[E] da Vinci S/Si	17,480	7,396	2,710	1,267	636	355	29,844
[E] da Vinci X/Xi	0	114,371	120,550	139,497	150,474	144,272	669,164
[E] Total	17,480	121,767	123,260	140,764	151,110	144,627	699,008
<u>SIS conversion factor</u>							
[F] da Vinci S/Si	15%	50%	70%	70%	70%	70%	
[F] da Vinci X/Xi		15%	50%	70%	70%	70%	
<u>SIS converted units</u>							
[G] da Vinci S/Si	2,622	3,698	1,897	887	445	249	9,798
[G] da Vinci X/Xi	0	17,156	60,275	97,648	105,332	100,990	381,401
[G] Total	2,622	20,854	62,172	98,535	105,777	101,239	391,199
[H] Collection rate of SIS market share units	70%	70%	70%	70%	70%	70%	70%
<u>SIS collected units</u>							
[I] da Vinci S/Si	1,835	2,589	1,328	621	312	174	6,859
[I] da Vinci X/Xi	0	12,009	42,193	68,354	73,732	70,693	266,981
[I] Total	1,835	14,598	43,521	68,975	74,044	70,867	273,840
[J] Repair yield of SIS would-have-been units	69.35%	69.35%	69.35%	69.35%	69.35%	69.35%	69.35%
<u>Would-have-been Lost EndoWrist repair units</u>							
[K] da Vinci S/Si	1,273	1,796	921	431	216	121	4,758
[K] da Vinci X/Xi	0	8,329	29,263	47,407	51,137	49,029	185,165
[K] Total	1,273	10,125	30,184	47,838	51,353	49,150	189,923
[L] Market penetration (% of total units)	2%	3%	8%	11%	11%	11%	9%

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Scenario 2 - Lost EndoWrist Repair Units (1 Year X/Xi Delay)

Second Rebuttal Schedule 4.5

	2020	2021	2022	2023	2024	2025	Total
<u>Actual conversion rate</u>							
[M] da Vinci S/Si					15%	50%	
[M] da Vinci X/Xi					15%	50%	
<u>Actual EndoWrist repair units</u>							
[N] da Vinci S/Si					46	86	132
[N] da Vinci X/Xi					10,958	35,021	45,979
[N] Total					11,004	35,107	46,111
<u>Lost EndoWrist repair units</u>							
[O] da Vinci S/Si	1,273	1,796	921	431	170	35	4,626
[O] da Vinci X/Xi	0	8,329	29,263	47,407	40,179	14,008	139,186
[O] Total	1,273	10,125	30,184	47,838	40,349	14,043	143,812

NOTES / SOURCES:

Note: Any minor differences are due to rounding.

[A] Per Second Rebuttal Schedule 6.0. Note: Marcus Engineering proposed a statement of work to Restore in late June 2019 for circumventing the X/Xi encryption and resetting the X/Xi EndoWrist use counter. I understand Marcus Engineering's efforts "have been successful in many of the aspects" of "reverse engineering on the Xi[.]" Based on progress as of November 2022, Restore anticipates that it will have the technical ability to reset the X/Xi EndoWrist use counter in "the third and fourth quarter, 2023." See May Dep. 40 and 60-61 (November 3, 2022) and May Dep. Exhibit 155. For purposes of my analysis, I assume X/Xi EndoWrist repairs start on January 1, 2021.

[B] Per Second Rebuttal Schedule 7.0.

[C] = [A] * [B]

[D] Per <https://web.archive.org/web/20191108191050/https://www.vizientinc.com/what-we-do> as of November 8, 2019, "50% of the nation's acute care providers are Vizient members." Per <https://www.vizientinc.com/> as of November 29, 2022, Vizient has ">60% of acute care hospitals in the U.S." For purposes of my analysis, I use 55%. See discussion in my report.

[E] = [C] * [D]

[F] Per discussion with Jean Sargent, I understand the conversion rate would have been at 30% at the end of year 1, 70% at the end of year 2 and 70% thereafter, recognizing SIS would not have gotten all hospitals. For purposes of my analysis, I use an average of 15% in year 1, 50% in year 2 and 70% thereafter. Also, per discussions with Greg Posdal and Keith Johnson, I understand SIS believed its ramp up period would have been one year.

[G] = [E] * [F]

[H] Per Morales 30(b)(6) Dep. Ex. 143 (Intuitive-00626597-626616 at 604), where Intuitive targets a collection rate of 70%. See *a/so*, Intuitive-00620200 where Intuitive assumes a collection rate of 70%. See *a/so*, Morales 30(b)(6) Dep. Ex. 141 (at pdf page 1), where Intuitive targets a collection rate of 80%. Per discussion with Jean Sargent, I understand for an expensive instrument such as an EndoWrist, a 75% collection rate would be reasonable.

[I] = [G] * [H]

[J] Deposition of Clifton Parker 43-45, 178-179 (October 25, 2022). Per Restore-00094918-00094956 at 922 (Parker Dep. Ex. 121), 215 out of 310 instruments (approximately 69.35%) collected in a 2-week sample that had lives on them passed Restore's inspection (i.e., were repairable). Note: Per Morales 30(b)(6) Dep. Ex. 143 (Intuitive-00626597-626616 at 609), where Intuitive realized a yield of 85%. See also, Morales 30(b)(6) Dep. Ex. 143 (Intuitive-00626597-626616 at 612), where Intuitive targeted a yield of 85% to 95%. Second Rebuttal Schedule 14.0 shows the repair yield of SIS collectable units was approximately 88%. For purposes of my analysis, I use approximately 69.35%.

Scenario 2 - Lost EndoWrist Repair Units (1 Year X/Xi Delay)

Second Rebuttal Schedule 4.5

2020	2021	2022	2023	2024	2025	Total
------	------	------	------	------	------	-------

[K] = [I] * [J]

[L] = [K] / [A]

[M] Assuming trial is resolved in or about January 1, 2024, SIS would then begin ramping up. For the Actual EndoWrist repair units, I use the Year 1, Year 2 and Year 3 market conversion rates addressed at [F] above. Currently, I assume Year 1 is 2024 and the first year SIS will begin selling its repair program again. Per May Dep. 60 (November 3, 2022), Restore will have the technical capability to change the usage limitations of the EndoWrist X/Xi's in the third or fourth quarter of 2023. For purposes of this analysis, I assume the conversion rate for the S/Si and X/Xi would be the same starting January 1, 2024.

[N] = [E] * [H] * [J] * [M]

[O] = [K] - [N]

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Scenario 2 - Discounted Lost Profits: Distributor Model (2 Year X/Xi Delay) Second Rebuttal Schedule 5.0

	2020	2021	2022	2023	2024	2025	Total
<u>Lost EndoWrist repair units</u>							
[A] da Vinci S/Si	1,273	1,796	921	431	170	35	4,626
[B] da Vinci X/Xi	0	0	8,779	33,862	40,179	14,008	96,828
[C] Total	1,273	1,796	9,700	34,293	40,349	14,043	101,454
<u>Lost revenues</u>							
[A] da Vinci S/Si	\$1,829,301	\$2,605,996	\$1,320,714	\$618,054	\$243,780	\$50,190	\$6,668,035
[B] da Vinci X/Xi	\$0	\$0	\$12,571,528	\$48,490,384	\$57,536,328	\$20,059,456	\$138,657,696
[C] Total	\$1,829,301	\$2,605,996	\$13,892,242	\$49,108,438	\$57,780,108	\$20,109,646	\$145,325,731
<u>Incremental costs</u>							
[A] da Vinci S/Si	\$991,667	\$1,426,024	\$713,775	\$334,025	\$131,750	\$27,125	\$3,624,366
[B] da Vinci X/Xi	\$0	\$0	\$6,821,283	\$26,310,774	\$31,219,083	\$10,884,216	\$75,235,356
[C] Total	\$991,667	\$1,426,024	\$7,535,058	\$26,644,799	\$31,350,833	\$10,911,341	\$78,859,722
<u>Lost profits (undiscounted)</u>							
[A] da Vinci S/Si	\$837,634	\$1,179,972	\$606,939	\$284,029	\$112,030	\$23,065	\$3,043,669
[B] da Vinci X/Xi	\$0	\$0	\$5,750,245	\$22,179,610	\$26,317,245	\$9,175,240	\$63,422,340
[C] Total	\$837,634	\$1,179,972	\$6,357,184	\$22,463,639	\$26,429,275	\$9,198,305	\$66,466,009
[D] Discount %					12%	12%	
[E] Discount period					0.5	1.5	
[F] Discount factor	1.00000	1.00000	1.00000	1.00000	0.94491	0.84367	
[G] Discounted lost profits	\$837,634	\$1,179,972	\$6,357,184	\$22,463,639	\$24,973,286	\$7,760,334	\$63,572,049

NOTES / SOURCES:

Note: Any minor differences are due to rounding.

[A] Per Second Rebuttal Schedule 5.1.

[B] Per Second Rebuttal Schedule 5.1.

[C] = [A] + [B]

[D] For the GICS 35101010, Health Care Equipment & Supplies, Duff and Phelps - Cost of Capital Composite, September 30, 2022, the average SIC/GICS Composite WACC (weighted average cost of capital) is 9.2% and median WACC is 8.9%. For the small composite, the WACC is 11.1% to 11.2% (CRSP Decile). For purposes of my analysis I use 12%, which is conservative. Note: The projections after 2022 do not include growth, therefore the discount rate would likely be less.

[E] Calculated using the mid-year convention to January 1, 2024, the approximate date of trial.

[F] = $(1 + [H])^{-[I]}$, rounded to 5 decimals.

[G] = Lost profits (undiscounted) per [C] * [F]

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Scenario 2 - Undiscounted Lost Profits: Distributor Model (2 Year X/Xi Delay)

Second Rebuttal Schedule 5.1

		2020	2021	2022	2023	2024	2025	Total
da Vinci S/Si								
[A] Lost EndoWrist repair units		1,273	1,796	921	431	170	35	4,626
Per unit								
[B] Average selling price		\$1,437	\$1,451	\$1,434	\$1,434	\$1,434	\$1,434	\$1,441
Incremental costs per unit								
[C] Repair costs (including chip costs)		\$593	\$605	\$589	\$589	\$589	\$589	\$596
[D] Vizient admin fees - % of sales	4%	\$57	\$58	\$57	\$57	\$57	\$57	\$57
[E] Additional SGA - % of sales	9%	\$129	\$131	\$129	\$129	\$129	\$129	\$130
[F] Total incremental costs		\$779	\$794	\$775	\$775	\$775	\$775	\$783
[G] Lost profits per unit		\$658	\$657	\$659	\$659	\$659	\$659	\$658
[H] Lost revenues		\$1,829,301	\$2,605,996	\$1,320,714	\$618,054	\$243,780	\$50,190	\$6,668,035
Incremental costs								
[I] Repair costs (including chip costs)		\$754,889	\$1,086,580	\$542,469	\$253,859	\$100,130	\$20,615	\$2,758,542
[J] Vizient admin fees - 4% of sales		\$72,561	\$104,168	\$52,497	\$24,567	\$9,690	\$1,995	\$265,478
[K] Additional SGA - % of sales		\$164,217	\$235,276	\$118,809	\$55,599	\$21,930	\$4,515	\$600,346
[L] Total incremental costs		\$991,667	\$1,426,024	\$713,775	\$334,025	\$131,750	\$27,125	\$3,624,366
[M] Lost profits - undiscounted		\$837,634	\$1,179,972	\$606,939	\$284,029	\$112,030	\$23,065	\$3,043,669
da Vinci X/Xi								
[A] Lost EndoWrist repair units		0	0	8,779	33,862	40,179	14,008	96,828
Per unit								
[B] Average selling price		\$1,414	\$1,425	\$1,432	\$1,432	\$1,432	\$1,432	\$1,432
Incremental costs per unit								
[C] Repair costs (including chip costs)		\$573	\$584	\$591	\$591	\$591	\$591	\$591
[D] Vizient admin fees - % of sales	4%	\$57	\$57	\$57	\$57	\$57	\$57	\$57
[E] Additional SGA - % of sales	9%	\$127	\$128	\$129	\$129	\$129	\$129	\$129
[F] Total incremental costs		\$757	\$769	\$777	\$777	\$777	\$777	\$777
[G] Lost profits per unit		\$657	\$656	\$655	\$655	\$655	\$655	\$655
[H] Lost revenues		\$0	\$0	\$12,571,528	\$48,490,384	\$57,536,328	\$20,059,456	\$138,657,696
Incremental costs								
[I] Repair costs (including chip costs)		\$0	\$0	\$5,188,389	\$20,012,442	\$23,745,789	\$8,278,728	\$57,225,348
[J] Vizient admin fees - 4% of sales		\$0	\$0	\$500,403	\$1,930,134	\$2,290,203	\$798,456	\$5,519,196
[K] Additional SGA - % of sales		\$0	\$0	\$1,132,491	\$4,368,198	\$5,183,091	\$1,807,032	\$12,490,812
[L] Total incremental costs		\$0	\$0	\$6,821,283	\$26,310,774	\$31,219,083	\$10,884,216	\$75,235,356
[M] Lost profits - undiscounted		\$0	\$0	\$5,750,245	\$22,179,610	\$26,317,245	\$9,175,240	\$63,422,340

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Scenario 2 - Undiscounted Lost Profits: Distributor Model (2 Year X/Xi Delay) Second Rebuttal Schedule 5.1

NOTES / SOURCES:

Note: Any minor differences are due to rounding.

[A] Per Second Rebuttal Schedule 4.2.

[B] Per Second Rebuttal Schedule 8.0. For purposes of my analysis, the ASP after 2022 is the same as 2022.

[C] Per Second Rebuttal Schedule 11.0. For purposes of my analysis, the cost per unit after 2022 is the same as 2022.

[D] = [B] * 4%. Per SIS169233-169280 at 238-239, SIS would have paid Vizient a GPO administrative fee of 4% of net sales. Per SIS319315, SIS would have paid Yankee a 3% administrative fee. SIS would not have paid an administrative fee for non-Vizient and non-Yankee customers. For purposes of my analysis, I assume all sales would have been subject to a 4% administrative fee, consistent with the Vizient Agreement.

[E] = [B] * 9% per Second Rebuttal Schedule 15.1.

[F] = [C] + [D] + [E]

[G] = [B] - [F]

[H] = [A] * [B]

[I] = [A] * [C]

[J] = [A] * [D]

[K] = [A] * [E]

[L] = [I] + [J] + [K]

[M] = [H] - [L]

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Scenario 2 - Discounted Lost Profits: Distributor Model (1 Year X/Xi Delay)

Second Rebuttal Schedule 5.2

	2020	2021	2022	2023	2024	2025	Total
<u>Lost EndoWrist repair units</u>							
[A] da Vinci S/Si	1,273	1,796	921	431	170	35	4,626
[B] da Vinci X/Xi	0	8,329	29,263	47,407	40,179	14,008	139,186
[C] Total	1,273	10,125	30,184	47,838	40,349	14,043	143,812
<u>Lost revenues</u>							
[A] da Vinci S/Si	\$1,829,301	\$2,605,996	\$1,320,714	\$618,054	\$243,780	\$50,190	\$6,668,035
[B] da Vinci X/Xi	\$0	\$11,868,825	\$41,904,616	\$67,886,824	\$57,536,328	\$20,059,456	\$199,256,049
[C] Total	\$1,829,301	\$14,474,821	\$43,225,330	\$68,504,878	\$57,780,108	\$20,109,646	\$205,924,084
<u>Incremental costs</u>							
[A] da Vinci S/Si	\$991,667	\$1,426,024	\$713,775	\$334,025	\$131,750	\$27,125	\$3,624,366
[B] da Vinci X/Xi	\$0	\$6,405,001	\$22,737,351	\$36,835,239	\$31,219,083	\$10,884,216	\$108,080,890
[C] Total	\$991,667	\$7,831,025	\$23,451,126	\$37,169,264	\$31,350,833	\$10,911,341	\$111,705,256
<u>Lost profits (undiscounted)</u>							
[A] da Vinci S/Si	\$837,634	\$1,179,972	\$606,939	\$284,029	\$112,030	\$23,065	\$3,043,669
[B] da Vinci X/Xi	\$0	\$5,463,824	\$19,167,265	\$31,051,585	\$26,317,245	\$9,175,240	\$91,175,159
[C] Total	\$837,634	\$6,643,796	\$19,774,204	\$31,335,614	\$26,429,275	\$9,198,305	\$94,218,828
[D] Discount %					12%	12%	
[E] Discount period					0.5	1.5	
[F] Discount factor	1.00000	1.00000	1.00000	1.00000	0.94491	0.84367	
[G] Discounted lost profits	\$837,634	\$6,643,796	\$19,774,204	\$31,335,614	\$24,973,286	\$7,760,334	\$91,324,868

NOTES / SOURCES:

Note: Any minor differences are due to rounding.

[A] Per Second Rebuttal Schedule 5.3.

[B] Per Second Rebuttal Schedule 5.3.

[C] = [A] + [B]

[D] For the GICS 35101010, Health Care Equipment & Supplies, Duff and Phelps - Cost of Capital Composite, September 30, 2022, the average WACC (weighted average cost of capital) is 9.2% and median WACC is 8.9%. For the small composite, the WACC is 11.1% to 11.2% (CRSP Decile). For purposes of my analysis I use 12%, which is conservative. Note: The projections after 2022 do not include growth, therefore the discount rate would likely be less.

[E] Calculated using the mid-year convention to January 1, 2024, the approximate date of trial.

[F] = $(1 + [H])^{-[I]}$, rounded to 5 decimals.

[G] = Lost profits (undiscounted) per [C] * [F]

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Scenario 2 - Undiscounted Lost Profits: Distributor Model (1 Year X/Xi Delay)

Second Rebuttal Schedule 5.3

		2020	2021	2022	2023	2024	2025	Total
da Vinci S/Si								
[A] Lost EndoWrist repair units		1,273	1,796	921	431	170	35	4,626
Per unit								
[B] Average selling price		\$1,437	\$1,451	\$1,434	\$1,434	\$1,434	\$1,434	\$1,441
Incremental costs per unit								
[C] Repair costs (including chip costs)		\$593	\$605	\$589	\$589	\$589	\$589	\$596
[D] Vizient admin fees - % of sales	4%	\$57	\$58	\$57	\$57	\$57	\$57	\$57
[E] Additional SGA - % of sales	9%	\$129	\$131	\$129	\$129	\$129	\$129	\$130
[F] Total incremental costs		\$779	\$794	\$775	\$775	\$775	\$775	\$783
[G] Lost profits per unit		\$658	\$657	\$659	\$659	\$659	\$659	\$658
[H] Lost revenues		\$1,829,301	\$2,605,996	\$1,320,714	\$618,054	\$243,780	\$50,190	\$6,668,035
Incremental costs								
[I] Repair costs (including chip costs)		\$754,889	\$1,086,580	\$542,469	\$253,859	\$100,130	\$20,615	\$2,758,542
[J] Vizient admin fees - 4% of sales		\$72,561	\$104,168	\$52,497	\$24,567	\$9,690	\$1,995	\$265,478
[K] Additional SGA - % of sales		\$164,217	\$235,276	\$118,809	\$55,599	\$21,930	\$4,515	\$600,346
[L] Total incremental costs		\$991,667	\$1,426,024	\$713,775	\$334,025	\$131,750	\$27,125	\$3,624,366
[M] Lost profits - undiscounted		\$837,634	\$1,179,972	\$606,939	\$284,029	\$112,030	\$23,065	\$3,043,669
da Vinci X/Xi								
[A] Lost EndoWrist repair units		0	8,329	29,263	47,407	40,179	14,008	139,186
Per unit								
[B] Average selling price		\$1,414	\$1,425	\$1,432	\$1,432	\$1,432	\$1,432	\$1,432
Incremental costs per unit								
[C] Repair costs (including chip costs)		\$573	\$584	\$591	\$591	\$591	\$591	\$591
[D] Vizient admin fees - % of sales	4%	\$57	\$57	\$57	\$57	\$57	\$57	\$57
[E] Additional SGA - % of sales	9%	\$127	\$128	\$129	\$129	\$129	\$129	\$129
[F] Total incremental costs		\$757	\$769	\$777	\$777	\$777	\$777	\$777
[G] Lost profits per unit		\$657	\$656	\$655	\$655	\$655	\$655	\$655
[H] Lost revenues		\$0	\$11,868,825	\$41,904,616	\$67,886,824	\$57,536,328	\$20,059,456	\$199,256,049
Incremental costs								
[I] Repair costs (including chip costs)		\$0	\$4,864,136	\$17,294,433	\$28,017,537	\$23,745,789	\$8,278,728	\$82,200,623
[J] Vizient admin fees - 4% of sales		\$0	\$474,753	\$1,667,991	\$2,702,199	\$2,290,203	\$798,456	\$7,933,602
[K] Additional SGA - % of sales		\$0	\$1,066,112	\$3,774,927	\$6,115,503	\$5,183,091	\$1,807,032	\$17,946,665
[L] Total incremental costs		\$0	\$6,405,001	\$22,737,351	\$36,835,239	\$31,219,083	\$10,884,216	\$108,080,890
[M] Lost profits - undiscounted		\$0	\$5,463,824	\$19,167,265	\$31,051,585	\$26,317,245	\$9,175,240	\$91,175,159

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Scenario 2 - Undiscounted Lost Profits: Distributor Model (1 Year X/Xi Delay) Second Rebuttal Schedule 5.3

NOTES / SOURCES:

Note: Any minor differences are due to rounding.

[A] Per Second Rebuttal Schedule 4.5.

[B] Per Second Rebuttal Schedule 8.0. For purposes of my analysis, the ASP after 2022 is the same as 2022.

[C] Per Second Rebuttal Schedule 11.0. For purposes of my analysis, the cost per unit after 2022 is the same as 2022.

[D] = [B] * 4%. Per SIS169233-169280 at 238-239, SIS would have paid Vizient a GPO administrative fee of 4% of net sales. Per SIS319315, SIS would have paid Yankee a 3% administrative fee. SIS would not have paid an administrative fee for non-Vizient and non-Yankee customers. For purposes of my analysis, I assume all sales would have been subject to a 4% administrative fee, consistent with the Vizient Agreement.

[E] = [B] * 9% per Second Rebuttal Schedule 15.1.

[F] = [C] + [D] + [E]

[G] = [B] - [F]

[H] = [A] * [B]

[I] = [A] * [C]

[J] = [A] * [D]

[K] = [A] * [E]

[L] = [I] + [J] + [K]

[M] = [H] - [L]

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Intuitive's U.S. EndoWrist Instrument Units - Actual and Forecasted: 2014 - 2025

Second Rebuttal Schedule 6.0

2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2020-2021 decline
------	------	------	------	------	------	------	------	------	------	------	------	----------------------

Actual EndoWrist instrument units

[A] da Vinci S/Si												
[A] da Vinci X/Xi												
[A] da Vinci Xi 2.0/Xi R												
[A] Total												

% share of units by system

[B] da Vinci S/Si	95.0%	81.4%	70.0%	57.2%	43.2%	28.2%	15.0%	6.1%	2.2%
[B] da Vinci X/Xi	5.0%	18.6%	30.0%	42.8%	56.8%	71.8%	85.0%	93.9%	97.8%
[B] da Vinci Xi 2.0/Xi R	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
[B] Total	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

Projected % of units by system

[C] da Vinci S/Si								0.9%	0.4%	0.2%
[C] da Vinci X/Xi								99.1%	94.6%	81.2%
[C] da Vinci Xi 2.0/Xi R								0.0%	5.0%	18.6%
								100.0%	100.0%	100.0%

[D] Expected growth in procedures

--	--	--

Forecasted EndoWrist instrument units

[E] da Vinci S/Si	3,839	1,928	1,077
[E] da Vinci X/Xi	422,719	455,982	437,186
[E] da Vinci Xi 2.0/Xi R	0	24,101	100,144
[E] Total	426,558	482,011	538,406

Actual & forecasted EndoWrist instrument units

[F] da Vinci S/Si				3,839	1,928	1,077
[F] da Vinci X/Xi				422,719	455,982	437,186
[F] da Vinci Xi 2.0/Xi R				0	24,101	100,144
[F] Total				426,558	482,011	538,406
[F] Sub-total S/Si and X/Xi				426,558	457,910	438,263

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Intuitive's U.S. EndoWrist Instrument Units - Actual and Forecasted: 2014 - 2025

Second Rebuttal Schedule 6.0

NOTES / SOURCES:

Note: Any minor differences are due to rounding.

[A] Per Second Rebuttal Schedule 13.0. Note: Actual unit sales per Second Rebuttal Schedule 13.0 are through June 2022. 2022 unit sales shown herein are annualized.

[B] Calculated based on the amounts herein.

[C] Units sales of da Vinci S/Si are projected to decline in the future at the same rate that sales declined (57.7%) between 2020 and 2021.

I understand the next generation da Vinci system could be introduced as some time in 2024 (See Somayaji Dep. 128-130). For purposes of this analysis, I assume the start of 2024. The share of sales of instruments for that next-generation system (da Vinci Xi 2.0/Xi R) are projected using the same penetration rates experienced by da Vinci X/Xi when it was introduced in 2014 (i.e., 5.0% in first year, 18.6% in second year, and so on), which is conservative given the next generation system (da Vinci Xi 2.0/Xi R) will face more legacy da Vinci systems when it is introduced.

Unit sales of da Vinci X/Xi is projected as 100% less the projected shares of da Vinci X/Xi and the next generation system.

[D] Per Intuitive forecasted annual growth rates for da Vinci surgical procedures in the United States. See Intuitive-01261766.

[E] Total forecast instrument sales calculated each year by applying growth rate **[D]** to total sales during prior year. Sales are allocated by system using shares from **[C]**.

[F] Calculated based on the amounts herein.

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Potential EndoWrist Instrument Units, Net Sales Dollars and Average Selling Price by System (Using Intuitive Sales Volumes and September 2019 Vizient Amended Agreement Prices): 2018 - June 2022

Second Rebuttal Schedule 8.0

	2018	2019	2020	2021	2022	Total	%
					thru June		
Units							
[A] da Vinci S/Si							
[B] da Vinci X/Xi							
[C] Total							
Net sales dollars							
[A] da Vinci S/Si							
[B] da Vinci X/Xi							
[C] Total							
ASP per unit							
[D] da Vinci S/Si	\$1,431	\$1,432	\$1,437	\$1,451	\$1,434	\$1,434	
[D] da Vinci X/Xi	\$1,418	\$1,411	\$1,414	\$1,425	\$1,432	\$1,420	
[D] Total	\$1,424	\$1,417	\$1,418	\$1,427	\$1,432	\$1,423	

NOTES / SOURCES:

Note: Any minor differences are due to rounding.

[A] Per Second Rebuttal Schedule 8.1.

[B] Per Second Rebuttal Schedule 8.2.

[C] = [A] + [B]

[D] Calculated based on the amounts herein.

2018	2019	2020	2021	2022	Total	%
				thru June		

[illegible]

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Potential EndoWrist Instrument Units, Net Sales Dollars and ASP by Product (Instrument Number) - da Vinci S/Si (Using Intuitive Sales Volumes and September 2019 Vizient Amended Agreement Prices): 2018 - June 2022

Second Rebuttal Schedule 8.1

	2018	2019	2020	2021	2022 thru June	Total	%
ASP							
[B] 420179	\$1,700	\$1,700	\$1,700	\$1,700	\$1,700	\$1,700	
[B] 420006	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	
[B] 420093	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	
[B] 420205	\$1,600	\$1,600	\$1,600	\$1,600	\$1,600	\$1,600	
[B] 420309	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	
[B] 420194	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	
[B] 420172	\$1,600	\$1,600	\$1,600	\$1,600	\$1,600	\$1,600	
[B] 420049	\$1,100	\$1,100	\$1,100	\$1,100	\$1,100	\$1,100	
[B] 420227	\$1,600	\$1,600	\$1,600	\$1,600	\$1,600	\$1,600	
[B] 420183	\$1,100	\$1,100	\$1,100	\$1,100	\$1,100	\$1,100	
[B] 420296	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	
[B] 420230	\$1,100	\$1,100	\$1,100	\$1,100	\$1,100	\$1,100	
[B] 420184	\$1,100	\$1,100	\$1,100	\$1,100	\$1,100	\$1,100	
[B] 420327	\$1,100	\$1,100	\$1,100	\$1,100	\$1,100	\$1,100	
[B] 420207	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	
[B] 420190	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	
[B] 420189	\$1,100	\$1,100	\$1,100	\$1,100	\$1,100	\$1,100	
[B] 420110	\$1,600	\$1,600	\$1,600	\$1,600	\$1,600	\$1,600	
[B] 420048	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	
[B] 420318	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	
[B] 420003	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	
[B] 420001	\$1,100	\$1,100	\$1,100	\$1,100	\$1,100	\$1,100	
[B] 420007	\$1,100	\$1,100	\$1,100	\$1,100	\$1,100	\$1,100	
[B] 420278	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	
[B] 420344	\$1,600	\$1,600	\$1,600	\$1,600	\$1,600	\$1,600	
[B] 420033	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Potential EndoWrist Instrument Units, Net Sales Dollars and ASP by Product (Instrument Number) - da Vinci S/Si (Using Intuitive Sales Volumes and September 2019 Vizient Amended Agreement Prices): 2018 - June 2022


Second Rebuttal Schedule 8.1

	2018	2019	2020	2021	2022 thru June	Total	%
[B] 420036	\$1,100	\$1,100	\$1,100	\$1,100	\$1,100	\$1,100	
[B] 420178	\$1,100	\$1,100	\$1,100	\$1,100	\$1,100	\$1,100	
[B] 420171	\$1,600	\$1,600	\$1,600	\$1,600	\$1,600	\$1,600	
[B] 420246	\$1,600	\$1,600	\$1,600	\$1,600	\$1,600	\$1,600	
[B] 420249	\$1,600	\$1,600	\$1,600	\$1,600	\$1,600	\$1,600	
[B] 420181	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	
[B] 420157	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	
[B] 420204	\$1,600	\$1,600	\$1,600	\$1,600	\$1,600	\$1,600	
[B] 420121	\$1,600	\$1,600	\$1,600	\$1,600	\$1,600	\$1,600	
[B] 420215	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	
[B] 420203	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	
[B] 420192	\$1,100	\$1,100	\$1,100	\$1,100	\$1,100	\$1,100	

Potential EndoWrist Instrument Units, Net Sales Dollars and ASP by Product (Instrument Number) - da Vinci S/Si (Using Intuitive Sales Volumes and September 2019 Vizient Amended Agreement Prices): 2018 - June 2022

Second Rebuttal Schedule 8.1

2018	2019	2020	2021	2022	Total	%
				thru June		

[C]						
[C]						
[C]						
[C]						
[C]						
[C]						
[C]						
[C]						
[C]						
[C]						
[C]						
[C]						
[C]						
[C]						
[C]						
[C]	Total net sales dollars					

NOTES / SOURCES:

Note: Any minor differences are due to rounding.

[A] Per Second Rebuttal Schedule 13.1.

[B] Per Second Rebuttal Schedule 12.0.

[C] = [A] * [B]

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Potential EndoWrist Instrument Units, Net Sales Dollars and ASP by Product (Instrument Number) - da Vinci X/Xi (Using Intuitive Sales Volumes and September 2019 Vizient Amended Agreement Prices): 2018 - June 2022

Second Rebuttal Schedule 8.2

	2018	2019	2020	2021	2022 thru June	Total	%
ASP							
[B] 470179	\$1,700	\$1,700	\$1,700	\$1,700	\$1,700	\$1,700	
[B] 470205	\$1,600	\$1,600	\$1,600	\$1,600	\$1,600	\$1,600	
[B] 471205	\$1,600	\$1,600	\$1,600	\$1,600	\$1,600	\$1,600	
[B] 470006	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	
[B] 470093	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	
[B] 470309	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	
[B] 471309	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	
[B] 470183	\$1,100	\$1,100	\$1,100	\$1,100	\$1,100	\$1,100	
[B] 471093	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	
[B] 471006	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	
[B] 470194	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	
[B] 470049	\$1,100	\$1,100	\$1,100	\$1,100	\$1,100	\$1,100	
[B] 470172	\$1,600	\$1,600	\$1,600	\$1,600	\$1,600	\$1,600	
[B] 471049	\$1,100	\$1,100	\$1,100	\$1,100	\$1,100	\$1,100	
[B] 471172	\$1,600	\$1,600	\$1,600	\$1,600	\$1,600	\$1,600	
[B] 470327	\$1,100	\$1,100	\$1,100	\$1,100	\$1,100	\$1,100	
[B] 470230	\$1,100	\$1,100	\$1,100	\$1,100	\$1,100	\$1,100	
[B] 470318	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	
[B] 470296	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	
[B] 471296	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	
[B] 470184	\$1,100	\$1,100	\$1,100	\$1,100	\$1,100	\$1,100	
[B] 470207	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	
[B] 470001	\$1,100	\$1,100	\$1,100	\$1,100	\$1,100	\$1,100	
[B] 470344	\$1,600	\$1,600	\$1,600	\$1,600	\$1,600	\$1,600	
[B] 470007	\$1,100	\$1,100	\$1,100	\$1,100	\$1,100	\$1,100	
[B] 470190	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Potential EndoWrist Instrument Units, Net Sales Dollars and ASP by Product (Instrument Number) - da Vinci X/Xi (Using Intuitive Sales Volumes and September 2019 Vizient Amended Agreement Prices): 2018 - June 2022

Second Rebuttal Schedule 8.2

	2018	2019	2020	2021	2022 thru June	Total	%
[B] 471190	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	
[B] 471344	\$1,600	\$1,600	\$1,600	\$1,600	\$1,600	\$1,600	
[B] 470048	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	
[B] 470036	\$1,100	\$1,100	\$1,100	\$1,100	\$1,100	\$1,100	
[B] 471048	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	
[B] 470033	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	
[B] 470249	\$1,600	\$1,600	\$1,600	\$1,600	\$1,600	\$1,600	
[B] 470171	\$1,600	\$1,600	\$1,600	\$1,600	\$1,600	\$1,600	
[B] 470246	\$1,600	\$1,600	\$1,600	\$1,600	\$1,600	\$1,600	
[B] 471171	\$1,600	\$1,600	\$1,600	\$1,600	\$1,600	\$1,600	
[B] 470215	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	
[B] 470181	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	\$1,300	

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

SIS's Estimated EndoWrist Instrument Repair Cost: 2020 - June 2022 Second Rebuttal Schedule 9.0

	2020	2021	2022 thru June	Total
Actual Intuitive instrument sales units for "Top 5" X/Xi instruments				
[A] 470006 / 471006 (Large Needle Driver)				
[A] 470179 (Hot Shears (Monopolar Curved Scissors))				
[A] 470205 / 471205 (Fenestrated Bipolar Forceps)				
[A] 470093 / 471093 (ProGrasp Forceps)				
[A] 470172 / 471172 (Maryland Bipolar Forceps)				
[B] Total	188,638	213,879	113,918	516,435
Intuitive COGS for refurbishment per unit (SIS's estimated repair cost per unit)				
[C] 470006 / 471006 (Large Needle Driver)				
[C] 470179 (Hot Shears (Monopolar Curved Scissors))				
[C] 470205 / 471205 (Fenestrated Bipolar Forceps)				
[C] 470093 / 471093 (ProGrasp Forceps)				
[C] 470172 / 471172 (Maryland Bipolar Forceps)				
Total Intuitive COGS for refurbishment per unit (SIS's estimated repair cost)				
[D] 470006 / 471006 (Large Needle Driver)				
[D] 470179 (Hot Shears (Monopolar Curved Scissors))				
[D] 470205 / 471205 (Fenestrated Bipolar Forceps)				
[D] 470093 / 471093 (ProGrasp Forceps)				
[D] 470172 / 471172 (Maryland Bipolar Forceps)				
[E] Total	\$27,926,837	\$33,072,546	\$17,812,049	\$78,811,432
[F] SIS's estimated weighted average repair cost per instrument (rounded)	\$148.00	\$155.00	\$156.00	\$153.00

SIS's Estimated EndoWrist Instrument Repair Cost: 2020 - June 2022 Second Rebuttal Schedule 9.0

NOTES / SOURCES:

Note: Any minor differences are due to rounding.

[A] Per Second Rebuttal Schedule 9.1.

[B] Sum of [A]

[C] Intuitive anticipated refurbishment costs are per Morales 30(b)(6) Dep. at Ex. 143 (Intuitive 00626597-626616 at 626612). For purposes of my analysis, I assume SIS's repair costs per unit would have approximated Intuitive anticipated refurbishment cost per unit. However, based on discussions with Greg Posdal, I understand SIS's material cost would generally fall below \$10 per unit, less than Intuitive's anticipated \$48 to \$141 per unit. Instrument numbers identified per comparison of Morales 30(b)(6) Dep. Ex. 141 (at pdf page 3) and Morales 30(b)(6) Dep. at Ex. 143 (Intuitive 00626597-626616 at 626612). For purposes of my analysis, I assume the Intuitive cost for the "replacement" instrument number is the same as the amount shown for the "original" instrument number.

[D] = [A] * [C]

[E] Sum of [D]

[F] = [E] / [B]

Intuitive's "Top 5" X/Xi EndoWrist Instrument Units: 2018 - June 2022 Second Rebuttal Schedule 9.1

2018	2019	2020	2021	2022	Total
				thru June	

[A]
[A]
[B]

[A]

[A]
[A]
[B]

[A]
[A]
[B]

NOTES / SOURCES:

Note: Any minor differences are due to rounding.

[A] Per Second Rebuttal Schedule 13.2. Instrument numbers identified based on Instrument numbers identified per comparison of Morales 30(b)(6) Dep. Ex. 141 (at pdf page 3). For purposes of this analysis, I also include the "replacement" instrument number.

[B] Calculated based on the amounts herein.

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

SIS's Estimated Interceptor Chip Cost (Based on Rebotix's Sales to Restore)

Second Rebuttal Schedule 10.0

	Date	Memo	Item	Quantity	Sale Price	Amount
[A]	5/15/2019	Interceptor assembly programmed with 10 Uses	Interceptor-010 (Interceptor assembly programmed with 10 Uses)	30	\$800	\$24,000
[A]	5/15/2019	New Customer Repair Credits	Discount		(\$10,400)	(\$10,400)
[A]	9/4/2019	Interceptor assembly programmed with 10 Uses	Interceptor-010 (Interceptor assembly programmed with 10 Uses)	25	\$800	\$20,000
[A]	9/4/2019	Less Credit for providing 7 free units to new customers	Discount		(\$5,600)	(\$5,600)
[A]	10/15/2019	Interceptor assembly programmed with 10 Uses	Interceptor-010 (Interceptor assembly programmed with 10 Uses)	5	\$800	\$4,000
[B]	Total			60		\$32,000
[C] Average cost per Interceptor chip (rounded) based on limited volumes						\$533.00
[D] Average cost per Interceptor chip						\$350.00

NOTES / SOURCES:

Note: Any minor differences are due to rounding.

[A] Per REBOTIX175326. Calculation above is based on Rebotix's sales to Restore.

[B] Sum of [A]

[C] = Amount per [B] / Quantity per [B]. Based on this limited volume, I now use the Average cost per Interceptor chip as described in [D].

[D] In January 2020, a Memorandum of Understanding was drafted between SIS and Rebotix, which contained proposed pricing terms for Interceptor chips, including a maximum price per Interceptor chip of \$800 and volume discounts up to \$450 per Interceptor chip at 300 units (Gibson Dep. Ex.'s 13 and 14) (*Rebotix Repair LLC v. Intuitive Surgical, Inc.*, No. 8:20-cv-02274-VMC-TGW (M.D. Fla. filed Sept. 28, 2020)). Per discussion with Chris Gibson and as described in my report, volume discounts for thousands of annual units would have been greater than \$450 per chip. This means the Interceptor chip prices (i.e., SIS's costs) would have been, at most, the net \$350 cost. Rebotix's Interceptor chip prices (net of volume discounts) would have likely been less than \$350 per chip to SIS. They would have likely been \$200 to \$300 per chip at SIS purchase volumes approaching 50,000 annual chips. For purposes of my analysis, I use \$350 as the average cost per Interceptor chip.

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Rebotix Sales to SIS: June 27, 2019 - November 21, 2019

Second Rebuttal Schedule 10.1

	Date	Num	Memo	Item	Quantity	Sale Price	Amount
[A]	6/27/2019	26674	Mega SutureCut Needle Driver EndoWrist Repair Service	420309-SVC (Mega SutureCut Needle Driver EndoWrist Repair Service)	1	\$900	\$900
[A]	6/27/2019	26674	New Customer Discount	Discount		(\$900)	(\$900)
[A]	7/17/2019	26680	Mega SutureCut Needle Driver EndoWrist Repair Service	420309-SVC (Mega SutureCut Needle Driver EndoWrist Repair Service)	1	\$900	\$900
[A]	8/8/2019	26696	Monopolar Curved Scissors EndoWrist Repair Service	420179-SVC (Monopolar Curved Scissors EndoWrist Repair Service)	1	\$1,300	\$1,300
[A]	8/8/2019	26696	Fenestrated Bipolar Forceps EndoWrist Repair Service	420205-SVC (Fenestrated Bipolar Forceps EndoWrist Repair Service)	1	\$1,200	\$1,200
[A]	8/8/2019	26696	ProGrasp Forceps EndoWrist Repair Service	420093-SVC (ProGrasp Forceps EndoWrist Repair Service)	1	\$900	\$900
[A]	8/8/2019	26696	Mega Needle Driver EndoWrist Repair Service	420194-SVC (Mega Needle Driver EndoWrist Repair Service)	1	\$900	\$900
[A]	8/8/2019	26696	Trial Wrists	Discount		(\$4,300)	(\$4,300)
[A]	9/9/2019	26702	Small Grasping Retractor EndoWrist Repair Service	420318-SVC (Small Grasping Retractor EndoWrist Repair Service)	1	\$900	\$900
[A]	9/9/2019	26702	Small Grasping Retractor EndoWrist Repair Service	420318-SVC (Small Grasping Retractor EndoWrist Repair Service)	1	\$900	\$900
[A]	9/9/2019	26702	Large Needle Driver EndoWrist Repair Service	420006-SVC (Large Needle Driver EndoWrist Repair Service)	1	\$900	\$900
[A]	9/9/2019	26702	Cadiere Forceps EndoWrist Repair Service	420049-SVC (Cadiere Forceps EndoWrist Repair Service)	1	\$750	\$750
[A]	9/9/2019	26702	ProGrasp Forceps EndoWrist Repair Service	420093-SVC (ProGrasp Forceps EndoWrist Repair Service)	1	\$900	\$900
[A]	9/9/2019	26702	Maryland Bipolar Forceps EndoWrist Repair Service	420172-SVC (Maryland Bipolar Forceps EndoWrist Repair Service)	0	\$1,200	\$0
[A]	9/9/2019	26702	Maryland Bipolar Forceps EndoWrist Repair Service	420172-SVC (Maryland Bipolar Forceps EndoWrist Repair Service)	0	\$1,200	\$0
[A]	9/9/2019	26702	Maryland Bipolar Forceps EndoWrist Repair Service	420172-SVC (Maryland Bipolar Forceps EndoWrist Repair Service)	0	\$1,200	\$0
[A]	10/8/2019	26738	Cadiere Forceps EndoWrist Repair Service	420049-SVC (Cadiere Forceps EndoWrist Repair Service)	0	\$750	\$0
[A]	10/8/2019	26738	Cadiere Forceps EndoWrist Repair Service	420049-SVC (Cadiere Forceps EndoWrist Repair Service)	1	\$750	\$750
[A]	10/8/2019	26738	ProGrasp Forceps EndoWrist Repair Service	420093-SVC (ProGrasp Forceps EndoWrist Repair Service)	1	\$900	\$900
[A]	10/18/2019	26746	Maryland Bipolar Forceps EndoWrist Repair Service	420172-SVC (Maryland Bipolar Forceps EndoWrist Repair Service)	1	\$1,200	\$1,200
[A]	10/18/2019	26746	Large SutureCut Needle Driver EndoWrist Repair Service	420296-SVC (Large SutureCut Needle Driver EndoWrist Repair Service)	1	\$900	\$900
[A]	10/18/2019	26746	Mega Needle Driver EndoWrist Repair Service	420194-SVC (Mega Needle Driver EndoWrist Repair Service)	1	\$900	\$900
[A]	10/18/2019	26746	Mega Needle Driver EndoWrist Repair Service	420194-SVC (Mega Needle Driver EndoWrist Repair Service)	1	\$900	\$900
[A]	10/18/2019	26746	DeBakey Forceps EndoWrist Repair Service	420036-SVC (DeBakey Forceps EndoWrist Repair Service)	1	\$750	\$750
[A]	10/25/2019	26748	Large Needle Driver EndoWrist Repair Service	420006-SVC (Large Needle Driver EndoWrist Repair Service)	0	\$900	\$0
[A]	10/25/2019	26748	Used EndoWrist Instrument	EndoWrist (Used EndoWrist Instrument)	1	\$100	\$100
[A]	10/25/2019	26748	Large Needle Driver EndoWrist Repair Service	420006-SVC (Large Needle Driver EndoWrist Repair Service)	1	\$900	\$900
[A]	10/25/2019	26748	Estimate 26748:	Discount		(\$100)	(\$100)
[A]	10/25/2019	26749	Fenestrated Bipolar Forceps EndoWrist Repair Service	420205-SVC (Fenestrated Bipolar Forceps EndoWrist Repair Service)	0	\$1,200	\$0
[A]	10/25/2019	26749	Used EndoWrist Instrument	EndoWrist (Used EndoWrist Instrument)	1	\$100	\$100
[A]	10/25/2019	26749	Fenestrated Bipolar Forceps EndoWrist Repair Service	420205-SVC (Fenestrated Bipolar Forceps EndoWrist Repair Service)	1	\$1,200	\$1,200
[A]	10/25/2019	26749	Estimate 26749:	Discount		(\$100)	(\$100)
[A]	10/25/2019	26750	PK Dissecting Forceps EndoWrist Repair Service	420227-SVC (PK Dissecting Forceps EndoWrist Repair Service)	1	\$1,200	\$1,200
[A]	10/25/2019	26751	ProGrasp Forceps EndoWrist Repair Service	420093-SVC (ProGrasp Forceps EndoWrist Repair Service)	1	\$900	\$900
[A]	10/25/2019	26752	ProGrasp Forceps EndoWrist Repair Service	420093-SVC (ProGrasp Forceps EndoWrist Repair Service)	1	\$900	\$900
[A]	10/31/2019	26754	Large SutureCut Needle Driver EndoWrist Repair Service	420296-SVC (Large SutureCut Needle Driver EndoWrist Repair Service)	1	\$900	\$900
[A]	10/31/2019	26754	Cadiere Forceps EndoWrist Repair Service	420049-SVC (Cadiere Forceps EndoWrist Repair Service)	1	\$750	\$750
[A]	10/31/2019	26755	Large Needle Driver EndoWrist Repair Service	420006-SVC (Large Needle Driver EndoWrist Repair Service)	1	\$900	\$900
[A]	10/31/2019	26756	Large Needle Driver EndoWrist Repair Service	420006-SVC (Large Needle Driver EndoWrist Repair Service)	1	\$900	\$900
[A]	11/12/2019	26760	Large Clip Applier EndoWrist Repair Service	420230-SVC (Large Clip Applier EndoWrist Repair Service)	1	\$750	\$750
[A]	11/12/2019	26760	Maryland Bipolar Forceps EndoWrist Repair Service	420172-SVC (Maryland Bipolar Forceps EndoWrist Repair Service)	1	\$1,200	\$1,200
[A]	11/12/2019	26760	Mega SutureCut Needle Driver EndoWrist Repair Service	420309-SVC (Mega SutureCut Needle Driver EndoWrist Repair Service)	1	\$900	\$900
[A]	11/12/2019	26760	Monopolar Curved Scissors EndoWrist Repair Service	420179-SVC (Monopolar Curved Scissors EndoWrist Repair Service)	1	\$1,300	\$1,300
[A]	11/12/2019	26760	Cadiere Forceps EndoWrist Repair Service	420049-SVC (Cadiere Forceps EndoWrist Repair Service)	0	\$750	\$0
[A]	11/12/2019	26760	Monopolar Curved Scissors EndoWrist Repair Service	420179-SVC (Monopolar Curved Scissors EndoWrist Repair Service)	0	\$1,300	\$0
[A]	11/12/2019	26760	Mega Needle Driver EndoWrist Repair Service	420194-SVC (Mega Needle Driver EndoWrist Repair Service)	0	\$900	\$0
[A]	11/12/2019	26760	Large Clip Applier EndoWrist Repair Service	420230-SVC (Large Clip Applier EndoWrist Repair Service)	0	\$750	\$0
[A]	11/12/2019	26760	Used EndoWrist Instrument	EndoWrist (Used EndoWrist Instrument)	4	\$100	\$400
[A]	11/12/2019	26760	Cadiere Forceps EndoWrist Repair Service	420049-SVC (Cadiere Forceps EndoWrist Repair Service)	1	\$750	\$750
[A]	11/12/2019	26760	Monopolar Curved Scissors EndoWrist Repair Service	420179-SVC (Monopolar Curved Scissors EndoWrist Repair Service)	1	\$1,300	\$1,300
[A]	11/12/2019	26760	Mega Needle Driver EndoWrist Repair Service	420194-SVC (Mega Needle Driver EndoWrist Repair Service)	1	\$900	\$900
[A]	11/12/2019	26760	Large Clip Applier EndoWrist Repair Service	420230-SVC (Large Clip Applier EndoWrist Repair Service)	1	\$750	\$750
[A]	11/12/2019	26760	New Customer Discount	Discount		(\$400)	(\$400)
[A]	11/20/2019	26762	Large Needle Driver EndoWrist Repair Service	420006-SVC (Large Needle Driver EndoWrist Repair Service)	1	\$900	\$900

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Rebotix Sales to SIS: June 27, 2019 - November 21, 2019

Second Rebuttal Schedule 10.1

	Date	Num	Memo	Item	Quantity	Sale Price	Amount
[A]	11/21/2019	26763	Large Clip Applier EndoWrist Repair Service	420230-SVC (Large Clip Applier EndoWrist Repair Service)	1	\$750	\$750
[A]	11/21/2019	26763	Monopolar Curved Scissors EndoWrist Repair Service	420179-SVC (Monopolar Curved Scissors EndoWrist Repair Service)	1	\$1,300	\$1,300
[A]	11/21/2019	26763	Fenestrated Bipolar Forceps EndoWrist Repair Service	420205-SVC (Fenestrated Bipolar Forceps EndoWrist Repair Service)	1	\$1,200	\$1,200
[A]	11/21/2019	26763	Monopolar Curved Scissors EndoWrist Repair Service	420179-SVC (Monopolar Curved Scissors EndoWrist Repair Service)	1	\$1,300	\$1,300
[A]	11/21/2019	26763	Maryland Bipolar Forceps EndoWrist Repair Service	420172-SVC (Maryland Bipolar Forceps EndoWrist Repair Service)	1	\$1,200	\$1,200
[A]	11/21/2019	26763	Tenaculum Forceps EndoWrist Repair Service	420207-SVC (Tenaculum Forceps EndoWrist Repair Service)	0	\$900	\$0
[A]	11/21/2019	26763	Used EndoWrist Instrument	EndoWrist (Used EndoWrist Instrument)	1	\$100	\$100
[A]	11/21/2019	26763	New Customer Discount	Discount		(\$100)	(\$100)
[A]	11/21/2019	26763	Tenaculum Forceps EndoWrist Repair Service	420207-SVC (Tenaculum Forceps EndoWrist Repair Service)	1	\$900	\$900
[B]	Total				49		\$35,500

NOTES / SOURCES:

Note: Any minor differences are due to rounding.

[A] Summarized per REBOTIX175326.

[B] Sum of [A].

Potential EndoWrist Instrument Units, Costs and Costs per Unit by System (Using Intuitive Sales Volumes and Rebotix Pricing): 2018 - June 2022

Second Rebuttal Schedule 11.0

	2018	2019	2020	2021	2022 thru June	Total	%
Units							
[A] da Vinci S/Si							
[B] da Vinci X/Xi							
[C] Total							
Costs							
[A] da Vinci S/Si							
[B] da Vinci X/Xi							
[C] Total							
Cost per unit							
[D] da Vinci S/Si	\$587	\$588	\$593	\$605	\$589	\$590	
[D] da Vinci X/Xi	\$576	\$569	\$573	\$584	\$591	\$578	
[D] Total	\$581	\$575	\$576	\$585	\$591	\$580	

NOTES / SOURCES:

Note: Any minor differences are due to rounding.

[A] Per Second Rebuttal Schedule 11.1.

[B] Per Second Rebuttal Schedule 11.2.

[C] = [A] + [B]

[D] Calculated based on the amounts herein.

[illegible]Units

[A]
[A]
[A]
[A]
[A]
[A]
[A]
[A]
[A]

[B] 420179	\$850	\$850	\$850	\$850	\$850	\$850
[B] 420006	\$450	\$450	\$450	\$450	\$450	\$450
[B] 420093	\$450	\$450	\$450	\$450	\$450	\$450
[B] 420205	\$750	\$750	\$750	\$750	\$750	\$750
[B] 420309	\$450	\$450	\$450	\$450	\$450	\$450
[B] 420194	\$450	\$450	\$450	\$450	\$450	\$450
[B] 420172	\$750	\$750	\$750	\$750	\$750	\$750
[B] 420049	\$300	\$300	\$300	\$300	\$300	\$300
[B] 420227	\$750	\$750	\$750	\$750	\$750	\$750
[B] 420183	\$300	\$300	\$300	\$300	\$300	\$300
[B] 420296	\$450	\$450	\$450	\$450	\$450	\$450
[B] 420230	\$300	\$300	\$300	\$300	\$300	\$300
[B] 420184	\$300	\$300	\$300	\$300	\$300	\$300
[B] 420327	\$300	\$300	\$300	\$300	\$300	\$300
[B] 420207	\$450	\$450	\$450	\$450	\$450	\$450
[B] 420190	\$450	\$450	\$450	\$450	\$450	\$450
[B] 420189	\$300	\$300	\$300	\$300	\$300	\$300
[B] 420110	\$750	\$750	\$750	\$750	\$750	\$750
[B] 420048	\$450	\$450	\$450	\$450	\$450	\$450
[B] 420318	\$450	\$450	\$450	\$450	\$450	\$450

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Potential EndoWrist Instrument Units, Costs and Costs per Unit by Product (Instrument Number) - da Vinci S/Si (Using Intuitive Sales Volumes and Rebotix Pricing): 2018 - June 2022

Second Rebuttal Schedule 11.1

	2018	2019	2020	2021	2022 thru June	Total	%
[B] 420003	\$450	\$450	\$450	\$450	\$450	\$450	
[B] 420001	\$300	\$300	\$300	\$300	\$300	\$300	
[B] 420007	\$300	\$300	\$300	\$300	\$300	\$300	
[B] 420278	\$450	\$450	\$450	\$450	\$450	\$450	
[B] 420344	\$750	\$750	\$750	\$750	\$750	\$750	
[B] 420033	\$450	\$450	\$450	\$450	\$450	\$450	
[B] 420036	\$300	\$300	\$300	\$300	\$300	\$300	
[B] 420178	\$300	\$300	\$300	\$300	\$300	\$300	
[B] 420171	\$750	\$750	\$750	\$750	\$750	\$750	
[B] 420246	\$750	\$750	\$750	\$750	\$750	\$750	
[B] 420249	\$750	\$750	\$750	\$750	\$750	\$750	
[B] 420181	\$450	\$450	\$450	\$450	\$450	\$450	
[B] 420157	\$450	\$450	\$450	\$450	\$450	\$450	
[B] 420204	\$750	\$750	\$750	\$750	\$750	\$750	
[B] 420121	\$750	\$750	\$750	\$750	\$750	\$750	
[B] 420215	\$450	\$450	\$450	\$450	\$450	\$450	
[B] 420203	\$450	\$450	\$450	\$450	\$450	\$450	
[B] 420192	\$300	\$300	\$300	\$300	\$300	\$300	

Costs

[C]
[C]
[C]
[C]
[C]
[C]
[C]
[C]
[C]
[C]
[C]

[illegible][illegible]

Potential EndoWrist Instrument Units, Costs and Costs per Unit by Product (Instrument Number) - da Vinci S/Si (Using Intuitive Sales Volumes and Rebotix Pricing): 2018 - June 2022

Second Rebuttal Schedule 11.1

2018	2019	2020	2021	2022 thru June	Total	%
------	------	------	------	-------------------	-------	---

NOTES / SOURCES:

Note: Any minor differences are due to rounding.

[A] Per Second Rebuttal Schedule 13.1.

[B] Per Second Rebuttal Schedule 12.0.

[C] = **[A]** * **[B]**

[illegible]Units

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Potential EndoWrist Instrument Units, Costs and Costs per Unit by Product (Instrument Number) - da Vinci X/Xi (Using Intuitive Sales Volumes and Rebotix Pricing): 2018 - June 2022

Second Rebuttal Schedule 11.2

2018	2019	2020	2021	2022	Total	%
				thru June		

[A]	
[A]	
[A]	
[A]	
[A]	
[A]	
[A]	
[A]	

[A] Total units

Cost per unit

[B] 470179	\$850	\$850	\$850	\$850	\$850	\$850
[B] 470205	\$750	\$750	\$750	\$750	\$750	\$750
[B] 471205	\$750	\$750	\$750	\$750	\$750	\$750
[B] 470006	\$450	\$450	\$450	\$450	\$450	\$450
[B] 470093	\$450	\$450	\$450	\$450	\$450	\$450
[B] 470309	\$450	\$450	\$450	\$450	\$450	\$450
[B] 471309	\$450	\$450	\$450	\$450	\$450	\$450
[B] 470183	\$300	\$300	\$300	\$300	\$300	\$300
[B] 471093	\$450	\$450	\$450	\$450	\$450	\$450
[B] 471006	\$450	\$450	\$450	\$450	\$450	\$450
[B] 470194	\$450	\$450	\$450	\$450	\$450	\$450
[B] 470049	\$300	\$300	\$300	\$300	\$300	\$300
[B] 470172	\$750	\$750	\$750	\$750	\$750	\$750
[B] 471049	\$300	\$300	\$300	\$300	\$300	\$300
[B] 471172	\$750	\$750	\$750	\$750	\$750	\$750
[B] 470327	\$300	\$300	\$300	\$300	\$300	\$300
[B] 470230	\$300	\$300	\$300	\$300	\$300	\$300
[B] 470318	\$450	\$450	\$450	\$450	\$450	\$450
[B] 470296	\$450	\$450	\$450	\$450	\$450	\$450
[B] 471296	\$450	\$450	\$450	\$450	\$450	\$450

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Potential EndoWrist Instrument Units, Costs and Costs per Unit by Product (Instrument Number) - da Vinci X/Xi (Using Intuitive Sales Volumes and Rebotix Pricing): 2018 - June 2022

Second Rebuttal Schedule 11.2

	2018	2019	2020	2021	2022 thru June	Total	%
[B] 470184	\$300	\$300	\$300	\$300	\$300	\$300	
[B] 470207	\$450	\$450	\$450	\$450	\$450	\$450	
[B] 470001	\$300	\$300	\$300	\$300	\$300	\$300	
[B] 470344	\$750	\$750	\$750	\$750	\$750	\$750	
[B] 470007	\$300	\$300	\$300	\$300	\$300	\$300	
[B] 470190	\$450	\$450	\$450	\$450	\$450	\$450	
[B] 471190	\$450	\$450	\$450	\$450	\$450	\$450	
[B] 471344	\$750	\$750	\$750	\$750	\$750	\$750	
[B] 470048	\$450	\$450	\$450	\$450	\$450	\$450	
[B] 470036	\$300	\$300	\$300	\$300	\$300	\$300	
[B] 471048	\$450	\$450	\$450	\$450	\$450	\$450	
[B] 470033	\$450	\$450	\$450	\$450	\$450	\$450	
[B] 470249	\$750	\$750	\$750	\$750	\$750	\$750	
[B] 470171	\$750	\$750	\$750	\$750	\$750	\$750	
[B] 470246	\$750	\$750	\$750	\$750	\$750	\$750	
[B] 471171	\$750	\$750	\$750	\$750	\$750	\$750	
[B] 470215	\$450	\$450	\$450	\$450	\$450	\$450	
[B] 470181	\$450	\$450	\$450	\$450	\$450	\$450	

Costs


[C]
[C]
[C]
[C]
[C]
[C]
[C]
[C]
[C]
[C]
[C]

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Potential EndoWrist Instrument Units, Costs and Costs per Unit by Product (Instrument Number) - da Vinci X/Xi (Using Intuitive Sales Volumes and Rebotix Pricing): 2018 - June 2022

Second Rebuttal Schedule 11.2

2018	2019	2020	2021	2022	Total	%
				thru June		

[C]						
[C]						
[C]						
[C]						
[C]						
[C]						
[C]						
[C]						
[C]						
[C]						
[C]						
[C]						
[C]						
[C]						
[C]						
[C]						
[C]						
[C]						
[C]						
[C]						
[C]	Total costs					

Potential EndoWrist Instrument Units, Costs and Costs per Unit by Product (Instrument Number) - da Vinci X/Xi (Using Intuitive Sales Volumes and Rebotix Pricing): 2018 - June 2022

Second Rebuttal Schedule 11.2

2018	2019	2020	2021	2022 thru June	Total	%
------	------	------	------	-------------------	-------	---

NOTES / SOURCES:

Note: Any minor differences are due to rounding.

[A] Per Second Rebuttal Schedule 13.2.

[B] Per Second Rebuttal Schedule 12.1.

[C] = [A] * [B]

SIS's EndoWrist Instrument Sales Prices and Costs (from Rebotix) - da Vinci S/Si Second Rebuttal Schedule 12.0

[1]	[1]	[1]	[2]	[3]	[4]
Instrument Number	Description	SIS sales price	SIS cost from Rebotix	Discount	SIS cost (net of volume discounts from Rebotix)
420179	Hot Shears (Monopolar Curved Scissors)	\$1,700	\$1,300	\$450	\$850
420110	PreCise Bipolar Forceps	\$1,600	\$1,200	\$450	\$750
420121	Fine Tissue Forceps	\$1,600	\$1,200	\$450	\$750
420171	Micro Bipolar Forceps	\$1,600	\$1,200	\$450	\$750
420172	Maryland Bipolar Forceps	\$1,600	\$1,200	\$450	\$750
420204	Atrial Retractor	\$1,600	\$1,200	\$450	\$750
420205	Fenestrated Bipolar Forceps	\$1,600	\$1,200	\$450	\$750
420227	PK® Dissecting Forceps	\$1,600	\$1,200	\$450	\$750
420246	Atrial Retractor Short Right	\$1,600	\$1,200	\$450	\$750
420249	Dual Blade Retractor	\$1,600	\$1,200	\$450	\$750
420344	Curved Bipolar Dissector	\$1,600	\$1,200	\$450	\$750
420003	Small Clip Applier	\$1,300	\$900	\$450	\$450
420006	Large Needle Driver	\$1,300	\$900	\$450	\$450
420033	Black Diamond Micro Forceps	\$1,300	\$900	\$450	\$450
420048	Long Tip Forceps	\$1,300	\$900	\$450	\$450
420093	ProGrasp Forceps	\$1,300	\$900	\$450	\$450
420157	Snap-fit™ Scalpel Instrument	\$1,300	\$900	\$450	\$450
420181	Resano Forceps	\$1,300	\$900	\$450	\$450
420190	Cobra Grasper	\$1,300	\$900	\$450	\$450

SIS's EndoWrist Instrument Sales Prices and Costs (from Rebotix) - da Vinci S/Si Second Rebuttal Schedule 12.0

[1]	[1]	[1]	[2]	[3]	[4]
Instrument Number	Description	SIS sales price	SIS cost from Rebotix	Discount	SIS cost (net of volume discounts from Rebotix)
420194	Mega Needle Driver	\$1,300	\$900	\$450	\$450
420203	Pericardial Dissector	\$1,300	\$900	\$450	\$450
420207	Tenaculum Forceps	\$1,300	\$900	\$450	\$450
420215	Cardiac Probe Grasper	\$1,300	\$900	\$450	\$450
420278	Graptor (Grasping Retractor)	\$1,300	\$900	\$450	\$450
420296	Large SutureCut™ Needle Driver	\$1,300	\$900	\$450	\$450
420309	Mega™ SutureCut™ Needle Driver	\$1,300	\$900	\$450	\$450
420318	Small Graptor (Grasping Retractor)	\$1,300	\$900	\$450	\$450
420001	Potts Scissors	\$1,100	\$750	\$450	\$300
420007	Round Tip Scissors	\$1,100	\$750	\$450	\$300
420036	DeBakey Forceps	\$1,100	\$750	\$450	\$300
420049	Cadiere Forceps	\$1,100	\$750	\$450	\$300
420178	Curved Scissors	\$1,100	\$750	\$450	\$300
420183	Permanent Cautery Hook	\$1,100	\$750	\$450	\$300
420184	Permanent Cautery Spatula	\$1,100	\$750	\$450	\$300
420189	Double Fenestrated Grasper	\$1,100	\$750	\$450	\$300
420192	Valve Hook	\$1,100	\$750	\$450	\$300
420230	Large Clip Applier	\$1,100	\$750	\$450	\$300
420327	Medium-Large Clip Applier	\$1,100	\$750	\$450	\$300

SIS's EndoWrist Instrument Sales Prices and Costs (from Rebotix) - da Vinci S/Si Second Rebuttal Schedule 12.0

[1]	[1]	[1]	[2]	[3]	[4]
Instrument Number	Description	SIS sales price	SIS cost from Rebotix	Discount	SIS cost (net of volume discounts from Rebotix)

NOTES / SOURCES:

- [1] Per SIS000047-49. See also, Keith Johnson Dep. Ex. 137 (at SIS097181), SIS000035-45 at 44 and SIS000024. Prices shown above are also consistent with prices shown on Second Rebuttal Schedule 14.0, representing actual sales from SIS to
- [2] Per REBOTIX162208-162212 at 212. Prices above reflect the distributor price offered by Rebotix to distributors. See also, Second Rebuttal Schedule 10.1 showing sales from Rebotix to SIS.
- [3] In January 2020, a Memorandum of Understanding was drafted between SIS and Rebotix, which contained proposed pricing terms for Interceptor chips, including volume discounts up to \$450 per Interceptor chip at 300 units (Gibson Dep. Ex. 14) (*Rebotix Repair LLC v. Intuitive Surgical, Inc.*, No. 8:20-cv-02274-VMC-TGW (M.D. Fla. filed Sept. 28, 2020)). Per discussion with Chris Gibson and as described in my report, volume discounts for thousands of annual units would have been greater than \$450 per chip. For purposes of my analysis, I apply a \$450 discount herein.
- [4] = [2] - [3]

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

SIS's EndoWrist Instrument Sales Prices and Costs (from Rebotix) - da Vinci X/Xi

Second Rebuttal Schedule 12.1

			[1]	[2]	[3]	[4]
Instrument Number	Description	Source of Identification	SIS sales price	SIS cost from Rebotix	Discount	SIS cost (net of volume discounts from Rebotix)
470179	Hot Shears (Monopolar Curved Scissors)	Corresponding Da Vinci S/Si Material Number per Second Rebuttal Schedule 12.0 - 420179	\$1,700	\$1,300	\$450	\$850
470110	PreCise Bipolar Forceps	Corresponding Da Vinci S/Si Material Number per Second Rebuttal Schedule 12.0 - 420110	\$1,600	\$1,200	\$450	\$750
470121	Fine Tissue Forceps	Corresponding Da Vinci S/Si Material Number per Second Rebuttal Schedule 12.0 - 420121	\$1,600	\$1,200	\$450	\$750
470171	Micro Bipolar Forceps	Corresponding Da Vinci S/Si Material Number per Second Rebuttal Schedule 12.0 - 420171	\$1,600	\$1,200	\$450	\$750
471171	Micro Bipolar Forceps	Da Vinci X/Xi Instrument & Accessory Catalog October 2021	\$1,600	\$1,200	\$450	\$750
470172	Maryland Bipolar Forceps	Corresponding Da Vinci S/Si Material Number per Second Rebuttal Schedule 12.0 - 420172	\$1,600	\$1,200	\$450	\$750
471172	Maryland Bipolar Forceps	Da Vinci X/Xi Instrument & Accessory Catalog October 2021	\$1,600	\$1,200	\$450	\$750
470204	Atrial Retractor	Corresponding Da Vinci S/Si Material Number per Second Rebuttal Schedule 12.0 - 420204	\$1,600	\$1,200	\$450	\$750
470205	Fenestrated Bipolar Forceps	Corresponding Da Vinci S/Si Material Number per Second Rebuttal Schedule 12.0 - 420205	\$1,600	\$1,200	\$450	\$750
471205	Fenestrated Bipolar Forceps	Da Vinci X/Xi Instrument & Accessory Catalog October 2021	\$1,600	\$1,200	\$450	\$750
470227	PK® Dissecting Forceps	Corresponding Da Vinci S/Si Material Number per Second Rebuttal Schedule 12.0 - 420227	\$1,600	\$1,200	\$450	\$750
470246	Atrial Retractor Short Right	Corresponding Da Vinci S/Si Material Number per Second Rebuttal Schedule 12.0 - 420246	\$1,600	\$1,200	\$450	\$750
470249	Dual Blade Retractor	Corresponding Da Vinci S/Si Material Number per Second Rebuttal Schedule 12.0 - 420249	\$1,600	\$1,200	\$450	\$750
470344	Curved Bipolar Dissector	Corresponding Da Vinci S/Si Material Number per Second Rebuttal Schedule 12.0 - 420344	\$1,600	\$1,200	\$450	\$750
471344	Curved Bipolar Dissector	Da Vinci X/Xi Instrument & Accessory Catalog October 2021	\$1,600	\$1,200	\$450	\$750
470003	Small Clip Applier	Corresponding Da Vinci S/Si Material Number per Second Rebuttal Schedule 12.0 - 420003	\$1,300	\$900	\$450	\$450
470006	Large Needle Driver	Corresponding Da Vinci S/Si Material Number per Second Rebuttal Schedule 12.0 - 420006	\$1,300	\$900	\$450	\$450
471006	Large Needle Driver	Da Vinci X/Xi Instrument & Accessory Catalog October 2021	\$1,300	\$900	\$450	\$450
470033	Black Diamond Micro Forceps	Corresponding Da Vinci S/Si Material Number per Second Rebuttal Schedule 12.0 - 420033	\$1,300	\$900	\$450	\$450
470048	Long Tip Forceps	Corresponding Da Vinci S/Si Material Number per Second Rebuttal Schedule 12.0 - 420048	\$1,300	\$900	\$450	\$450
471048	Long Tip Forceps	Da Vinci X/Xi Instrument & Accessory Catalog October 2021	\$1,300	\$900	\$450	\$450
470093	ProGrasp Forceps	Corresponding Da Vinci S/Si Material Number per Second Rebuttal Schedule 12.0 - 420093	\$1,300	\$900	\$450	\$450
471093	ProGrasp Forceps	Da Vinci X/Xi Instrument & Accessory Catalog October 2021	\$1,300	\$900	\$450	\$450
470157	Snap-fit™ Scalpel Instrument	Corresponding Da Vinci S/Si Material Number per Second Rebuttal Schedule 12.0 - 420157	\$1,300	\$900	\$450	\$450
470181	Resano Forceos	Corresponding Da Vinci S/Si Material Number per Second Rebuttal Schedule 12.0 - 420181	\$1,300	\$900	\$450	\$450
470190	Cobra Grasper	Corresponding Da Vinci S/Si Material Number per Second Rebuttal Schedule 12.0 - 420190	\$1,300	\$900	\$450	\$450
471190	Cobra Grasper	Da Vinci X/Xi Instrument & Accessory Catalog October 2021	\$1,300	\$900	\$450	\$450
470194	Mega Needle Driver	Corresponding Da Vinci S/Si Material Number per Second Rebuttal Schedule 12.0 - 420194	\$1,300	\$900	\$450	\$450
470203	Pericardial Dissector	Corresponding Da Vinci S/Si Material Number per Second Rebuttal Schedule 12.0 - 420203	\$1,300	\$900	\$450	\$450
470207	Tenaculum Forceos	Corresponding Da Vinci S/Si Material Number per Second Rebuttal Schedule 12.0 - 420207	\$1,300	\$900	\$450	\$450
470215	Cardiac Probe Grasper	Corresponding Da Vinci S/Si Material Number per Second Rebuttal Schedule 12.0 - 420215	\$1,300	\$900	\$450	\$450
470278	Graptor (Grasping Retractor)	Corresponding Da Vinci S/Si Material Number per Second Rebuttal Schedule 12.0 - 420278	\$1,300	\$900	\$450	\$450
470296	Large SutureCut™ Needle Driver	Corresponding Da Vinci S/Si Material Number per Second Rebuttal Schedule 12.0 - 420296	\$1,300	\$900	\$450	\$450
471296	Large SutureCut™ Needle Driver	Da Vinci X/Xi Instrument & Accessory Catalog October 2021	\$1,300	\$900	\$450	\$450
470309	Mega™ SutureCut™ Needle Driver	Corresponding Da Vinci S/Si Material Number per Second Rebuttal Schedule 12.0 - 420309	\$1,300	\$900	\$450	\$450
471309	Mega™ SutureCut™ Needle Driver	Da Vinci X/Xi Instrument & Accessory Catalog October 2021	\$1,300	\$900	\$450	\$450
470318	Small Graptor (Grasping Retractor)	Corresponding Da Vinci S/Si Material Number per Second Rebuttal Schedule 12.0 - 420318	\$1,300	\$900	\$450	\$450
470001	Potts Scissors	Corresponding Da Vinci S/Si Material Number per Second Rebuttal Schedule 12.0 - 420001	\$1,100	\$750	\$450	\$300
470007	Round Tip Scissors	Corresponding Da Vinci S/Si Material Number per Second Rebuttal Schedule 12.0 - 420007	\$1,100	\$750	\$450	\$300
470036	DeBakey Forceps	Corresponding Da Vinci S/Si Material Number per Second Rebuttal Schedule 12.0 - 420036	\$1,100	\$750	\$450	\$300

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

SIS's EndoWrist Instrument Sales Prices and Costs (from Rebotix) - da Vinci X/Xi

Second Rebuttal Schedule 12.1

			[1]	[2]	[3]	[4]
Instrument Number	Description	Source of Identification	SIS sales price	SIS cost from Rebotix	Discount	SIS cost (net of volume discounts from Rebotix)
470049	Cadiere Forceps	Corresponding Da Vinci S/Si Material Number per Second Rebuttal Schedule 12.0 - 470049	\$1,100	\$750	\$450	\$300
471049	Cadiere Forceps	Da Vinci X/Xi Instrument & Accessory Catalog October 2021	\$1,100	\$750	\$450	\$300
470178	Curved Scissors	Corresponding Da Vinci S/Si Material Number per Second Rebuttal Schedule 12.0 - 420178	\$1,100	\$750	\$450	\$300
470183	Permanent Cautery Hook	Corresponding Da Vinci S/Si Material Number per Second Rebuttal Schedule 12.0 - 420183	\$1,100	\$750	\$450	\$300
470184	Permanent Cautery Spatula	Corresponding Da Vinci S/Si Material Number per Second Rebuttal Schedule 12.0 - 420184	\$1,100	\$750	\$450	\$300
470189	Double Fenestrated Grasper	Corresponding Da Vinci S/Si Material Number per Second Rebuttal Schedule 12.0 - 420189	\$1,100	\$750	\$450	\$300
470192	Valve Hook	Corresponding Da Vinci S/Si Material Number per Second Rebuttal Schedule 12.0 - 420192	\$1,100	\$750	\$450	\$300
470230	Large Clip Applier	Corresponding Da Vinci S/Si Material Number per Second Rebuttal Schedule 12.0 - 420230	\$1,100	\$750	\$450	\$300
470327	Medium-Large Clip Applier	Corresponding Da Vinci S/Si Material Number per Second Rebuttal Schedule 12.0 - 420327	\$1,100	\$750	\$450	\$300

NOTES / SOURCES:

Note: Per the Deposition of Grant Duque 25-36, 48-52 and 156-157 (November 8, 2022), I understand Intuitive's S/Si and X/Xi EndoWrist instruments are used for the same applications and essentially perform the same functions.

- [1] Per SIS000047-49, pricing was based on the da Vinci S/Si platform. I assume a similar price for the X/Xi platform. This appears reasonable, as per Second Rebuttal Schedules 13.1 and 13.2, the Intuitive average selling price for similar instrument numbers appear to be the approximately the same (i.e., 420179 and 470179). This would suggest the SIS price to its customers would be approximately the same.
- [2] Per REBOTIX162208-162212 at 212, pricing (cost) was based on the da Vinci S/Si platform. I assume a similar price (cost) for the X/Xi platform. This appears reasonable, as per Second Rebuttal Schedules 13.1 and 13.2, the Intuitive average selling price for similar instrument numbers appear to be the approximately the same (i.e., 420179 and 470179). This would suggest the price (cost) to SIS would be approximately the same.
- [3] In January 2020, a Memorandum of Understanding was drafted between SIS and Rebotix, which contained proposed pricing terms for Interceptor chips, including volume discounts up to \$450 per Interceptor chip at 300 units (Gibson Dep. Ex. 14) (*Rebotix Repair LLC v. Intuitive Surgical, Inc.*, No. 8:20-cv-02274-VMC-TGW (M.D. Fla. filed Sept. 28, 2020)). Per discussion with Chris Gibson and as described in my report, volume discounts for thousands of annual units would have been greater than \$450 per chip. For purposes of my analysis, I apply a \$450 discount herein.

[4] = [2] - [3]

SIS's EndoWrist Instrument Sale Price vs Intuitive Sales Price - da Vinci S/Si Second Rebuttal Schedule 12.2

[1]	[1]	[1]	[2]	[3]	[4]
Instrument Number	Description	SIS sales price	Intuitive sales price	Difference	% Discount
420179	Hot Shears (Monopolar Curved Scissors)	\$1,700	\$3,200	(\$1,500)	-47%
420110	PreCise Bipolar Forceps	\$1,600	\$2,708	(\$1,108)	-41%
420121	Fine Tissue Forceps	\$1,600	\$2,864	(\$1,264)	-44%
420171	Micro Bipolar Forceps	\$1,600	\$2,755	(\$1,155)	-42%
420172	Maryland Bipolar Forceps	\$1,600	\$2,705	(\$1,105)	-41%
420204	Atrial Retractor	\$1,600	\$2,964	(\$1,364)	-46%
420205	Fenestrated Bipolar Forceps	\$1,600	\$2,702	(\$1,102)	-41%
420227	PK® Dissecting Forceps	\$1,600	\$2,904	(\$1,304)	-45%
420246	Atrial Retractor Short Right	\$1,600	\$2,963	(\$1,363)	-46%
420249	Dual Blade Retractor	\$1,600	\$2,332	(\$732)	-31%
420344	Curved Bipolar Dissector	\$1,600	\$2,735	(\$1,135)	-41%
420003	Small Clip Applier	\$1,300	\$2,410	(\$1,110)	-46%
420006	Large Needle Driver	\$1,300	\$2,200	(\$900)	-41%
420033	Black Diamond Micro Forceps	\$1,300	\$2,519	(\$1,219)	-48%
420048	Long Tip Forceps	\$1,300	\$2,473	(\$1,173)	-47%
420093	ProGrasp Forceps	\$1,300	\$2,201	(\$901)	-41%
420157	Snap-fit™ Scalpel Instrument	\$1,300	\$3,011	(\$1,711)	-57%
420181	Resano Forceps	\$1,300	\$2,228	(\$928)	-42%
420190	Cobra Grasper	\$1,300	\$2,213	(\$913)	-41%
420194	Mega Needle Driver	\$1,300	\$2,201	(\$901)	-41%
420203	Pericardial Dissector	\$1,300	\$2,221	(\$921)	-41%
420207	Tenaculum Forceps	\$1,300	\$2,221	(\$921)	-41%

SIS's EndoWrist Instrument Sale Price vs Intuitive Sales Price - da Vinci S/Si Second Rebuttal Schedule 12.2

[1]	[1]	[1]	[2]	[3]	[4]
Instrument Number	Description	SIS sales price	Intuitive sales price	Difference	% Discount
420215	Cardiac Probe Grasper	\$1,300	\$2,248	(\$948)	-42%
420278	Graptor (Grasping Retractor)	\$1,300	\$2,433	(\$1,133)	-47%
420296	Large SutureCut™ Needle Driver	\$1,300	\$2,402	(\$1,102)	-46%
420309	Mega™ SutureCut™ Needle Driver	\$1,300	\$2,405	(\$1,105)	-46%
420318	Small Graptor (Grasping Retractor)	\$1,300	\$2,115	(\$815)	-39%
420001	Potts Scissors	\$1,100	\$1,970	(\$870)	-44%
420007	Round Tip Scissors	\$1,100	\$1,980	(\$880)	-44%
420036	DeBakey Forceps	\$1,100	\$1,866	(\$766)	-41%
420049	Cadiere Forceps	\$1,100	\$2,005	(\$905)	-45%
420178	Curved Scissors	\$1,100	\$2,026	(\$926)	-46%
420183	Permanent Cautery Hook	\$1,100	\$2,008	(\$908)	-45%
420184	Permanent Cautery Spatula	\$1,100	\$2,014	(\$914)	-45%
420189	Double Fenestrated Grasper	\$1,100	\$2,014	(\$914)	-45%
420192	Valve Hook	\$1,100	\$1,799	(\$699)	-39%
420230	Large Clip Applier	\$1,100	\$1,408	(\$308)	-22%
420327	Medium-Large Clip Applier	\$1,100	\$1,410	(\$310)	-22%
Average (simple)					-42%

SIS's EndoWrist Instrument Sale Price vs Intuitive Sales Price - da Vinci S/Si Second Rebuttal Schedule 12.2

[1]	[1]	[1]	[2]	[3]	[4]
Instrument Number	Description	SIS sales price	Intuitive sales price	Difference	% Discount

NOTES / SOURCES:

[1] Per Second Rebuttal Schedule 12.0.

[2] Per Second Rebuttal Schedule 13.1.

[3] SIS sales price per [1] - [2]

[4] = [3] / [2]

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Intuitive's EndoWrist Instrument Units, Net Sales Dollars and Average Selling Price by System: 2014 - June 2022

Second Rebuttal Schedule 13.0

		2014	2015	2016	2017	2018	2019	2020	2021	2022 thru June	Total	%	2022 Annualized
Units													
[A]	da Vinci S/Si												
[B]	da Vinci X/Xi												
[C]	Total units												
Net sales dollars													
[A]	da Vinci S/Si												
[B]	da Vinci X/Xi												
[C]	Total net sales dollars												
ASP per unit													
[D]	da Vinci S/Si	\$2,508	\$2,511	\$2,518	\$2,521	\$2,528	\$2,537	\$2,572	\$2,659	\$2,538	\$2,524		\$2,538
[D]	da Vinci X/Xi	\$2,417	\$2,453	\$2,477	\$2,486	\$2,499	\$2,491	\$2,542	\$2,657	\$2,666	\$2,557		\$2,666
[D]	Total ASP per unit	\$2,503	\$2,500	\$2,506	\$2,506	\$2,512	\$2,504	\$2,546	\$2,658	\$2,663	\$2,544		\$2,663

NOTES / SOURCES:

Note: Any minor differences are due to rounding.

[A] Per Second Rebuttal Schedule 13.1.

[B] Per Second Rebuttal Schedule 13.2.

[C] = [A] + [B]

[D] Calculated based on the amounts herein.

2014	2015	2016	2017	2018	2019	2020	2021	2022	Total	%
								thru Jun		

[illegible]**Total units**

2014	2015	2016	2017	2018	2019	2020	2021	2022	Total	%
								thru Jun		

[illegible]**Total net sales dollars**

2014	2015	2016	2017	2018	2019	2020	2021	2022	Total	%
								thru Jun		

[illegible]

Total ASP	\$2,508	\$2,511	\$2,518	\$2,521	\$2,528	\$2,537	\$2,572	\$2,659	\$2,538	\$2,524
------------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Intuitive's EndoWrist Instrument Units and Net Sales Dollars by Product (Instrument Number) - da Vinci S/Si: 2014 - June 2022

Second Rebuttal Schedule 13.1

2014	2015	2016	2017	2018	2019	2020	2021	2022 thru Jun	Total	%
------	------	------	------	------	------	------	------	------------------	-------	---

NOTES / SOURCES:

- Note: Any minor differences are due to rounding.
- Note: U.S. sales were identified by using the "Comp Code" field and filtering for "2000" and using the "Unit" field and filtering for "EA." Each S/Si instrument above was selected based on SIS000047-49 (see *a/so*, Second Rebuttal Schedule 12.0). Per REBOTIX162208-162212 at 212, I understand all of the S/Si EndoWrists identified above are repairable by Rebotix.
- [A] Summarized per Intuitive-00595406-413, Intuitive-00595415-428, Intuitive-00595434-437, Intuitive-00695231-233, Intuitive-01101508 and Intuitive-02025757-759.
- [B] Calculated based on the amounts herein.

2014	2015	2016	2017	2018	2019	2020	2021	2022	Total	%
								thru June		

[illegible]

[B] Total units

[illegible]**Total net sales dollars**

2014	2015	2016	2017	2018	2019	2020	2021	2022	Total	%
								thru June		

[illegible]

Total ASP	\$2,417	\$2,453	\$2,477	\$2,486	\$2,499	\$2,491	\$2,542	\$2,657	\$2,666	\$2,557
------------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Intuitive's EndoWrist Instrument Units and Net Sales Dollars by Product
(Instrument Number) - da Vinci X/Xi: 2014 - June 2022
Second Rebuttal Schedule 13.2

2014	2015	2016	2017	2018	2019	2020	2021	2022	Total	%
								thru June		

NOTES / SOURCES:

- Note: Any minor differences are due to rounding.
- Note: U.S. sales were identified by using the "Comp Code" field and filtering for "2000" and using the "Unit" field and filtering for "EA." Each X/Xi instrument was selected as described on Second Rebuttal Schedule 12.1.
- [A] Summarized per Intuitive-00595406-413, Intuitive-00595415-428, Intuitive-00595434-437, Intuitive-00695231-233, Intuitive-01101508 and Intuitive-02025757-759.
- [B] Calculated based on the amounts herein.

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

SIS's EndoWrist Instrument Repair Summary

Second Rebuttal Schedule 14.0

[1]	[1]	[1]	[1]	[1]	[2]	[1]	[1]	[1]	[3]	[3]	[3]	[3]	[3]
Order date	Customer	Invoice #	Quantity	Price	Sales	Item (EndoWrist Instrument Number)	Item description	Item comments	Total count	Repaired count	Not repaired count	Expired count	Not supported count
11/14/18	ALEXIAN BROTHERS MEDICAL CTR	60576-1	1	\$0.00	N/A	470001	DaVinci Potts Scissors	Severely damaged. BEYOND REPAIR. Needs replacement	1		1		
06/28/19	LEGACY GOOD SAMARITAN	61059-1	1	\$1,300.00	\$1,300.00	420309	Needle Driver, Mega Suture Cut	Refurbish tool end. Clean. Mechanical inspection and testing. Electrical safety testing. Use count reset and test all functions	2	1			
07/18/19	LEGACY GOOD SAMARITAN	61064-1	1	\$1,300.00	\$1,300.00	420309	Needle Driver, Mega Suture Cut	Refurbish tool end. Clean. Mechanical inspection and testing. Electrical safety testing. Use count reset and test all functions	3	2			
08/27/19	KAISER FONTANA	95513-1	1	\$1,700.00	\$0.00	420179	Monopolar Curved Scissors	Monopolar Curved Scissors EndoWrist Repair Services	4	3			
08/27/19	KAISER FONTANA	95513-1	1	\$1,600.00	\$0.00	420205	Fenestrated Bipolar Forceps	Fenestrated Bipolar Forceps EndoWrist Repair Services	5	4			
08/27/19	KAISER FONTANA	95513-1	1	\$1,300.00	\$0.00	420093	ProGrasp Forceps	ProGrasp Forceps EndoWrist Repair Services	6	5			
08/27/19	KAISER FONTANA	95513-1	1	\$1,300.00	\$0.00	420194	Mega Needle Driver	Mega Needle Driver EndoWrist Repair Services	7	6			
09/09/19	KAISER FONTANA	60733-1	1	\$1,300.00	\$1,300.00	420318	Small Graptor (Grasping Retractor)	Refurbish tool end. Clean. Mechanical inspection and testing. Electrical safety testing. Use count reset and test all functions	8	7			
09/09/19	KAISER FONTANA	60733-1	1	\$1,300.00	\$1,300.00	420006	Needle Driver, Large	Refurbish tool end. Clean. Mechanical inspection and testing. Electrical safety testing. Use count reset and test all functions	9	8			
09/09/19	KAISER FONTANA	60733-1	1	\$1,300.00	\$1,300.00	420093	Forceps, ProGrasp	Refurbish tool end. Clean. Mechanical inspection and testing. Electrical safety testing. Use count reset and test all functions	10	9			
09/09/19	KAISER FONTANA	60733-1	1	\$1,300.00	\$1,300.00	420318	Small Graptor (Grasping Retractor)	Refurbish tool end. Clean. Mechanical inspection and testing. Electrical safety testing. Use count reset and test all functions	11	10			
09/09/19	KAISER FONTANA	60733-1	1	\$1,100.00	\$1,100.00	420049	Forceps, Cadiere	Refurbish tool end. Clean. Mechanical inspection and testing. Electrical safety testing. Use count reset and test all functions	12	11			
09/09/19	KAISER FONTANA	60733-2	1	\$0.00	N/A	420172	Bipolar Forceps, Maryland	BEYOND REPAIR. Needs replacement	13		2		
09/09/19	KAISER FONTANA	60733-2	1	\$0.00	N/A	420172	Bipolar Forceps, Maryland	BEYOND REPAIR. Needs replacement	14		3		
09/09/19	KAISER FONTANA	60733-2	1	\$0.00	N/A	420172	Bipolar Forceps, Maryland	BEYOND REPAIR. Needs replacement	15		4		
	ADVOCATE GOOD SAMARITAN	95713-1	1	\$0.00	N/A	420205	Fenestrated Bipolar Forceps	Expired. BEYOND REPAIR. SIS is unable to provide a replacement	16			1	
10/29/19	MARIN HEALTH MEDICAL CENTER	90009-1	1	\$1,300.00	\$1,300.00	420296	Needle Driver, Large Suture Cut	Refurbish tool end. Clean. Mechanical inspection and testing. Electrical safety testing. Use count reset and test all functions	17	12			
10/29/19	MARIN HEALTH MEDICAL CENTER	90009-1	1	\$1,300.00	\$1,300.00	420194	Needle Driver, Mega	Refurbish tool end. Clean. Mechanical inspection and testing. Electrical safety testing. Use count reset and test all functions	18	13			
10/29/19	MARIN HEALTH MEDICAL CENTER	90009-1	1	\$1,100.00	\$1,100.00	420036	Forceps, DeBakey	Refurbish tool end. Clean. Mechanical inspection and testing. Electrical safety testing. Use count reset and test all functions	19	14			
10/29/19	MARIN HEALTH MEDICAL CENTER	90009-1	1	\$1,600.00	\$1,600.00	420172	Bipolar Forceps, Maryland	Refurbish tool end. Clean. Mechanical inspection and testing. Electrical safety testing. Use count reset and test all functions	20	15			
10/29/19	MARIN HEALTH MEDICAL CENTER	90009-1	1	\$1,300.00	\$1,300.00	420194	Needle Driver, Mega	Refurbish tool end. Clean. Mechanical inspection and testing. Electrical safety testing. Use count reset and test all functions	21	16			
10/30/19	ADVOCATE SOUTH SUBURBAN HOSP	61148-1	1	\$1,600.00	\$1,600.00	420205	Fenestrated Bipolar Forceps	Repair/Exchange. Received SN: N10190207	22	17			
10/30/19	ADVOCATE SOUTH SUBURBAN HOSP	61148-2	1	\$1,600.00	\$1,600.00	420227	PK® Dissecting Forceps	Refurbish tool end. Clean. Mechanical inspection and testing. Electrical safety testing. Use count reset and test all functions	23	18			
10/30/19	ADVOCATE SOUTH SUBURBAN HOSP	61148-3	1	\$1,300.00	\$1,300.00	420093	Forceps, ProGrasp	Refurbish tool end. Clean. Mechanical inspection and testing. Electrical safety testing. Use count reset and test all functions	24	19			
10/30/19	ADVOCATE SOUTH SUBURBAN HOSP	61148-4	1	\$1,300.00	\$1,300.00	420093	Forceps, ProGrasp	Refurbish tool end. Clean. Mechanical inspection and testing. Electrical safety testing. Use count reset and test all functions	25	20			
10/30/19	ADVOCATE SOUTH SUBURBAN HOSP	61148-5	1	\$1,300.00	\$1,300.00	420006	Needle Driver, Large	Refurbish tool end. Clean. Mechanical inspection and testing. Repair/Exchange. Received SN: N10190327	26	21			
10/30/19	ADVOCATE SOUTH SUBURBAN HOSP	61148-6	1	\$1,100.00	\$1,100.00	420049	Forceps, Cadiere	Refurbish tool end. Clean. Mechanical inspection and testing. Electrical safety testing. Use count reset and test all functions	27	22			
10/30/19	ADVOCATE SOUTH SUBURBAN HOSP	61148-7	1	\$1,300.00	\$1,300.00	420093	Forceps, ProGrasp	Refurbish tool end. Clean. Mechanical inspection and testing. Electrical safety testing. Use count reset and test all functions	28	23			
10/29/19	ADVOCATE SOUTH SUBURBAN HOSP	61148-8	1	\$0.00	N/A	420049	Forceps, Cadiere	Expired and disposed of. BEYOND REPAIR. SIS is unable to provide a replacement.	29			2	
11/06/19	ADVOCATE SOUTH SUBURBAN HOSP	61156-1	1	\$1,300.00	\$1,300.00	420006	Needle Driver, Large	Refurbish tool end. Clean. Mechanical inspection and testing. Electrical safety testing. Use count reset and test all functions	30	24			
11/06/19	ADVOCATE SOUTH SUBURBAN HOSP	61156-2	1	\$1,300.00	\$1,300.00	420006	Needle Driver, Large	Refurbish tool end. Clean. Mechanical inspection and testing. Electrical safety testing. Use count reset and test all functions	31	25			
11/14/19	MARIN HEALTH MEDICAL CENTER	60137-1	1	\$1,300.00	\$1,300.00	420296	Needle Driver, Large Suture Cut	Refurbish tool end. Clean. Mechanical inspection and testing. Electrical safety testing. Use count reset and test all functions	32	26			
11/14/19	MARIN HEALTH MEDICAL CENTER	60137-1	1	\$1,100.00	\$1,100.00	420049	Forceps, Cadiere	Refurbish tool end. Clean. Mechanical inspection and testing. Electrical safety testing. Use count reset and test all functions	33	27			
11/15/19	MARIN HEALTH MEDICAL CENTER	90008-1	1	\$1,700.00	N/A	420179	Scissors, Curved Monopolar	Repair/Exchange. Received SN: N12190701	34	28			
11/15/19	MARIN HEALTH MEDICAL CENTER	90008-1	1	\$1,300.00	N/A	420309	Needle Driver, Mega Suture Cut	Refurbish tool end. Clean. Mechanical inspection and testing. Electrical safety testing. Use count reset and test all functions	35	29			
11/15/19	MARIN HEALTH MEDICAL CENTER	90008-1	1	\$1,700.00	N/A	420179	Scissors, Curved Monopolar	Refurbish tool end. Clean. Mechanical inspection and testing. Electrical safety testing. Use count reset and test all functions	36	30			

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

SIS's EndoWrist Instrument Repair Summary
Second Rebuttal Schedule 14.0

[1]	[1]	[1]	[1]	[1]	[2]	[1]	[1]	[1]	[3]	[3]	[3]	[3]	[3]
Order date	Customer	Invoice #	Quantity	Price	Sales	Item (EndoWrist Instrument Number)	Item description	Item comments	Total count	Repaired count	Not repaired count	Expired count	Not supported count
11/15/19	MARIN HEALTH MEDICAL CENTER	90008-1	1	\$1,100.00	N/A	420049	Forceps, Cadiere	Repair/Exchange. Received SN: N10180822	37	31			
11/15/19	MARIN HEALTH MEDICAL CENTER	90008-1	1	\$1,100.00	N/A	420230	Applier, Large Clip	Refurbish tool end. Clean. Mechanical inspection and testing. Electrical safety testing. Use count reset and test all functions.	38	32			
11/15/19	MARIN HEALTH MEDICAL CENTER	90008-1	1	\$1,600.00	N/A	420172	Bipolar Forceps, Maryland	Refurbish tool end. Clean. Mechanical inspection and testing. Electrical safety testing. Use count reset and test all functions.	39	33			
11/15/19	MARIN HEALTH MEDICAL CENTER	90008-1	1	\$1,100.00	N/A	420230	Applier, Large Clip	Repair/Exchange. Received SN: N10170921	40	34			
11/15/19	MARIN HEALTH MEDICAL CENTER	90008-1	1	\$1,300.00	N/A	420194	Needle Driver, Mega	Repair/Exchange. Received SN: M10140121	41	35			
11/15/19	MARIN HEALTH MEDICAL CENTER	90008-1	1	\$0.00	N/A	420275	Shears, Harmonic Ace Curved	Model number is not supported. NO REPAIR	42				1
	ADVOCATE GOOD SAMARITAN	96156-1	1	\$1,300.00	N/A	420006	Needle Driver, Large	Refurbish tool end. Clean. Mechanical inspection and testing. Electrical safety testing. Use count reset and test all functions.	43	36			
12/10/19	MARIN HEALTH MEDICAL CENTER	90010-1	1	\$1,100.00	\$1,100.00	420230	Applier, Large Clip	Refurbish tool end. Clean. Mechanical inspection and testing. Electrical safety testing. Use count reset and test all functions.	44	37			
12/10/19	MARIN HEALTH MEDICAL CENTER	90010-1	1	\$1,300.00	\$1,300.00	420207	Forceps, Tenaculum	Repair/Exchange. Received SN: M10100316	45	38			
12/10/19	MARIN HEALTH MEDICAL CENTER	90010-1	1	\$1,600.00	\$1,600.00	420172	Bipolar Forceps, Maryland	Refurbish tool end. Clean. Mechanical inspection and testing. Electrical safety testing. Use count reset and test all functions.	46	39			
12/10/19	MARIN HEALTH MEDICAL CENTER	90010-1	1	\$1,600.00	\$1,600.00	420172	Bipolar Forceps, Maryland	Refurbish tool end. Clean. Mechanical inspection and testing. Electrical safety testing. Use count reset and test all functions.	47	40			
12/10/19	MARIN HEALTH MEDICAL CENTER	90010-1	1	\$1,700.00	\$1,700.00	420179	Scissors, Curved Monopolar	Refurbish tool end. Clean. Mechanical inspection and testing. Electrical safety testing. Use count reset and test all functions.	48	41			
12/10/19	MARIN HEALTH MEDICAL CENTER	90010-1	1	\$1,600.00	\$1,600.00	420205	Fenestrated Bipolar Forceps	Refurbish tool end. Clean. Mechanical inspection and testing. Electrical safety testing. Use count reset and test all functions.	49	42			
					\$38,900.00	Total			49	42	4	2	1
[A] Repair yield of SIS collectable units									88%				

NOTES / SOURCES:

Note: Any minor differences are due to rounding.
Note: Column headings are based on a review of invoices, for example, SIS000097-112.

- [1] Summarized per SIS000167.
[2] Summarized per SIS000097-112. I have indicated "N/A" for records where invoices could not be located.
[3] Count based on "Item Comments."
[A] Calculated as Repaired Count / (Repaired Count + Not Repaired Count + Expired Count).

SIS's Financial Statements: 2019 - October 2021

Second Rebuttal Schedule 15.0

	[1]		[2]		[3]	
	2019		2020		2021 (thru Oct)	
	Amount	%	Amount	%	Amount	%
Revenue	\$6,996,108	100.0%	\$10,723,980	100.0%	\$10,092,079	100.0%
Cost of goods sold	\$4,084,286	58.4%	\$5,863,755	54.7%	\$5,813,610	57.6%
Gross profit	\$2,911,822	41.6%	\$4,860,225	45.3%	\$4,278,469	42.4%
Expenses:						
Selling	\$1,415,642	20.2%	\$1,893,403	17.7%	\$1,899,002	18.8%
General and admin	\$1,125,420	16.1%	\$1,224,361	11.4%	\$1,428,002	14.1%
Total expenses	\$2,541,062	36.3%	\$3,117,764	29.1%	\$3,327,004	33.0%
Operating income	\$370,760	5.3%	\$1,742,461	16.2%	\$951,465	9.4%
Other income and (expense)	(\$2,175)	0.0%	\$571,623	5.3%	\$1,208	0.0%
Profit before taxes	\$368,585	5.3%	\$2,314,084	21.6%	\$952,673	9.4%

NOTES / SOURCES:

Note: Any minor differences are due to rounding.

[1] Per SIS320176-188 at 176.

[2] Per SIS320922-935 at 922.

[3] Per SIS327629-636 at 629. Note: Per discussions with Greg Posdal, SIS's 2021 sales approximated \$12.4 million.

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

SIS's Detailed SGA: 2019 - October 2021
Second Rebuttal Schedule 15.1

	[1]		[2]		[3]				[4]	[4]	[4]
	2019		2020		2021 (thru Oct)		Total		Fixed / Variable	Variable as a % of revenue	Notes
	Amount	%	Amount	%	Amount	%	Amount	%			
Revenue	\$6,996,108	100.00%	\$10,723,980	100.00%	\$10,092,079	100.00%	\$27,812,167	100.00%			
Cost of goods sold	\$4,084,286	58.38%	\$5,863,755	54.68%	\$5,813,610	57.61%	\$15,761,651	56.67%			
Gross profit	\$2,911,822	41.62%	\$4,860,225	45.32%	\$4,278,469	42.39%	\$12,050,516	43.33%			
Expenses:											
<u>Selling:</u>											
Wages - Sales	\$611,469	8.74%	\$732,356	6.83%	\$688,552	6.82%	\$2,032,377	7.31%	Partially variable	2.00%	Currently have approximately 10-12 Associate Sales Representatives ("ASRs") managing more than 1 million annual repair units, which approximates 80,000-100,000 repair units per ASR. According to discussion with Greg Posdal, SIS would potentially add up to as many as 10 additional ASRs to sell both EndoWrist repairs and other SIS products/services. New ASRs cost approximately \$50,000 in wages annually. Ten ASRs would approximate \$500,000 in wages per year, which represents less than 1% of the maximum annual lost EndoWrist repair revenue of approximately \$68.5 million as shown on Second Rebuttal Schedule 2.0. In addition, SIS pays a 1% commission for each EndoWrist sale. For purposes of my analysis, I use 2% as variable.
Depreciation	\$99,593	1.42%	\$138,413	1.29%	\$186,331	1.85%	\$424,337	1.53%	Fixed		Consists of depreciation for larger equipment, machining center, loaner inventory, vehicles and on-site repair vans.
Rent	\$132,070	1.89%	\$138,389	1.29%	\$125,989	1.25%	\$396,448	1.43%	Fixed		No need for additional space for EndoWrist repairs.
Insurance Group	\$110,040	1.57%	\$151,624	1.41%	\$123,787	1.23%	\$385,451	1.39%	Partially variable	1.39%	Consists of employee health insurance premiums. For purposes of my analysis, I treat this as variable.
Professional Fees	\$76,345	1.09%	\$101,522	0.95%	\$134,047	1.33%	\$311,914	1.12%	Fixed		Consists of attorney and accountant fees and one off fees for consultant and training.
Insurance	\$61,858	0.88%	\$87,102	0.81%	\$86,377	0.86%	\$235,337	0.85%	Partially variable	0.85%	Consists of life insurance, workers comp, general liability insurance premiums. For purposes of my analysis, I treat this as variable.
Outside Services	\$40,858	0.58%	\$80,989	0.76%	\$90,703	0.90%	\$212,550	0.76%	Fixed		Consists of IT support and temporary employee labor fees.
Sales - Bonus		0.00%	\$100,000	0.93%	\$87,386	0.87%	\$187,386	0.67%	Variable	0.67%	
Operating Supplies	\$28,480	0.41%	\$86,029	0.80%	\$62,804	0.62%	\$177,313	0.64%	Variable	0.64%	Consists of non-inventory production, lab supplies and small tools.
Maintenance & Repair	\$33,229	0.47%	\$69,539	0.65%	\$47,595	0.47%	\$150,363	0.54%	Fixed		Fire prevention, janitorial cleaning, small repairs, lawn service and HVAC.
Office Expense	\$50,009	0.71%	\$59,239	0.55%	\$27,090	0.27%	\$136,338	0.49%	Partially variable	0.49%	For purposes of my analysis, I treat this as variable.
Real Estate Taxes	\$40,773	0.58%	\$45,735	0.43%	\$41,176	0.41%	\$127,684	0.46%	Fixed		SIS would not require additional space.
Entertainment	\$47,255	0.68%	\$40,153	0.37%	\$32,022	0.32%	\$119,430	0.43%	Variable	0.43%	
Payroll Fees	\$10,525	0.15%	\$17,306	0.16%	\$56,617	0.56%	\$84,448	0.30%	Variable	0.05%	Calculated as (0.30% Payroll Fees / (7.31% Wages - Sales + 0.67% Sales - Bonus + 4.10% Salaries/Employees + 2.65% Salaries/Officers + 0.10% Salaries Office AZ) *(2.00% Wages - Sales + 0.20% Salaries/Employees) as I understand this relates to selling, general and administrative wages and bonuses paid.
Interest Expense	\$34,572	0.49%	\$19,034	0.18%	\$9,679	0.10%	\$63,285	0.23%	Fixed		Consists of interest on the line of credit which would potentially decrease.
Sales & Marketing	\$1,827	0.03%	\$325	0.00%	\$45,346	0.45%	\$47,498	0.17%	Variable	0.17%	
Dues & Subscriptions	\$16,747	0.24%	\$7,796	0.07%	\$7,387	0.07%	\$31,930	0.11%	Fixed		
Printing & Advertise	\$5,572	0.08%	\$6,252	0.06%	\$10,994	0.11%	\$22,818	0.08%	Variable	0.08%	
Meals		0.00%		0.00%	\$22,469	0.22%	\$22,469	0.08%	Variable	0.08%	
Misc Expense		0.00%	\$5,000	0.05%	\$6,903	0.07%	\$11,903	0.04%	Variable	0.04%	
Licenses & Permits	\$6,550	0.09%	\$2,562	0.02%	\$511	0.01%	\$9,623	0.03%	Fixed		
Promotional & Gifts	\$1,948	0.03%	\$1,098	0.01%	\$3,286	0.03%	\$6,332	0.02%	Variable	0.02%	
Postage	\$2,278	0.03%	\$1,613	0.02%	\$1,878	0.02%	\$5,769	0.02%	Variable	0.02%	
Amortization	\$3,644	0.05%	\$1,302	0.01%		0.00%	\$4,946	0.02%	Fixed		
Professional Mktg Fees		0.00%	\$25	0.00%	\$73	0.00%	\$98	0.00%	Fixed		
Total selling	\$1,415,642	20.23%	\$1,893,403	17.66%	\$1,899,002	18.82%	\$5,208,047	18.73%		6.93%	

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

SIS's Detailed SGA: 2019 - October 2021 Second Rebuttal Schedule 15.1

	[1]		[2]		[3]				[4]	[4]	[4]
	2019		2020		2021 (thru Oct)		Total		Fixed / Variable	Variable as a % of revenue	Notes
	Amount	%	Amount	%	Amount	%	Amount	%			
General and admin:											
Salaries/Employees	\$267,488	3.82%	\$356,501	3.32%	\$516,607	5.12%	\$1,140,596	4.10%	Essentially fixed	0.20%	Consists of IT, HR/Payroll, Recruiting, Accounting, COO and Account Managers. If SIS added approximately 2 Account Managers at approximately \$50,000 each, or \$100,000 in total wages, this would approximate 0.15% of the maximum annual lost EndoWrist repair revenue of approximately \$68.5 million as shown on Second Rebuttal Schedule 2.0. For purposes of my analysis, I use 0.20% as variable.
Payroll Tax FICA	\$192,098	2.75%	\$272,758	2.54%	\$273,616	2.71%	\$738,472	2.66%	Variable	0.40%	Calculated as (2.66% Payroll Tax FICA / (7.31% Wages - Sales + 0.67% Sales - Bonus + 4.10% Salaries/Employees + 2.65% Salaries/Officers + 0.10% Salaries Office AZ) *(2.00% Wages - Sales + 0.20% Salaries/Employees) as I understand this relates to all selling, general and administrative wages and bonuses paid.
Salaries/Officers	\$254,886	3.64%	\$291,238	2.72%	\$190,923	1.89%	\$737,047	2.65%	Fixed		
Travel	\$234,380	3.35%	\$173,676	1.62%	\$248,886	2.47%	\$656,942	2.36%	Partially variable	1.00%	Large portion of current expenses is related to technical assistance or educational travel. For purposes of my analysis, treat this as variable.
Telephone	\$30,596	0.44%	\$38,251	0.36%	\$31,391	0.31%	\$100,238	0.36%	Fixed		
Seminars/Conferences	\$49,859	0.71%	\$10,400	0.10%	\$23,376	0.23%	\$83,635	0.30%	Fixed		
Payroll Tax - Other	\$18,828	0.27%	\$24,850	0.23%	\$33,876	0.34%	\$77,554	0.28%	Variable	0.04%	Calculated as (0.28% Payroll Tax - Other / (7.31% Wages - Sales + 0.67% Sales - Bonus + 4.10% Salaries/Employees + 2.65% Salaries/Officers + 0.10% Salaries Office AZ) *(2.00% Wages - Sales + 0.20% Salaries/Employees) as I understand this relates to selling, general and administrative wages and bonuses paid.
Utilities	\$24,226	0.35%	\$22,605	0.21%	\$26,145	0.26%	\$72,976	0.26%	Fixed	0.26%	For purposes of my analysis, I treat this as variable.
Bad Debts	\$23,805	0.34%	\$20,000	0.19%	\$2,164	0.02%	\$45,969	0.17%	Fixed		
Employee Recruitment	\$6,892	0.10%	\$5,287	0.05%	\$24,267	0.24%	\$36,446	0.13%	Variable	0.13%	
Moving Expense	\$8,590	0.12%		0.00%	\$19,669	0.19%	\$28,259	0.10%	Fixed		
Salaries Office AZ		0.00%		0.00%	\$26,428	0.26%	\$26,428	0.10%	Fixed		Represents one employee.
Medical Reimburse	\$5,120	0.07%	\$1,569	0.01%	\$7,107	0.07%	\$13,796	0.05%	Fixed		
Credit Card Fees	\$5,249	0.08%	\$5,247	0.05%	\$3,168	0.03%	\$13,664	0.05%	Fixed		
Vehicle	\$2,853	0.04%		0.00%	(\$453)	0.00%	\$2,400	0.01%	Fixed		
Bank Charges	\$777	0.01%	\$470	0.00%	\$825	0.01%	\$2,072	0.01%	Fixed		
Sales Tax	(\$227)	0.00%	\$1,509	0.01%	\$7	0.00%	\$1,289	0.00%	Fixed		
Sub-total G&A expenses	\$1,125,420	16.09%	\$1,224,361	11.42%	\$1,428,002	14.15%	\$3,777,783	13.58%		2.03%	
Total expenses	\$2,541,062	36.32%	\$3,117,764	29.07%	\$3,327,004	32.97%	\$8,985,830	32.31%	Rounded to	8.96%	
										9.00%	

NOTES / SOURCES:

Note: Any minor differences are due to rounding.

[1] Per SIS320176-188 at 176.

[2] Per SIS320922-935 at 922.

[3] Per SIS327629-636 at 629. Note: Per discussions with Greg Posdal, SIS's 2021 sales approximated \$12.4 million.

[4] Per discussions with Greg Posdal.

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Intuitive EndoWrist Instrument Average Selling Price, Units and Net Sales Dollars: 2020 - 2025

Second Rebuttal Schedule 16.0

	2020	2021	2022	2023	2024	2025	Total
ASP per unit							
[A] da Vinci S/Si	\$2,572	\$2,659	\$2,538	\$2,538	\$2,538	\$2,538	\$2,588
[A] da Vinci X/Xi	\$2,542	\$2,657	\$2,666	\$2,666	\$2,666	\$2,666	\$2,649
[A] Total ASP per unit	\$2,546	\$2,658	\$2,663	\$2,663	\$2,663	\$2,663	\$2,646
Units							
[B] da Vinci S/Si				3,839	1,928	1,077	90,439
[B] da Vinci X/Xi				422,719	455,982	437,186	2,327,724
[B] Total units				426,558	457,910	438,263	2,418,163
Net sales dollars							
[C] da Vinci S/Si				\$9,743,382	\$4,893,264	\$2,733,426	\$234,046,893
[C] da Vinci X/Xi				\$1,126,968,854	\$1,215,648,012	\$1,165,537,876	\$6,165,398,677
[C] Total net sales dollars				\$1,136,712,236	\$1,220,541,276	\$1,168,271,302	\$6,399,445,570

NOTES / SOURCES:

Note: Any minor differences are due to rounding.

[A] Per Second Rebuttal Schedule 13.0. ASP per unit after June 2022 is based on Intuitive ASP through June 2022. Total ASP is calculated based on the amounts herein.

[B] Per Second Rebuttal Schedule 6.0.

[C] = [A] * [B]

HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY

Lanham Act Based on Scenario 2 - Unenforceable Contracts (2 Year X/Xi Delay): 2020 - 2025 Second Rebuttal Schedule 16.1

	2020	2021	2022	2023	2024	2025	Total
Intuitive's ASP per unit							
[A] da Vinci S/Si	\$2,572	\$2,659	\$2,538	\$2,538	\$2,538	\$2,538	\$2,594
[A] da Vinci X/Xi	\$2,542	\$2,657	\$2,666	\$2,666	\$2,666	\$2,666	\$2,666
Lost EndoWrist repair units							
[B] da Vinci S/Si	1,273	1,796	921	431	170	35	4,626
[B] da Vinci X/Xi	0	0	8,779	33,862	40,179	14,008	96,828
[B] Total units	1,273	1,796	9,700	34,293	40,349	14,043	101,454
Net sales dollars (undiscounted)							
[C] da Vinci S/Si	\$3,274,156	\$4,775,564	\$2,337,498	\$1,093,878	\$431,460	\$88,830	\$12,001,386
[C] da Vinci X/Xi	\$0	\$0	\$23,404,814	\$90,276,092	\$107,117,214	\$37,345,328	\$258,143,448
[C] Total net sales dollars	\$3,274,156	\$4,775,564	\$25,742,312	\$91,369,970	\$107,548,674	\$37,434,158	\$270,144,834
[D] Discount %					12%	12%	
[E] Discount period					0.5	1.5	
[F] Discount factor	1.00000	1.00000	1.00000	1.00000	0.94491	0.84367	
[G] Discounted net sales dollars	\$3,274,156	\$4,775,564	\$25,742,312	\$91,369,970	\$101,623,818	\$31,582,076	\$258,367,896

Lanham Act Based on Scenario 2 - Unenforceable Contracts (2 Year X/Xi Delay): 2020 - 2025 Second Rebuttal Schedule 16.1

NOTES / SOURCES:

Note: Any minor differences are due to rounding.

[A] Per Second Rebuttal Schedule 13.0. ASP per unit after June 2022 is based on Intuitive ASP through June 2022. Total ASP is calculated based on the amounts herein.

[B] Per Second Rebuttal Schedule 4.2.

[C] = **[A]** * **[B]**

[D] For the GICS 35101010, Health Care Equipment & Supplies, Duff and Phelps - Cost of Capital Composite, September 30, 2022, the average SIC/GICS Composite WACC (weighted average cost of capital) is 9.2% and median WACC is 8.9%. For the small composite, the WACC is 11.1% to 11.2% (CRSP Decile). For purposes of my analysis I use 12%, which is conservative. Note: The projections after 2022 do not include growth, therefore the discount rate would likely be less.

[E] Calculated using the mid-year convention to January 1, 2024, the approximate date of trial.

[F] = $(1 + \text{[H]})^{-\text{[I]}}$, rounded to 5 decimals.

[G] = Net sales dollars (undiscounted) per **[C]** * **[F]**

Lanham Act Based on Scenario 2 - Unenforceable Contracts (1 Year X/Xi Delay): 2020 - 2025 Second Rebuttal Schedule 16.2

	2020	2021	2022	2023	2024	2025	Total
Intuitive's ASP per unit							
[A] da Vinci S/Si	\$2,572	\$2,659	\$2,538	\$2,538	\$2,538	\$2,538	\$2,594
[A] da Vinci X/Xi	\$2,542	\$2,657	\$2,666	\$2,666	\$2,666	\$2,666	\$2,665
Lost EndoWrist repair units							
[B] da Vinci S/Si	1,273	1,796	921	431	170	35	4,626
[B] da Vinci X/Xi	0	8,329	29,263	47,407	40,179	14,008	139,186
[B] Total units	1,273	10,125	30,184	47,838	40,349	14,043	143,812
Net sales dollars (undiscounted)							
[C] da Vinci S/Si	\$3,274,156	\$4,775,564	\$2,337,498	\$1,093,878	\$431,460	\$88,830	\$12,001,386
[C] da Vinci X/Xi	\$0	\$22,130,153	\$78,015,158	\$126,387,062	\$107,117,214	\$37,345,328	\$370,994,915
[C] Total net sales dollars	\$3,274,156	\$26,905,717	\$80,352,656	\$127,480,940	\$107,548,674	\$37,434,158	\$382,996,301
[D] Discount %					12%	12%	
[E] Discount period					0.5	1.5	
[F] Discount factor	1.00000	1.00000	1.00000	1.00000	0.94491	0.84367	
[G] Discounted net sales dollars	\$3,274,156	\$26,905,717	\$80,352,656	\$127,480,940	\$101,623,818	\$31,582,076	\$371,219,363

Lanham Act Based on Scenario 2 - Unenforceable Contracts (1 Year X/Xi Delay): 2020 - 2025 Second Rebuttal Schedule 16.2

NOTES / SOURCES:

Note: Any minor differences are due to rounding.

[A] Per Second Rebuttal Schedule 13.0. ASP per unit after June 2022 is based on Intuitive ASP through June 2022. Total ASP is calculated based on the amounts herein.

[B] Per Second Rebuttal Schedule 4.5.

[C] = **[A]** * **[B]**

[D] For the GICS 35101010, Health Care Equipment & Supplies, Duff and Phelps - Cost of Capital Composite, September 30, 2022, the average SIC/GICS Composite WACC (weighted average cost of capital) is 9.2% and median WACC is 8.9%. For the small composite, the WACC is 11.1% to 11.2% (CRSP Decile). For purposes of my analysis I use 12%, which is conservative. Note: The projections after 2022 do not include growth, therefore the discount rate would likely be less.

[E] Calculated using the mid-year convention to January 1, 2024, the approximate date of trial.

[F] = $(1 + \text{[H]})^{\text{[I]}}$, rounded to 5 decimals.

[G] = Net sales dollars (undiscounted) per **[C]** * **[F]**